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The Ultra High Risk (UHR) state is a clinical syndrome that is associated with a high 
risk for imminent psychotic disorder. Examination of the symptoms in the UHR 
population using a dimensional approach could improve our understanding of the 
clinical and neurobiological heterogeneity within UHR samples, as it has done in 
schizophrenia. 
Two previous studies in UHR subjects have found that the symptoms measured by 
the CAARMS cluster on to underlying psychopathological dimensions. Moreover, 
both found a link between severity of scores on negative and disorganised factors 
and the risk of later transition to psychosis. However, one study described five 
symptom dimensions whereas the other described a three dimensional model, and 
neither structure has been independently replicated.  
In the present study, CAARMS data from a total of 461 UHR subjects were used to 
perform principle axis factoring (PAF) and confirmatory factor analysis (CFA). Scores 
for each factor of the structure found to best fit the data were then correlated with 
resting regional cerebral blood flow (rCBF) at presentation and with clinical 
outcomes after two years of follow up. 
PAF revealed a five factor structure, which was confirmed using CFA. In the 
subsample of subjects who were studied with neuroimaging, scores on the 
disorganisation factor were associated with reduced rCBF in the thalamus, scores 
on the anxiety factor were associated with reduced rCBF in the insula, and Total 
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CAARMS scores were associated with reduced rCBF in the left hippocampus. Higher 
scores on the anxiety factor and a higher total CAARMS score were associated with 
an increased risk of later transition to psychosis, while higher scores on the 
disorganisation factor was associated with worse functional outcome. These 
findings suggest that symptom dimensions in the UHR state have distinct neural 
substrates and clinical correlates. Variation in these dimensions may contribute to 
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1.1 Ultra High Risk for Psychosis 
1.1.1 Early Intervention in Psychiatry 
Over the last several decades there has been an increased focus on early 
intervention in psychiatry (Birchwood et al., 1998; Edwards & McGorry, 2002; 
Falloon, 1992); alongside prevention and health promotion, early intervention has 
been found to be an effective and efficient response to mental health needs 
(Falloon, 1992; Herrman, 2014; McGorry et al., 2008). In the field of psychotic 
disorders, symptoms preceding the onset of a psychotic episode have long been 
recognised (Beiser, 1993; Sullivan, 1927) and due to the strong correlation between 
duration of the illness and poor prognosis or outcome (Harrigan et al., 2003; 
Marshall et al., 2005; Perkins et al., 2005), focus has been directed towards 
identifying and treating this potentially prodromal stage, in order that a patient’s 
presenting mental state might be prevented from deteriorating and the possible 
onset of psychosis might be delayed, lessened in severity or even prevented (H. J. 
Jackson & McGorry, 2009; McGorry et al., 2001; Yung et al., 1998).  
McGlashan (1988) noted that the progression of symptoms in psychosis was not 
linear and appeared to plateau after an initial period of deterioration – the plateau 
effect. This idea was developed further by Birchwood et al. (1998), who described 
the period preceding the plateau as the “critical period”: a period of rapid 
symptomatic, functional and psychological decline, and the period in which 
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intervention may offer “major opportunities for secondary prevention of the 
impairments and disabilities that accompany psychosis”.  
More recently, Raballo and Larøi (2009) further examined the critical period, 
breaking it down in to a four stage clinical model, on a continuum of increasing risk, 
gradually progressing towards a diagnostic classification of first episode of 
psychosis. Moreover, increased duration of untreated psychosis has been shown by 
Crumlish et al. (2009) to be associated with lower odds of remission, severity of 
positive psychotic symptoms, worse social functioning, and poor psychosocial 
outcome. These factors clearly highlight the importance of intervention as close to 
onset as possible.  
Early studies examining the effectiveness of identification and intervention at this 
stage (Addington et al., 2007) have found improved outcome, and reduction of risk 
of relapse and rehospitalisation (Linszen et al., 1998; McGlashan, 1998; McGlashan 
& Johannessen, 1996) prompting further investigation as to best use of resources, 
as well as clarification of the clinical characteristics, presentation and prognosis of 
the prodrome 
1.1.2 Ultra High Risk for Psychosis 
Yung and McGorry (1996a) examined the potentially prodromal period of 
disturbance preceding a first psychotic episode, primarily characterised by the 
emergence of clinical symptoms and altered functioning, and its potential 
importance for early intervention. 
17 
 
They noted that the symptoms present in the prodromal period are not specific to 
psychosis, and include symptoms of depression, anxiety, and social withdrawal 
(Yung & McGorry, 1996b); whilst psychotic-like experiences also occur in the 
general population and are not in themselves indicative of imminent psychosis 
(Yung et al., 2006). This means that more stringent criteria are needed to correctly 
identify those at risk and lower the chances of being deemed at risk unnecessarily.  
They used a “close-in strategy” to identify a combination of genetic and clinical risk 
factors that pose an imminent high risk for psychotic disorder (Yung & McGorry, 
1996a). Through a combination of interviews with first episode patients in recovery 
after a first acute episode of psychosis and exploration of literature of past and 
current conceptualisations, they investigated the period leading up to psychosis. 
This highlighted confusion as to the nature of prodromal features and concerns 
regarding the reliability of their measurement, and thus they advised for the 
development of a methodology for systematic evaluation and measurement of a 
psychotic prodrome. 
Yung and McGorry described the descriptive and qualitative aspects of this putative 
prodromal phase, associated with a wide range of symptoms: as well as 
‘attenuated’ (i.e. less severe) forms of psychotic symptoms that are evident in 
psychotic disorders, there may also be symptoms that are associated with non-
psychotic conditions, such as depressive and anxiety symptoms, and personality 
disorders. 
Raballo and Larøi (2009) argue that where the Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition (DSM-IV) (American Psychiatric Association, 2000) and 
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The ICD-10 classification of mental and behavioural disorders (ICD-10) (World 
Health Organisation, 1992) do not describe a clear diagnostic framework for 
subthreshold symptomatology characteristic of the early phases of psychosis, the 
clinical staging model, incorporating the UHR state will give a clearer picture of the 
progression towards psychosis. Through the study of the UHR state and presenting 
symptomatology, the work presented in this thesis aims to contribute to the 
predictive model and identification of clinical vulnerability for psychosis. 
There are two semi structured interviews used to measure symptoms and 
determine UHR status: the Comprehensive Assessment of At-Risk Mental States 
(CAARMS) (Yung et al., 2005), developed in the Personal Assessment and Crisis 
Evaluation (PACE) clinic in Melbourn, used in Australia, Europe and Asia; and the 
Structured Interview for Prodromal Syndromes (SIPS) and Scale of Prodromal 
Symptoms (SOPS). The SIPS and SOPS were developed by the Prevention through 
Risk Identification, Management, and Education (PRIME) prodromal research team 
at Yale University and are used in North American Studies (Miller et al., 1999). 
The CAARMS and the SIPS address the same construct and use similar criteria, 
however they differ on: psychopathological definitions of the Attenuated Psychotic 
Symptoms (APS), time and frequency criteria, functional decline criteria, Breif 
Limited Intermittent Psychosis (BLIPS) criteria, and assessment of comorbidities and 
substance misuse. Despite this, they have been shown by Fusar-Poli et al., (2016)       
to have very high diagnostic comparability and substantial agreement in the 




1.1.3 Comprehensive Assessment of At-Risk Mental States  
The CAARMS (Yung et al., 2005), was designed to incorporate reliable methodology 
to clearly differentiate categorical criteria for identification and intervention in the 
psychosis prodrome (shown in full in Appendix 1). It examines clinical 
psychopathology thought to be continuous with psychosis, both positive symptoms, 
on which UHR status is determined, as well as affective symptoms and 
psychopathological domains such as: cognitive changes, emotional disturbances, 
negative symptoms, behavioural changes, motor and physical changes, and general 
psychopathology. According to Yung et al. (2005), it has two aims: 
(i) To assess psychopathology thought to indicate imminent development of a 
first-episode psychotic disorder;  
(ii) To determine if an individual meets criteria for being at UHR for onset of 
first psychotic disorder.  
The CAARMS assesses clinical features using specialised semi-structured interviews, 
and to meet UHR criteria, at least one of the following conditions must be met: 
(i) Group 1: Attenuated Psychotic Symptoms (APS) sub-threshold in frequency 
or intensity 
(ii) Group 2: Brief Limited Intermittent Psychotic Symptoms (BLIPS) that 
resolved within a week without use of anti-psychotic medication 




By identifying the UHR state thorough CAARMS criteria, it may be possible to find a 
clinically useful and predictive model of the development of psychotic disorders. 
Although not all patients who meet UHR criteria go on to develop a psychotic 
disorder, many studies have found a significantly increased risk of developing a 
psychotic disorder compared to the general population (Ruhrmann et al., 2003; 
Yung et al., 2003) with the rate of transition to psychosis has been found to vary 
from 13% (Miller et al., 2003) to 50% (Haroun et al., 2006) in the first 12 months. 
1.1.4 Transition to Psychosis  
A meta-analysis by Fusar-Poli et al. (2012) established a transition rate of 22% over 
the first 12 months and up to 29% after two-years. A meta-analysis of the incidence 
in the general population published the same year, estimated the occurrence of 
psychosis in 31.7 per 100,000 people per year (95%CI: 24.6–40.9) (Kirkbride et al., 
2012); thus, this represents over 700 fold increase compared to the general 
population making the UHR an extremely powerful and interesting research 
paradigm for understanding the early stages of psychosis.  
However due to the high false positive rate, it is necessary to differentiate the 
heterogeneous sample in order to focus intervention where needed and make 
research in this area valuable. Several studies have looked at the effectiveness of 
intervention in the UHR population (McGorry et al., 2009; Morrison et al., 2004; 
Ruhrmann et al., 2010a), however this raises ethical and resource issues such as 
over use of antipsychotic treatment and the stigma of mental health diagnoses, 
leading to questions of whether intervention at this level is warranted (De Koning et 
al., 2009) given that the majority of cases will not develop a psychotic disorder. 
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Thus further distinction is needed in order to distinguish those who truly are 
experiencing the prodrome of a psychotic episode. 
A categorical approach aims to differentiate the UHR sample on the basis of UHR 
criteria subgroups, such as the seven subgroups into which the CAARMS is split 
(positive, cognitive, emotional, negative, behavioural, motor/physical and general), 
or individual symptoms. Several studies have found positive symptoms such as 
unusual thought content and perceptual abnormalities are associated with later 
transition (Haroun et al., 2006; Ruhrmann et al., 2010b), whilst others have found 
that negative symptoms such as depression have a stronger link to transition (Lencz 
et al., 2004; Yung et al., 2003). This implies that, as suggested by Liddle (1987) and 
Peralta et al. (1992) the positive-negative dichotomy may not be sufficient to 
explain the variance of symptoms and that there may be clusters of symptoms that 
are phenomenologically and clinically different, with different trajectories and risk 
of transition. 
 
1.2 Symptom Dimensions 
1.2.1 A Dimensional Approach 
The categorical approach to psychiatric disorders originated from Kraepelin’s 
concept of “natural disease units” (natürliche Krankheitseinheiten) (Berrios & 
Porter, 1995) and proposes that mental disorders can be defined as distinct 
phenomena, and studied and treated as such. It has remained the foundation for 
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diagnosis and psychiatric research, and categorical diagnoses are used to study the 
genetics, neural basis, and treatment of psychiatric disorders (Heckers, 2011). 
A dimensional approach argues that a Kraepelinian categorical approach such as 
that used in the DSM-IV and ICD-10, where diagnosis is determined on the basis of 
symptoms and characteristics typical of a disorder into discrete and distinct 
disorders, does not accurately represent clinical presentation. Such a categorical 
approach does not take into account that significant overlap may exist between 
different diagnostic categories, while imposing categories on dimensional 
phenomena may lead to a simplistic picture, missing valuable clinical information, 
due to the need to achieve diagnostic reliability (Brown & Barlow, 2009).  
Proponents of a dimensional approach do not argue that the categorical approach 
is invalid, rather that it can be complemented by a dimensional approach. In 
particular, that examination of psychopathological syndromes or dimensions not 
categorically defined may give a more representative picture of symptomatology, 
which in turn may be of better use to determine course and outcome. 
This has been found in psychosis in studies such as (van Os et al., 1996) who noted 
that a dimensional representation of symptoms was of better prognostic use in a 
cohort of cross diagnosis patients admitted with functional psychosis, accounting 
for associations with outcome independent of diagnosis. This association of 
symptom dimensions and course, outcome and treatment response, irrespective of 
diagnosis has since then been confirmed in many other studies (Marengo et al., 




The recent fifth edition of DSM - DSM-5 introduces an integration of a dimensional 
approach to diagnosis and classification with the categorical approach. Previous 
editions of DSM used a strictly categorical model requiring a clinician to determine 
that a disorder was present or absent. The dimensional approach, which allows a 
clinician to assess the severity of a condition and does not imply a concrete 
threshold between “normality” and a disorder, is now incorporated via select 
diagnoses.  
The dimensional approach may therefore offer a better understanding of 
presenting symptoms and characteristics of illness, and may be useful in 
examination of the symptomatology of psychosis to give a clearer picture of the 
phenomenology and progression. 
1.2.2 Symptom Dimensions in Psychosis 
Underlying clusters or symptom dimensions have long been established in 
psychosis. In 1987, Liddle suggested that the psychopathology of psychosis may be 
best represented by three underlying symptom dimensions  - positive (reality 
distortion, delusions and hallucinations), negative (poverty of speech, flatness of 
affect and decreased spontaneous movement) and disorganised (disorders of the 
form of thought and inappropriate affect). Liddle argued that these three 
dimensions represent three distinguishable, but related neuropathological 
processes in schizophrenia. This three factor model has been confirmed in 
subsequent studies (Andreasen et al., 1995; Liddle et al., 1992; Mortimer et al., 
1990; Peralta et al., 1992), and the associations with clinical presentation, 
neurobiology and outcome have been investigated showing distinct 
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neuropsychological correlates (O'Leary et al., 2000), patterns of cerebral blood 
perfusion (P. F. Liddle et al., 1992) and varying course and outcome (Arndt et al., 
1995). 
However, more recently, several studies have found alternative models of four 
(McIntosh et al., 2001), five (Dikeos et al., 2006; Lindenmayer et al., 1995a; 
McGorry et al., 1998) and seven factor models (van Os et al., 1996), creating an 
inconsistent picture and Peralta and Cuesta (1999) suggest that the structure of 
psychotic symptoms is more complex than was previously acknowledged. 
1.2.3 Symptom Dimensions in UHR 
As has been found in psychosis (Liddle, 1987; Peralta & Cuesta, 1999; Van Os et al., 
2009) presentation of an inconsistent picture of both three and five factor models 
has been found in the UHR population. Four studies have examined symptom 
dimensions in this population: two using SOPS, two using CAARMS. 
Hawkins et al. (2004) performed a factor analysis on the Scale of Prodromal 
Syndromes (SOPS) finding an underlying 3 factor model, grouping roughly in to 
negative, disorganised and general factors. This was replicated by Fernández et al. 
(2006) who found a similar three factor structure in SOPS. 
There have been two studies that have looked at the symptom dimension in UHR 
using the CAARMS. Demjaha et al. (2010) used principle axis factor analysis and 
found a five factor underlying structure, accounting for 37% of the total variance 
(sample size = 122). The five factors were Disorganised, Negative, Anxiety, Self-
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Harm and Affective Instability. Disorganised and Negative factors were found to be 
predictors of transition to psychosis. 
Raballo et al. (2011) used principal component analysis and found a three factor 
underlying structure accounting for 39% of the total variance (sample size = 223). 
The three factors were: negative/interpersonal, 
communication/cognitive/behavioural disorganisation, and perceptual/affective 
instability. The disorganised factor was the strongest predictor of transition to 
psychosis. 
Using factor analyses, Demjaha et al. and Raballo et al. both report symptom 
dimensions that may be useful for predicting transition to psychosis, however, 
despite using similar recruitment pathways through clinical services in community 
based catchment areas these studies report conflicting three and five factor 
structures based on different samples in different geographical locations. 
Despite inconsistent findings for the number of included factors, the underlying 
factor structure of baseline presenting symptoms seems to be a consistent feature 
of both psychosis and UHR states and has been shown to have an association with 
longitudinal outcome in UHR. However, as yet, neither of the underlying three or 
five factor structures described above have been replicated in an independent UHR 
sample and the disagreement between factor structures outlined above shows that 
further investigation is needed to establish if these factors are generalizable across 
samples and have temporal stability across time points.  
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This project will explore whether the five factor structure found by Demjaha et al. 
(2010), the three factor structure found by Raballo et al. (2011) or a different 
structure all together fits CAARMS symptom data from a new, independent cohort 
of 512 UHR subjects recruited from clinical centres in the UK, Netherlands, Austria, 
Switzerland, France, Spain, Turkey, Australia, Belgium, Germany and Brazil. This will 
be done using Confirmatory Factor Analysis (CFA) and Exploratory Factor Analysis 
(EFA).  
 
1.3 Neurobiology of Symptom Dimensions 
1.3.1 Neurobiology of Symptoms Dimensions in Psychosis 
The heterogeneity in symptom presentation and wide range of courses and 
outcomes in schizophrenia complicates the search for neurobiological substrates of 
the disorder. It may therefore be more beneficial to examine neural correlates 
using a dimensional approach – refining analyses to look at groups of presenting 
symptoms, rather than a categorical approach, combining all symptoms under the 
diagnostic category of schizophrenia. Division of a sample by phenotypic variation 
can be used to form subgroups, which are more homogeneous and therefore may 
enable a more simple and accurate investigation of neural pathology. 
Liddle et al. (1992) argued that the clinical heterogeneity of schizophrenia must 
reflect the heterogeneity in underlying neuropathology.  After having established 
and replicated the three distinct syndromes (Liddle, 1987; Liddle & Barnes, 1990) 
(positive (reality distortion, delusions and hallucinations), negative (poverty of 
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speech, flatness of affect and decreased spontaneous movement) and disorganised 
(disorders of the form of thought and inappropriate affect)), Liddle and colleagues 
went on to examine their neurobiological correlates. Using Positron Emission 
Tomography (PET), they examined regional brain activity through measuring 
Cerebral Blood Flow (CBF), and found that the three distinct syndromes described 
above, were each associated with different patterns of CBF. More notably, the 
neuronal dysfunction fit with the specific predictions based on the clinical and 
neuropsychological characteristics of each syndrome (P. F. Liddle et al., 1992).  
The distinct neuroanatomical alterations associated with the established three 
syndromes in schizophrenia have been subsequently replicated in many studies. 
Nenadic et al. (2010) found distinct grey matter abnormalities associated with 
positive, negative and disorganised symptoms, and further established that the 
pattern of regionally distributed alterations in brain structure would provide 
sufficiently accurate classification (95.8%) of a given scan to be assigned to the 
schizophrenia subgroup as determined by psychopathology. While Goghari et al. 
(2010) reviewed 25 task based fMRI studies examining the relationship between 
symptom dimensions and regional brain activity and found distinct patterns of 
neural function according to positive, negative and disorganised symptoms, 
providing consistent links between the manifest symptoms of schizophrenia and 
brain dysfunction. 
More recently, Cerebral Blood Flow (CBF) has been examined using arterial spin 
labelling (ASL) perfusion MRI - a technique that allows for quantitative 
measurement of CBF by using magnetically labelled arterial blood water as an 
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endogenous tracer. Pinkham et al. (2011) used this technique to distinguish 
differences in CBF associated with positive and negative symptoms. Severity of 
negative symptoms was associated with reduced CBF in bilateral superior temporal 
gyrus, cingulate gyrus, and left middle frontal gyrus, while severity of positive 
symptoms was related to both higher CBF in cingulate gyrus and superior frontal 
gyrus and decreased CBF in precentral gyrus/middle frontal gyrus. 
1.3.2 Resting Cerebral Blood Flow in Ultra High Risk 
Recently animal models have been used to help understand the neurobiological 
mechanisms underlying the development of psychosis. Preclinical models such as 
the methylazoxymethanol acetate (MAM) Model, posit a key role for the 
hippocampal-midbrain-striatal circuit in the development of psychosis, and suggest 
that prior to onset of psychosis in humans, resting hippocampal activity may be 
elevated (Lodge & Grace, 2011). In keeping with this, several studies have shown 
reduced hippocampal volume and increased hippocampal perfusion in subjects 
meeting UHR criteria (Mechelli et al., 2011; Pantelis et al., 2003; Schobel et al., 
2009). 
Resting hippocampal activity can be assessed by measuring resting cerebral blood 
flow (rCBF), which allows for an indirect gauge of neural function (Hirano et al., 
2011). This can be measured using pseudo-Continuous Arterial Spin Labelling (p-
CASL), and allows for the mechanism proposed in the MAM model to be directly 
investigated in subjects at high risk for psychosis. Recent studies such as Allen et al. 
(2016) have shown in a longitudinal study of UHR subjects, that as well as resting 
state hyperperfusion evident in the hippocampus, midbrain, and basal ganglia of 
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UHR subjects at onset of symptoms, this perfusion reduces in line with subsequent 
symptomatic improvement. Reduced rCBF in the hippocampus and ventral striatum 
were observed at follow-up for those showing symptomatic improvement and 
subjects whose symptoms had resolved and no longer met ultra-high-risk criteria 
showed a reduction in left hippocampal rCBF not present in subjects who 
transitioned to psychosis, or who still met Ultra High Risk criteria. 
These findings confirmed the findings of a previous study, measuring rCBF using a 
steady-state gadolinium-enhanced fMRI technique rather than ASL by Schobel et al. 
(2009), and provide evidence that increased resting hippocampal activity described 
in preclinical models can be applied to the psychopathology of psychosis.  
1.3.3 Neurobiology of Symptom Dimensions in Ultra High Risk 
As described above, perfusion alterations are a consistent finding in UHR studies, in 
keeping with the developmental mechanisms described using the MAM model. 
Additionally, although early evidence in schizophrenia using PET (P. F. Liddle et al., 
1992) and more recent examination using MRI (Pinkham et al., 2011) has shown 
that different patterns and regions of perfusion can be distinguished according to 
symptomatic presentation, this has not yet been investigated in the UHR 
population. 
After having used factor analysis to establish if a dimensional representation of 
symptoms is applicable in the UHR population, this study will go on to investigate 
the neurobiological correlates of these dimensions through measuring resting 
Cerebral Blood Flow, using MRI to give a picture of neural rCBF (perfusion) 
associated with different types of symptoms. This may be able to give a biological 
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validation to statistically determined dimensions, and contribute to the 
understanding of the distinct cause, course and outcome associated with each of 
them. 
 
1.4 Clinical Application of Symptom Dimensions 
1.4.1 Symptom Dimension and Clinical Presentation/Outcome 
In order to clarify the degree to which psychotic symptoms are predictive of course 
and outcome of illness, it is necessary to relate dimensions longitudinally to clinical 
and functional follow-up data. Association of dimensions with various illness 
characteristics regarding onset, course and impairment has been reported in a 
number of studies in both psychosis (Owens et al., 2010; van Os et al., 1996; 
Wickham et al., 2001) and UHR (Demjaha et al., 2010; Johnstone et al., 2005; 
Raballo, 2011; Ziermans et al., 2014).  
The relationship between symptom dimensions and outcome has been examined in 
psychosis extensively, with many studies concluding that symptom dimensions 
prove to be a more powerful tool in explaining variance of outcome than 
categorical sub-diagnoses (Salokangas, 2003).  
Negative symptoms have been consistently linked with poor outcome in psychosis. 
In studies which examined the correlation between psychopathological dimensions 
and clinical characteristics, the negative factor was found to be associated with 
poor premorbid functioning (Wickham et al., 2001) earlier or insidious onset (Sato 
et al., 2004; van Os et al., 1996) or deteriorating/chronic course of illness (Levine & 
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Leucht, 2013; Sánchez-Torres et al., 2017). Disorganised symptoms have similarly 
been linked to poor functional outcome (Ortiz et al., 2015) and risk of remission 
(Owens et al., 2010).  
In order to examine the relationship between dimensions and outcome in the UHR 
population, we must ascertain definitive outcome measures, as this group does not 
have a categorically defined diagnosis or course of illness. 
Traditionally the outcome measure in UHR has been risk of transition to psychosis, 
as this is the predominant aim in defining the UHR criteria, with an average 
transition rate of around 29% in the following 2 years (Fusar-Poli et al., 2012). 
However, meeting UHR criteria, although indicative of a significant increase in risk 
for developing psychosis compared to the general population (Kirkbride et al., 
2006), is not indicative of a psychosis prodrome in the majority of subjects, and it is 
therefore important to determine outcome not only according to transition. 
There has been recent support for the increasing emphasis on functional decline as 
a critically important outcome to be considered alongside the rate of transition to 
psychosis (Cornblatt et al., 2012; Schlosser et al., 2012). The identification of factors 
that reliably differentiate UHR subjects that are at high risk for long term functional 
impairments from those who are not may provide a framework to understand the 
disability associated with both those who transition and those who do not. 
The link between severity of negative symptoms and poor outcome in psychosis has 
been confirmed in UHR by three studies examining symptom dimensions and 
outcome in UHR (Demjaha et al., 2010; Hawkins et al., 2004; Raballo et al., 2011), 
32 
 
all finding negative symptoms linked to increased risk of transition to psychosis. 
Demjaha et al. (2010) and Hawkins et al. (2004) also found a link between severity 
of disorganised symptoms and subsequent transition to psychosis. However, to 
date, no studies have examined the relationship between symptoms in UHR and 
functional outcome. 
 
1.5 Aims and Objectives of this Study 
This study will examine three main objectives in three distinct empirical chapters. 
Chapter 2 will present the current literature and theoretical framework behind 
symptom dimensions in psychosis and its application in UHR. It will then go on to 
examine the symptom dimensions present in a large multi-site sample of UHR 
subjects recruited from 13 centres in Europe, South America and Australia between 
2010 and 2016, in two factor analyses: an exploratory factor analysis to determine 
the structure present in this sample and a confirmatory factor analysis to compare 
the model fit of the structure found and the two structures previously found in the 
literature. The total sample comprises data from a wide range of clinical centres 
and as such may provide a sample that is more representative of the UHR subjects 
who present to such services rather than a sample derived from a single centre. 
Chapter 3 will present the neurobiological findings in psychosis and UHR with a 
specific focus on the neural correlates of symptoms and symptom dimensions. 
Resting cerebral blood flow will then be examined using MRI data in a subset of the 
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sample from London to determine the relationship between symptom dimensions 
and cerebral resting perfusion in UHR subjects. 
Finally, chapter 4 will present the current findings relating to presenting 
symptomatology, other clinical variables and longitudinal outcome data. The 
possible definitions of outcome in the UHR population will be considered, and how 
these are of clinical and research use. Regression analyses will be conducted in 
order to determine the relationship between the severity of scores on each 
symptom dimension and clinical outcome. 
Specific hypotheses will be outlined in their respective chapters.  
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2 Symptom Dimensions in individuals at Ultra High Risk for 
Psychosis 
2.1 Introduction 
2.1.1 Heterogeneity in Ultra High Risk for Psychosis  
An individual can meet the CAARMS criteria for the UHR state if their clinical 
features satisfy the inclusion criteria for one of three distinct (but not mutually 
exclusive) domains: Attenuated Psychotic Symptoms (APS), Brief Limited 
Intermittent Psychosis (BLIP), and Genetic Risk combined with a recent functional 
decline. Despite the majority of UHR meeting criteria for APS, the symptomatology 
in UHR subjects varies between individuals, and between samples, depending on 
which of the different types of inclusion criteria are met.  The UHR state is also 
associated with a high prevalence of  non-psychotic symptoms, with up to 70% of 
subjects meeting criteria for another comorbid psychiatric diagnosis (particularly 
depression and anxiety) in addition to the UHR state (Fusar-Poli et al., 2012). Again, 
the presence of comorbid diagnoses varies between UHR subjects, and between 
UHR samples. 
Variation in the presenting symptomatology between centres may contribute to the 
differences in the rates of transition to psychosis reported from different sites, with 
some describing rates as high as 40-50% (Miller et al., 2002; Yung et al., 2003) but 
others rates as low as 10% (Demjaha et al., 2010; Haroun et al., 2006).  This 
variability also applies to clinical outcomes among the UHR subjects who do not go 
on to develop psychosis, with between-site differences in the proportions of 
subjects who no longer meet criteria for the UHR state at follow up ranging from 
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15% (Miller et al., 2002) to 54% (Velthorst et al., 2011). A key factor underlying 
these differences is that the way UHR subjects are ascertained varies substantially 
between sites: some centres provide a full clinical service for UHR subjects, but 
others only recruit subjects to take part in research projects, and do not offer 
clinical care. There are also wide variations in the clinical presentation and intake 
group (Attenuate Psychotic Symptoms/Brief Limited Intermittent Psychosis/Genetic 
Risk and Functional Decline) of the individuals enrolled at different centres, as 
shown by Fusar-Poli et al. (2016), who found significant differences between 
studies in a meta-analysis of longitudinal UHR studies and significant differences in 
transition rate according to intake group, although the predominant intake groups 
was consistently APS. 
2.1.2 Comprehensive Assessment of At Risk Mental State (CAARMS) 
The CAARMS consists of 27 items that are designed to assess the psychopathology 
associated with the UHR state. However these items do not correspond to 27 
independent symptoms: many of them are highly inter-correlated. Examining 
symptom dimensions, as opposed to individual symptoms, provides a way of 
assessing how individual symptoms cluster together on common dimensions. It is 
possible that symptom dimensions are more closely related to etiological and 
pathophysiological risk factors for the UHR state than individual symptoms (Liddle, 
1987; P. F. Liddle et al., 1992). Similarly, variation in symptom dimensions may be 
more closely linked to variation in clinical outcomes in UHR subjects than 
differences in individual symptoms (Van Os et al., 2009). 
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The CAARMS is divided in to 7 subgroups of symptoms. Although these correspond 
to different kinds of symptoms (Positive, Cognitive, Emotional, Negative, 
Behavioural, Motor/Physical, and General), the basis of the subdivision is 
theoretical rather than empirical. In contrast, symptom dimensions reflect the 
statistical probability that subsets of different symptoms cluster together. By 
identifying such dimensions, factor analysis can reduce the number of observed 
variables (in this case symptoms) into a smaller number of latent variables (in this 
case symptom dimensions) by examining the covariation among the observed 
variables. This reveals a structure that reflects the underlying data, as opposed to a 
theoretical construct.  
2.1.3 Examination of Symptoms in UHR 
Factor analyses of symptoms in patients with psychosis initially produced a three 
factor model, consisting of positive, negative and disorganised factors (Liddle, 1987) 
which was widely replicated (Andreasen et al., 1995; Mortimer et al., 1990; Peralta 
et al., 1992). However, more recent analyses suggest that the structure of psychotic 
symptoms is more complex than was previously acknowledged (Peralta & Cuesta, 
1999; Van Os et al., 2009). 
In UHR data, Hawkins et al. (2004) performed a factor analysis in 94 subjects 
assessed using the Scale of Prodromal Syndromes (SOPS) and found a 3 factor 
model, comprising negative, disorganised and general factors. The three factors 
found in UHR models are similar to the model found in psychosis; however they 
lack the distinct positive factor, and instead had a general factor.Fernández et al. 
(2006) also found a similar three factor structure based on use of the SOPS in 30 
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UHR subjects. A three factor model was also found by Comparelli et al. (2011) in the 
Italian version of SOPS , however this differed from the previous two three factor 
structures and a study published in the same year found a contrasting four factor 
structure (Klaassen et al., 2011). The sample size used in the Comparelli et al. 
(2011) study was the largest sample (n = 128), and although the minimum sample 
size, or the minimum ratio of sample size to the number of variables, is variant 
across studies (MacCallum et al., 1999), this does not meet the rules of thumb for 
the minimum sample size necessary to obtain factor solutions that are adequately 
stable and that correspond closely to population factors. These small sample sizes 
may contribute to the variation in structures found. 
Two studies have looked at the symptom dimension in UHR state using the 
CAARMS. The CAARMS differs from the SOPS in some of the operational criteria 
such as time and frequency criteria, functional decline criteria and most notably in 
BLIPS criteria, where the SIPS considers “seriously disorganizing or dangerous” 
features as fully psychotic, whereas under CAARMS criteria, these are deemed UHR. 
Despite this, they have been shown by Fusar-Poli et al. (2016) to have very high 
diagnostic comparability and substantial agreement in the identification of UHR 
subjects. The two CAARMS models are described below. 
2.1.4 A Five Factor Model 
Demjaha et al. (2010) used principle axis factor analysis of CAARMS data and found 
a five factor underlying structure, accounting for 37% of the total variance (sample 
size = 122). The five factors were Disorganised, Negative, Anxiety, Self-Harm and 
Affective Instability. Nineteen of the Twenty-seven CAARMS items were included, 
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the five factors and the items that load on them, are shown in figure 1 below. One 
item (Observed Changes in Motor Functioning) was excluded as it was present in 
less than 10% of the sample, and seven items (OCD Symptoms, Impaired Bodily 
Sensation, Aggression/Dangerous Behaviour, Unusual Thought Content, Perceptual 
Abnormalities, Dissociative Symptoms, Observed Inappropriate Affect and Changes 
in Motor Functioning) were excluded because they did not have a robust loading of 
over 0.4 on any factor. The Disorganised and Negative factors were found to be 
predictors of subsequent transition to psychosis, as determined from clinical follow 
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2.1.5 A Three Factor Model 
Raballo et al. (2011) used principal component analysis in 223 UHR subjects with 
symptoms assessed using the CAARMS. They described a three factor structure that 
accounted for 39% of the total variance in all twenty-seven items at baseline. This 
included items with loadings over 0.3. The 3 factors were: negative/interpersonal, 
communication/cognitive/behavioural disorganisation, and perceptual/affective 
instability, and are shown in figure 2. Clinical follow up revealed that higher scores 
on the disorganised factor were associated with later transition to psychosis at 12-
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Both Demjaha et al. and Raballo et al. reported that scores on particular symptom 
dimensions may be associated with the risk of later transition to psychosis. 
However, the former identified a five-factor structure, and the latter only three. 
Although both studies recruited participants through catchment based clinical 
services, it is not clear to what extent this indicates differences in the 
symptomatology in the respective UHR samples from each site, reflecting the 
presence of different subtypes of UHR individual, which might be associated with 
different aetiologies, pathophysiologies and clinical outcomes. To date, neither a 
three or a five factor structure has been replicated or confirmed in an independent 
UHR sample.  
This thesis aimed to address this issue by examining the factor structure of CAARMS 
symptom data in a cohort of 512 (over double that used in the previous studies) 
UHR subjects recruited from centres in the UK, Netherlands, Austria, Switzerland, 
France, Spain, Turkey, Australia, Belgium, Germany and Brazil, using Confirmatory 
Factor Analysis (CFA) and Exploratory Factor Analysis (EFA).  
2.1.6  Factor Analysis 
Both EFA and CFA permit investigation of the relationship between observed 
measures (in this case scores on the 27 items of the CAARMS questionnaire), and 
latent variables, factors, or underlying dimensions. A large number of observed 
variables can thus be reduced to a smaller set of latent variables. EFA is a data 
driven approach, which does not allow for the specification of any structure or 
relationships. Rather, it is descriptive and will indicate the structure that best fits 
43 
 
the data according to the correlations and covariances present. This is valuable in 
the earlier stages of research, before a structure has been established for an 
instrument. Both the Demjaha and the Raballo studies used EFA for their initial 
investigation of CAARMS dimensions in UHR subjects. 
Whereas EFA is exploratory, CFA can be used to confirm previously established 
structures in new datasets, where a structure has previously been established on 
empirical or theoretical grounds. In the case of the present study the structures 
used in the CFA are the two identified in the previous UHR studies. 
One disadvantage of Exploratory Factor Analysis (EFA) is that although the results 
show factor loadings for each item in the dataset, there are no goodness of fit 
indices for the resulting model making it hard to determine how well the model fits 
the data. However, Confirmatory Factor Analysis (CFA) allows testing of the fit of a 
model to any dataset. A model that has been found in one data set, but cannot be 
confirmed subsequently in independent data sets has limited application. Therefore 
the aim of the present study is to use EFA to determine a model and then use CFA 
in an independent dataset to compare the previously found models to determine 
which, if any, structure is generalizable.  
The total sample comprises data from a wide range of clinical centres and as such 
may provide a sample that is more representative of the UHR subjects who present 
to such services rather than a sample derived from a single centre. The data 
collected from all centres will be compared to ensure statistical similarity before 
being pooled to create a larger sample. This approach is similar to the method used 
by van der Gaag et al. (2006), who used confirmatory factor analysis to test models 
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previously found in the literature on a large pooled dataset in which symptoms had 
been assessed using the Positive and Negative Syndrome Scale (PANSS). The 
relatively large size of the pooled sample in the present study (n=512) means that it 
can be split into two subsamples (UK and non-UK) to perform the exploratory and 
confirmatory factor analyses, respectively. This is because the two previous studies 
were conducted in UK (Demjaha et al., 2010) and non-UK samples (Raballo et al., 
2011). 
2.1.7 Aims and Objectives of this Study 
This chapter will describe a factor analysis conducted on CAARMS symptom data 
from a total sample of 557 UHR patients recruited from clinical centres in the UK, 
Netherlands, Austria, Switzerland, France, Spain, Turkey, Australia, Belgium, 
Germany and Brazil. This will involve splitting the data in to two, with the first half 
of the data used to conduct an Exploratory Factor Analysis (EFA) to determine a 
model, and the second used to conduct a Confirmatory Factor Analysis (CFA) to 
compare this model with previously found models, to determine which, if any, 




The total sample is comprised of 557 individuals meeting the PACE criteria for UHR, 
aged 18-35 recruited through three different studies conducted between 2008 and 
2017. Fifty-three participants were recruited through an MRC funded study at 
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King’s College London that aimed to examine neurobiological differences between 
UHR and healthy volunteers; ninety through a Wellcome Trust funded programme 
at King’s College London designed to ascertain which neurobiological factors best 
predicted transition/outcome in UHR subjects (collected by the author); and four 
hundred and fourteen from an FP7 project funded by the European Union, involving 
sites in the UK, Netherlands, Austria, Switzerland, France, Spain, Turkey, Australia, 
Belgium, Germany and Brazil. A breakdown of the total sample by location is shown 
in table 1 below. All studies had National Research Ethics Service (NRES) approval 




Table 1: Geographical Composition of Total Sample 
Study Location Number 
MRC study UK - London – South London 53 
Wellcome Study 
UK - London – South London 63 
UK - Cambridge 19 
UK  - London – West London 
8 
EU Study 
UK – London – South London 149 
The Netherlands – Amsterdam 20 
The Netherlands - Den Haag 69 
Austria – Vienna 8 
Switzerland – Basel 25 
Germany – Cologne 16 
Australia – Melbourne 29 
Belgium  - Kortenberg/Leuwen 45 
France – Paris 21 
Spain – Barcelona 23 
Brazil - Sao Paulo 9 
Total  557 
 
 
2.2.2 Eligibility Criteria 
Participants were recruited from specialist early intervention services and assessed 
by researchers trained to administer the CAARMS. According to the PACE criteria, 
an individual can be classed as UHR if they meet the threshold for one or more of 
the following subcategories: 
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Group 1: Attenuated Psychotic Symptoms (APS) sub-threshold in frequency or 
intensity (84%) 
Group 2: Brief Limited Intermittent Psychotic Symptoms (BLIPS) that resolved 
within a week without use of anti-psychotic medication (11%) 
Group 3: Genetic risk combined with a significant recent decline in functioning (5%) 
(The decline in functioning was only an inclusion criterion in the Genetic Risk group) 
In the present study, inclusion required that participants: 
➢ Met UHR criteria  
➢ Were aged 18 - 35 
 
The exclusion criteria were: 
➢ Neurological or medical illness or head injury 
➢ Presecribed antipsychotic medication for longer than 2 weeks 
➢ IQ lower than 70 
➢ Meeting DSM-IV criteria for drug/alcohol abuse or dependency 
➢ Treatment with antipsychotic medication for a week or more 
 
2.2.3 Measures 
The Comprehensive Assessment of At Risk Mental State (CAARMS) is a semi-
structured interview designed by (Yung et al., 2005). It aims to measure the 
dimensions of psychopathology needed to meet the criteria for UHR status, 
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including intensity, frequency, duration and distress associated with symptoms. The 
27 items1 are categorised in to 7 sections: 
1. Positive – including unusual thought content, non-bizarre ideas, 
perceptual abnormalities and disorganised speech (4 items) 
2. Cognitive Change – including subjective cognitive change and observed 
cognitive change (2 items) 
3. Emotional Disturbance – including subjective emotional disturbance, 
observer blunted affect and observed inappropriate affect (3 items) 
4. Negative – including alogia, avolition/apathy and anhedonia (3 items) 
5. Behavioural Change – including social isolation, impaired role 
functioning and aggression/dangerous behaviour (4 items) 
6. Motor/Physical Change – including subjective impaired motor 
functioning observed changes in motor functioning, subjective impaired 
bodily sensation and subjective impaired autonomic functioning (4 
items) 
7. General Psychopathology – including mania, depression, suicidality and 
self-harm, mood swings/lability, anxiety, OCD symptoms, dissociative 
symptoms and impaired tolerance to normal stress (7 items) 
Severity and Frequency are scored on a scale of 0-6, and distress is scored as a 
subject reported percentage. Sub-threshold intensity Attenuated Psychotic 
Symptoms are classified as a severity score of 3-5 on Unusual Thought Content and 
                                                     
1 A later version updated in 2006 included 28 items - item 1.1 Unusual Thought Content and Non 
Bizarre ideas was split in to two items 1.1 Unusual Thought Content and 1.2 Non Bizarre Ideas. A 
drop in functioning was also added as additional criteria for inclusion in the APS and BLIP groups. 
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Non Bizarre Ideas, 3-4 on Perceptual Abnormalities, and/or 4-5 on Disorganised 
Speech and a frequency score of 3-6 on any of the items in the Positive scale, Sub-
threshold frequency Attenuated Psychotic Symptoms are classified as a frequency 
score of 3 and a severity score of 6 on Unusual Thought Content and Non Bizarre 
Ideas, 6 on Disorganised Speech, and 5-6 on Perceptual abnormalities. A severity 
score of 6 on Unusual Thought Content and Non Bizarre Ideas, 6 on Disorganised 
Speech, and 5-6 on Perceptual abnormalities, with frequency greater than 4 on any 
of the items in the Positive scale is classified as Psychotic (group inclusion criteria is 
shown at the end of the CAARMS in Appendix 1). As in previous studies (Demjaha et 
al., 2010; Raballo, 2011), the Severity score was used to perform the analysis. 
Participants recruited through the MRC study (n=53) completed the earlier version 
of the CAARMS, and therefore a drop in functioning was not a requirement for 
meeting APS/BLIP criteria. Participants recruited in the subsequent two studies 
(n=504) used the 2006 CAARMS, where the drop in functioning was required. 
The CAARMS was implemented by a trained researcher at each site. Inter-rater 
reliability was ensured via online training tools for the CAARMS incorporating inter-
rater reliability standard requirement for completion of the training. Language 
inconsistencies for centres not conducting assessments in English was addressed 
through back translation. 
2.2.4 Missing Data 
Listwise deletion of missing data was used - cases were dropped from analysis if 
they had a missing value in at least one of the specified variables. This is because 
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Confirmatory Factor Analysis can only be applied to cases which have a complete 
set of data.  
There were forty five subjects who were included in more than one of the studies. 
Of an initial sample of 557, after removal of these subjects the sample size was 512. 
After removal of fifty one subjects for whom there were missing data the sample 
size was 461. This is roughly four times the size of the Demjaha et. al. sample and 
twice the size of the Raballo et. al. sample (n = 122 and 223 respectively) 
2.2.5 Statistical analysis 
As the data came from three different studies, an initial group comparison was 
performed to determine whether the respective data sets were sufficiently 
statistically similar to be pooled. This required that they have statistically similar 
subjects by age and gender, and shared the same structure of CAARMS scores, 
which would be expected if they represented different samples of the same 
population. 
Once grouped together, in order to perform both the Exploratory and Confirmatory 
factor analyses the data set was split into two subsets – Set 1 (EFA) and Set 2 (CFA). 
Confirmatory factor analysis can only validate a putative factor structure if it is 
performed on a separate data set to the one in which the original factor structure 
was found (through exploratory factor analysis), to avoid cross-validation. 
In the present study, the data set was split into two by location: UK (n= 235) and 
Non-UK (n= 226). This approach was adopted because the two previously found 
factor structures in UHR subjects were identified with samples from clinical centres 
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that were in the UK (Demjaha et al., 2010) and outside the UK (Melbourne, 
Australia (Raballo et al., 2011)), respectively. The UK data were used for the 
exploratory factor analysis to determine a structure in a unified sample from one 
centre and the non-UK data for the confirmatory factor analysis to see if the factor 
structure is generalizable to a more general multi-centre sample.  
Exploratory factor analysis was conducted using SPSS (version 23) using the severity 
scores of all 27 CAARMS items, and factors were subjected to a promax rotation to 
allow for correlation between factors. Only loadings greater than 0.4 were used to 
determine dimensions (Comrey, 1973). 
Confirmatory factor analysis was conducted using AMOS (version 23) to measure 
the goodness-of-fit of the alternative models. The indices used to determine 
goodness of fit were χ², Comparative Fit Index (CFI), Tucker-Lewis Index (TLI), 
Standardised Root Mean Square Residual (SRMR) and the Root Mean Square Error 
of Approximation (RMSEA). χ² should be close to 2, where 0 is a perfect fit, CFI and 
TLI should be above 0.90, where 1 is a perfect fit, SRMR should be below 0.08 and 
the RMSEA should be below 0.06 where 0 is a perfect fit (Schreiber et al., 2006). 
These are the fit indices recommended by Hu and Bentler (1999) and represent 
different measurement properties – absolute fit (χ² & SRMR) relative fit (TLI) and 
non-centrality based indices (CFI & RMSEA). 
Absolute fit indices are derived from the fit of the covariance matrices and 
maximum likelihood estimation of the data set, and do not use an alternative 
model as a base for comparison. Chi-square (χ²) is the original fit index for structural 
models and the basis for other fit indices. However it has been shown to be 
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affected by sample size (Marsh et al., 1988), model size (Schreiber et al., 2006) and 
the distribution of variables (Curran et al., 1996), so although it should be reported, 
it is rarely non-significant and it is recommended that other absolute fit indices be 
reported (Hu & Bentler, 1999). The residual based fixed index (SRMR) was therefore 
used as well.  
Relative fit indices compare a chi-square for the current model to one from a null 
model. The null model is a model in which all measured variables are uncorrelated - 
there are no latent variables. The relative fit index used in this analysis will be TLI 
(Tucker & Lewis, 1973) as it has been shown to be less effected by sample size  
(Bollen, 1990).  
Non-centrality based indices are all based on an estimation of the population non-
centrality parameter. Rather than testing the hypothesis that the fit is perfect, they 
test how bad the model fit is, and they allow confidence interval assessment as well 
as cut-off points used in other indices. CFI measures incremental fit, and RMSEA 
measures residuals bases fit, and both RMSEA and CFI have been shown to perform 
well with respect to model misspecification and sample size (Hu & Bentler, 1999; D. 
L. Jackson, 2007; Marsh et al., 1998). 
 
The models being tested were: 
1. One factor model of all CAARMS Items 
2. Three factor model from Raballo (2011) 
3. Five Factor Model from Demjaha et al. (2010) 
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4. Seven factor model of CAARMS symptom categories (the standard symptom 
divisions of the CAARMS) 
5. Model found following EFA of the UK data from the present Study 
 
2.3 Results 
2.3.1 Test of Homogeneity 
In order to combine the three data sets, Levine’s test of homogeneity of variance 
was performed on the CAARMS scores for the three data sets. This indicated equal 
variances of CAARMS scores (F = 1.59, p = .205) which suggested that the data sets 
could be pooled. A one way Anova showed no significant differences in age and a 
chi square test showed no significant differences in gender between the three 
samples 
2.3.2 Sample characteristics 
The final pooled sample consisted of CAARMS scores for 461 participants. The 
sample was 56% male, the mean age was 22 years and 4 months, and 57% of the 
subjects were white, 34% black and 9% from other ethnic minorities. 84% of the 
sample met the inclusion criteria for Attenuated Psychotic Symptoms (APS), 11% 
Brief Limited Psychotic Period (BLIP) and 5% Genetic Vulnerability. Gender, age, 
ethnicity and CAARMS intake group breakdowns for each sample are shown in the 
















SET 1 – 
UK 
SET 2 – 
Non-UK 
Sample Size 90 53 414 557   
Number included* 85 50 326 461 235 226 
Age  
Mean 22.47 22.56 22.22 22.66 22.62 21.95 



















































































* After removal of duplicate participants and listwise removal of missing data 
CAARMS scores recorded in the total sample ranged from 0-6 for each item, and 
every item was present in at least 10% of the sample. A breakdown of scores for 
each item is shown in the table 3 below. 
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Table 3: Mean, Standard Deviation and Range of All CAARMS Items 
CAARMS group Number CAARMS Item Minimum Maximum Mean SD 
1. Positive Symptoms 
1.1 Unusual thought content and non-bizarre ideas 0 6 2.66 1.53 
1.2 Perceptual abnormalities 0 6 2.82 1.82 
1.3 Disorganized speech 0 6 1.58 1.47 
2. Cognitive Change Attention/Concentration 
2.1 Subjective cognitive change 0 6 2.24 1.26 
2.2 Observed cognitive change 0 5 0.70 1.01 
3. Emotional Disturbance 
3.1 Subjective emotional disturbance 0 6 1.89 1.53 
3.2 Observed blunter affect 0 6 0.88 1.21 
3.3 Observed inappropriate affect 0 6 0.33 0.88 
4. Negative Symptoms 
4.1 Alogia 0 5 1.23 1.25 
4.2 Avolition/apathy 0 6 2.69 1.58 
4.3 Anhedonia 0 6 2.58 1.81 
5. Behavioural Change 
5.1 Social isolation 0 6 2.35 1.66 
5.2 Impaired role function 0 6 2.54 1.84 
5.3 Disorganizing/odd/stigmatising behaviour 0 5 0.56 1.07 
5.4 Aggression/dangerous behaviour 0 6 2.11 1.64 
6. Motor/Physical Changes 
6.1 Subjective complaints of impaired motor functioning 0 4 0.51 0.92 
6.2 Informant reported or observed changes in motor functioning 0 4 0.12 0.48 
6.3 Subjective complaints of impaired bodily sensation 0 6 0.64 1.28 
6.4 Subjective complaints of impaired autonomic functioning 0 5 0.85 1.37 
7. General Psychopathology 
7.1 Mania 0 6 0.68 1.29 
7.2 Depression 0 6 2.99 1.43 
7.3 Suicidality and self-harm 0 6 1.68 1.60 
7.4 Mood swings/lability 0 5 1.42 1.52 
7.5 Anxiety 0 6 2.79 1.62 
7.6 Obsessive compulsive symptoms 0 6 1.19 1.62 
7.7 Dissociative symptoms 0 6 1.06 1.53 
7.8 Impaired tolerance to normal stress 0 5 1.90 1.78 
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2.3.3 Test of normality 
CAARMS scores for each item were examined for any significant variation from normal 
distribution by looking at individual histograms for each item (Appendix 2). Normal 
distribution is not a pre-requisite for factor analysis, however as some items varied from 
normal distribution, Principle Axis Factoring was used as the extraction method, which is 
less sensitive to normality than Maximum Likelihood.  
2.3.4 Exploratory Factor Analysis 
Exploratory factor analysis was conducted using SPSS (version 23) on the severity scores 
of all items, and factors were subjected to an oblique rotation – promax, to allow for 
correlation between factors. Only loadings greater than 0.4 were used to determine 
dimensions (Comrey, 1973). 
The Keiser- Mayer-Olkin (KMO) measure of sampling adequacy and Bartlett’s test of 
sphericity showed the data’s suitability for factor analysis. KMO = 0.891 (above the 
recommended value of 0.6) and Bartlett’s test of sphericity was significant (χ² = 1482.4, 
df = 351, p<0.00). The data had a high level of internal consistency, as determined by a 
Cronbach's alpha of 0.821. 
Examination of the output showed that the removal of 3 items would result in an 
increase in Cronbach’s alpha: 3.2 - Observed Blunted affect, 7.1 – Mania and 7.6 – 
Obsessive Compulsive symptoms. These three also had low Corrected Item-Total 
Correlation, which would indicate they may need to be removed. The results are shown 
in the table 4 below. 
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Table 4: Internal Consistency Statistics for all CAARMS Items 




















Unusual thought content and 
non-bizarre ideas 
40.33 253.173 0.270 0.196 0.818 
1.2 Perceptual abnormalities 40.17 250.388 0.258 0.171 0.820 
1.3 Disorganized speech 41.41 253.696 0.272 0.290 0.818 
2.1 Subjective cognitive change 40.75 245.506 0.544 0.381 0.808 




41.10 242.264 0.503 0.349 0.808 
3.2 Observed blunted affect 42.66 264.900 0.103 0.230 **0.822 
3.3 Observed inappropriate affect 42.11 260.206 0.178 0.296 0.821 
4.1 Alogia 41.76 248.642 0.465 0.367 0.811 
4.2 Avolition/apathy 40.30 238.378 0.570 0.523 0.805 
4.3 Anhedonia 40.41 232.992 0.584 0.627 0.803 
5.1 Social isolation 40.64 237.456 0.555 0.449 0.805 








40.88 246.034 0.385 0.347 0.813 
6.1 
Subjective complaints of 
impaired motor functioning 
42.48 259.139 0.293 0.235 0.817 
6.2 
Informant reported or observed 
changes in motor functioning 
42.87 264.930 0.219 0.278 0.820 
6.3 
Subjective complaints of 
impaired bodily sensation 
42.35 258.669 0.202 0.182 0.820 
6.4 
Subjective complaints of 
impaired autonomic functioning 
42.14 254.657 0.277 0.184 0.818 
7.1 Mania 42.31 264.465 0.059 0.188 **0.825 
7.2 Depression 40.00 242.550 0.538 0.583 0.807 
7.3 Suicidality and self-harm 41.31 246.226 0.396 0.369 0.813 
7.4 Mood swings/lability 41.57 250.367 0.331 0.299 0.816 




41.80 257.587 0.162 0.160 **0.823 
7.7 Dissociative symptoms 41.93 255.318 0.224 0.164 0.820 
7.8 
Impaired tolerance to normal 
stress 
41.09 241.493 0.432 0.285 0.811 




Exploratory factor analysis was then conducted using Principal Axis Factoring (PAF) and 
promax rotation was applied to allow for correlation between the latent constructs. 
Initial EFA based on Eigen values showed 7 factors, accounting for 49% of the variance, 
however the scree plot (shown below in figure 3) indicated a clear break at 5 factors.  
 
Figure 3: Scree plot of Principle Axis Factoring of all CAARMS Items with Promax Rotation based on Eigen Values 
 
The communality for a given variable can be interpreted as the proportion of variation 
in that variable explained by the factors. A low communality of below 0.3 indicates that 
the item does not share any common variance and should not be included in the 
analysis. Communalities (shown in table 5 below) of three items (1.1 – Unusual Thought 
Content and Bizarre Ideas, 1.2 – Perceptual Abnormalities and 7.7 – Dissociative 
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Symptoms) were under the recommended value of 0.3 (Child, 1990), and were 
therefore excluded from the factor analysis. 
 
 
Table 5: Communalities of all CAARMS Items 
CAARMS group Number CAARMS Item Extraction 
1. Positive 
Symptoms 
1.1 Unusual thought content and non-bizarre ideas **0.247 
1.2 perceptual abnormalities **0.262 
1.3 Disorganized speech 0.512 
2. Cognitive 
Change 
2.1 Subjective cognitive change 0.546 
2.2 Observed cognitive change 0.309 
3. Emotional 
Disturbance 
3.1 Subjective emotional disturbance 0.475 
3.2 Observed blunter affect 0.511 
3.3 Observed inappropriate affect 0.316 
4. Negative 
Symptoms 
4.1 Alogia 0.601 
4.2 Avolition/apathy 0.663 
4.3 Anhedonia 0.814 
5. Behavioural 
Change 
5.1 Social isolation 0.517 
5.2 Impaired role function 0.450 
5.3 Disorganizing/odd/stigmatising behaviour 0.360 








Informant reported or observed changes in motor 
functioning 
0.509 
6.3 Subjective complaints of impaired bodily sensation 0.689 
6.4 





7.1 Mania 0.369 
7.2 Depression 0.762 
7.3 Suicidality and self-harm 0.494 
7.4 Mood swings/lability 0.430 
7.5 Anxiety 0.525 
7.6 Obsessive compulsive symptoms 0.358 
7.7 Dissociative symptoms **0.299 
7.8 Impaired tolerance to normal stress 0.423 




A further two items were subsequently eliminated (6.3 – Subjective Complaints of Bodily 
Sensation and 6.4 - Subjective complaints of impaired autonomic functioning) as they 
did not contribute to a simple factor structure and failed to meet a minimum criteria of 
having a primary factor loading of 0.4 or above, and no cross-loading of 0.3 or above.  
Principle Axis Factor Analysis of the remaining 19 items revealed a 5-factor structure, 
accounting for 40% of the variance. Factor loadings are shown in table 6, cross loadings 
greater than 0.3 are shown and a graphic representation of this factor structure for 




Table 6: Factor Loadings based on a Principle Axis Factoring with Promax rotation of 19 CAARMS Items 
CAARMS Item Factor 
4.3 ANHEDONIA 0.971     
4.2 AVOLITION/APATHY 0.819     
7.2 DEPRESSION 0.676     
3.1 SUBJECTIVE EMOTIONAL DISTURBANCE 0.496     
5.3 DISORGANISING/ODD/STIGMATISING 
BEHAVIOUR 
 0.765    
6.2 INFORMANT REPORTED OR OBSERVED 
CHANGES IN MOTOR FUNCTIONING 
 0.446    
6.1 SUBJECTIVE COMPLAINTS OF IMPAIRED 
MOTOR FUNCTIONING 
 0.406    
3.3 OBSERVED INAPPROPRIATE AFFECT  0.404    
1.3 DISORGANISED SPEECH   0.682   
4.1 ALOGIA   0.595   
2.2 OBSERVED COGNITIVE CHANGE   0.426   
2.1 SUBJECTIVE COGNITIVE CHANGE   0.405   
7.5 ANXIETY    0.620  
5.1 SOCIAL ISOLATION    0.478  
7.8 IMPAIRED TOLERANCE TO NORMAL STRESS    0.424  
5.2 IMPAIRED ROLE FUNCTION 0.338   0.407  
7.4 MOOD SWINGS/LABILITY     0.617 
5.4 AGGRESSION/DANGEROUS BEHAVIOUR     0.432 

















Impaired Motor Function - Observed





Cognitive Change - Observed
Cognitive Change - Subjective
Anxiety








Suicidality and Self Harm
63 
 
The Excluded Items were: 
• 1.1 UNUSUAL THOUGHT CONTENT AND NON BIZARRE IDEAS 
• 1.2 PERCEPTUAL ABNORMALITIES  
• 3.2 OBSERVED BLUNTER AFFECT  
• 6.3 SUBJECTIVE COMPLAINTS OF IMPAIRED BODILY SENSATION 
• 6.4 SUBJECTIVE COMPLAINTS OF IMPAIRED AUTONOMIC FUNCTIONING 
• 7.1 MANIA 
• 7.6 OCD SYMPTOMS  
• 7.7 DISSOCIATIVE SYMPTOMS  
 
2.3.5 Descriptive Statistics of Factor Scores 
 
Items loading on the Negative factor were reported most frequently (97% of cases), 
whereas items loading on the Disorganised - Behavioural factor were reported the least 
(46% of cases). Composite scores were then created for each of the five factors, based 
on the mean of the items which had their primary loadings on each factor. Negative and 
Anxiety factors had the highest severity ratings and skewness and kurtosis were within 
the range for assuming normal distribution for Negative, Affective Instability, Anxiety 
and Disorganised - Cognitive factors, (descriptive statistics are shown in table 7 below). 
However, the Disorganised - Behavioural factor was positively skewed.  Histograms are 
shown in Appendix 3.  
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As expected, all factors were highly correlated, with the exception of the Affective 






Table 7: Descriptive Statistics of Composite Factor Scores 
Factor 




Percentage of Cases Reporting 






Negative 0.000 5.500 2.536 1.254 -0.130 0.114 -0.744 0.227 97% 
Disorganised - 
Behavioural 
0.000 4.000 0.380 0.559 2.107 0.114 6.250 0.227 46% 
Disorganised - 
Cognitive 
0.000 4.000 1.438 0.862 0.156 0.114 -0.735 0.227 92% 
Anxiety 0.000 5.250 2.394 1.221 -0.182 0.114 -0.742 0.227 95% 
Affective 
Instability 



















1.000     
Sig. (2-
tailed) 





.191** 1.000    
Sig. (2-
tailed) 





.342** .335** 1.000   
Sig. (2-
tailed) 




.585** .259** .340** 1.000  
Sig. (2-
tailed) 





.463** 0.089 .249** .394** 1.000 
Sig. (2-
tailed) 





2.3.6 Confirmatory Factor Analysis 
 
Confirmatory Factor Analysis (CFA) was then conducted on the other (Non-UK) half of 
the data, using AMOS (version 23) to measure the goodness-of-fit of the alternative 
models.  
The indices used to determine goodness of fit were χ², Comparative Fit Index (CFI), 
Tucker-Lewis Index (TLI), Standardised Root Mean Square Residual (SRMR) and the Root 
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Mean Square Error of Approximation (RMSEA). χ² should be close to 2, where 0 is a 
perfect fit, CFI and TLI should be above 0.90, where 1 is a perfect fit, SRMR should be 
below 0.08 and the RMSEA should be below 0.06 where 0 is a perfect fit (Schreiber et 
al., 2006). 
The input matrix used was a variance-covariance matrix and maximum likelihood 
estimation method was chosen to calculate the fit indices, because this method is 
relatively insensitive to sample size, non-normality and model size. 
 
The models tested were: 
1. One factor model of all CAARMS Items (CAARMS1) 
2. Three factor model from Raballo (2011) (Raballo3) 
3. Five Factor Model from Demjaha et al. (2010) (Demjaha5) 
4. Five factor model found through EFA of UK data from this study (CAARMS5) 
5. Seven factor model of CAARMS categories (CAARMS7) 



























The Goodness of Fit indices are shown below in table 9 for comparison. 
Table 9: Comparative Goodness of Fit Indices for the 5 models tested using Confirmatory Factor Analysis 
Model χ² df 
χ²/df 
Cut off <2 
CFI  
Cut off >0.95 
TLI 
Cut off >0.95 
SRMR 
Cut off <0.08 
RMSEA 
Cut off <0.06 
CAARMS 1 919 324 2.838 0.483 0.440 0.103 0.091 
Raballo 3 924 296 3.122 0.660 0.627 0.094 0.095 
Demjaha 5 921 142 6.483 0.759 0.710 0.961 0.088 
CAARMS 5 187 142 **1.317 **0.95 0.928 **0.065 **0.052 
CAARMS 7 719 303 2.372 0.639 0.582 0.098 0.078 
** indicates value meets cut off point 
 
As can be seen in the table above, the 5 factor model found in the UK dataset met the 
criteria for goodness of fit for the Non-UK dataset for four of the six measures. 
 
2.4 Discussion 
2.4.1 Aims and results of the Study 
The aim of this study was to investigate symptom dimensions in a large dataset 
collected from individuals who presented to clinical Ultra High Risk services, and then 
compare the fit of these dimensions with those previously identified in other datasets 
involving this population in a second dataset.  
Exploratory Factor Analysis (EFA) of the UK data revealed a five factor structure, 
consisting of Negative, Disorganised - Behavioural, Disorganised - Cognitive, Anxiety and 
Affective Instability dimensions, each comprising three or more CAARMS items. There 
was good internal consistency, and this structure accounted for 40% of the total 
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variance. Confirmatory Factor Analysis (CFA) using the non-UK data to compare five 
theoretical structures (two described in the literature, one identified through EFA, and 
two using the CAARMS items as they are set out in the assessment instrument) showed 
that the five factor structure from the UK provided the best fit for the data, with 
goodness of fit indices CFI, SRMR, RMSEA, and χ²/df meeting the generally used cut off 
points recommended by Hu and Bentler (1999). Although the TLI of 0.932 did not meet 
the 0.95 cut off point and chi squared was not significant: χ²(142) = 184, p=0.000, many 
investigators have argued against the use of chi-square as a test of goodness of fit, due 
to its dependency on sample size (Marsh et al., 1988), model size (Schreiber et al., 2006) 
and distribution of variables (Curran et al., 1996), and it has been suggested that a 
significant chi-square value is not an indication of poor fit  (Schermelleh-Engel et al., 
2003). 
An important characteristic of any dimensional structure is that it must have face 
validity. Each of the factors in the structure that I have identified consists of 
psychopathological items that would be expected to cluster together, and each of the 
dimensions corresponds to a type of symptom that is prominent in UHR subjects. The 
structure is also in keeping with the factor structures that have previously been 
described in UHR subjects (Demjaha et al. (2010), and in first episode psychosis (Good et 
al., 2004; Peralta & Cuesta, 1999) and chronic schizophrenia (Dikeos et al., 2006; Drake 
et al., 2004; Lindenmayer et al., 1995a).  
There was a predominant negative factor, which accounted for more variance than the 
other four factors combined. This finding is similar to that reported for the negative 
dimension described in both chronic and first episode studies (Fernández et al., 2006; 
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Liddle, 1987; Van Os et al., 2009). It has also been evident in UHR subjects, regardless of 
whether symptoms were assessed using the Scale of Prodromal Symptoms - SOPS 
(Fernández et al., 2006; Hawkins et al., 2004) or the CAARMS (Demjaha et al., 2010; 
Raballo, 2011), and irrespective of the particular factor structure found. 
 
 
2.4.2 Comparison with Previous Studies  
 
A five dimensional structure has been found in many other studies, in patients with 
psychosis (Dikeos et al., 2006; Drake et al., 2004; Good et al., 2004; Lindenmayer et al., 
1995a; Lindenmayer et al., 1995b; Peralta & Cuesta, 1999) and in subjects at UHR for 
psychosis (Demjaha et al. (2010). The five factor structure identified in the present study 
does not exactly replicate Demjaha’s, as demonstrated in the poor goodness of fit 
indices for that structure in the CFA. Nevertheless, three of the five factors comprised 
similar items: in both models, the Negative factor included Avolition, Anhedonia and 
Depression, the Disorganised factor included Observed Cognitive Change, Subjective 
Cognitive Change and Disorganised Speech, and the Anxiety factor included Anxiety and 
Impaired Tolerance to Normal Stress. There was also some consistency between the 
structure found here and the three factor Model described by Raballo et al (2011): 
again, in both models the Negative factor included Avolition, Anhedonia and 
Depression, and the Affective Instability factor included Mood Swings, Aggression and 
Suicidality. In addition, all items loading on the Disorganised - Behavioural and 
Disorganised - Cognitive factor in the present dataset were combined into one factor 




Table 10: Comparison of Current and Previous CAARMS Models 
Demjaha  CAARMS 5  Raballo 
Negative  Negative  Negative 
4.3 ANHEDONIA   4.3 ANHEDONIA   4.3 ANHEDONIA  
4.2 AVOLITION/APATHY   4.2 AVOLITION/APATHY   4.2 AVOLITION/APATHY  
7.2 DEPRESSION   7.2 DEPRESSION   7.2 DEPRESSION  
3.2 OBSERVED BLUNTER AFFECT   3.1 SUBJECTIVE EMOTIONAL DISTURBANCE   5.2 IMPAIRED ROLE FUNCTION  
5.2 IMPAIRED ROLE FUNCTION     7.8 IMPAIRED TOLERANCE TO NORMAL STRESS 
5.1 SOCIAL ISOLATION     5.1 SOCIAL ISOLATION  
5.3 DISORGANISING/ODD BEHAVIOUR     7.5 ANXIETY  
    6.4 SUBJECTIVE AUTONOMIC FUNCTIONING 
Disorganised  Disorganised - Cognitive  Disorganised 
1.3 DISORGANISED SPEECH   1.3 DISORGANISED SPEECH   1.3 DISORGANISED SPEECH  
2.2 OBSERVED COGNITIVE CHANGE   2.2 OBSERVED COGNITIVE CHANGE   2.2 OBSERVED COGNITIVE CHANGE  
2.1 SUBJECTIVE COGNITIVE CHANGE  2.1 SUBJECTIVE COGNITIVE CHANGE  2.1 SUBJECTIVE COGNITIVE CHANGE 
  4.1 ALOGIA   4.1 ALOGIA  
    7.1 MANIA  
Self-Harm  Disorganised – Behavioural  7.7 DISSOCIATIVE SYMPTOMS 
7.3 SUICIDALITY AND SELF HARM   5.3 DISORGANISING/ODD BEHAVIOUR   5.3 DISORGANISING/ODD BEHAVIOUR  
3.1 SUBJECTIVE EMOTIONAL DISTURBANCE   
6.2 INFORMANT REPORTED OR OBSERVED 
CHANGES IN MOTOR FUNCTIONING  
6.2 INFORMANT REPORTED OR OBSERVED 
CHANGES IN MOTOR FUNCTIONING 
  
6.1 SUBJECTIVE COMPLAINTS OF IMPAIRED 
MOTOR FUNCTIONING   
6.1 SUBJECTIVE COMPLAINTS OF IMPAIRED 
MOTOR FUNCTIONING  
  3.3 OBSERVED INAPPROPRIATE AFFECT   3.3 OBSERVED INAPPROPRIATE AFFECT  
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Demjaha  CAARMS 5  Raballo 
     
    3.2 OBSERVED BLUNTER AFFECT  
    3.1 SUBJECTIVE EMOTIONAL DISTURBANCE  
    
1.1 UNUSUAL THOUGHT CONTENT AND NON 
BIZARRE IDEAS 
Manic  Affective Instability  Positive 
7.1 MANIA   7.4 MOOD SWINGS/LABILITY   7.4 MOOD SWINGS/LABILITY  
6.1 SUBJECTIVE COMPLAINTS OF IMPAIRED 
MOTOR FUNCTIONING   5.4 AGGRESSION/DANGEROUS BEHAVIOUR   5.4 AGGRESSION/DANGEROUS BEHAVIOUR  
  7.3 SUICIDALITY AND SELF HARM   7.3 SUICIDALITY AND SELF HARM  
    
6.3 SUBJECTIVE COMPLAINTS OF IMPAIRED 
BODILY SENSATION 
    1.2 PERCEPTUAL ABNORMALITIES  
Anxiety  Anxiety   
7.5 ANXIETY   7.5 ANXIETY    
7.8 IMPAIRED TOLERANCE TO NORMAL STRESS  7.8 IMPAIRED TOLERANCE TO NORMAL STRESS   
7.4 MOOD SWINGS/LABILITY   5.1 SOCIAL ISOLATION    
4.1 ALOGIA   5.2 IMPAIRED ROLE FUNCTION    
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Demjaha  CAARMS 5  Raballo 
EXCLUDED:  EXCLUDED:  EXCLUDED: 
7.6 OCD SYMPTOMS   7.6 OCD SYMPTOMS   7.6 OCD SYMPTOMS  
1.1 UNUSUAL THOUGHT CONTENT AND NON 
BIZARRE IDEAS  
1.1 UNUSUAL THOUGHT CONTENT AND NON 
BIZARRE IDEAS   
1.2 PERCEPTUAL ABNORMALITIES   1.2 PERCEPTUAL ABNORMALITIES    
6.3 SUBJECTIVE COMPLAINTS OF IMPAIRED 
BODILY SENSATION  
6.3 SUBJECTIVE COMPLAINTS OF IMPAIRED 
BODILY SENSATION   
7.7 DISSOCIATIVE SYMPTOMS   7.7 DISSOCIATIVE SYMPTOMS    
5.4 AGGRESSION/DANGEROUS BEHAVIOUR   3.2 OBSERVED BLUNTER AFFECT   
3.3 OBSERVED INAPPROPRIATE AFFECT   7.1 MANIA   
6.2 INFORMANT REPORTED OR OBSERVED 
CHANGES IN MOTOR FUNCTIONING  
6.4 SUBJECTIVE COMPLAINTS OF IMPAIRED 
AUTONOMIC FUNCTIONING   
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The most notable similarity across all of the three CAARMS models, and the SOPS 
(Fernández et al., 2006; Hawkins et al., 2004) model, is that a negative factor was 
predominant. In all of these models, this factor accounted for the most variance, 
consistent with findings in first episode and chronic patients (Dikeos et al., 2006; 
Liddle, 1987; Lindenmayer et al., 1995a). This is also the case with the 
Disorganised factor, which, although it accounts for less variance, is consistently 
reported across all UHR models. 
 
A notable difference between this and other models is the absence of a positive 
psychotic factor. Hawkins et al. (2004) described an “unusual thought content-
perceptual abnormalities” factor in a study of SOPS data from 94 UHR subjects, 
while Fernández et al. (2006) found an “unusual thought content-suspiciousness” 
factor in 30 patients. In the present study, Perceptual Abnormalities and Unusual 
Thought Content were excluded from the EFA because of low Communalities. This 
is in keeping with the Demjaha et al. (2010), who also failed to identify a positive 
symptom dimension, suggesting that this may be due to differences between the 
CAARMS and SOPS scales. Five of 19 SOPS items, as opposed to 3 of 27 CAARMS 
items relate to positive symptoms. Furthermore, with the CAARMS, inclusion as an 
UHR subject (via the Attenuated Psychotic Symptoms criteria) requires a score of 3 
or more on one of the positive symptom items.  In the UK, the majority of UHR 
subjects meet the Attenuated Symptoms criteria (86%) and have relatively high 
positive symptom scores. As a result, the variance associated with these items 
within the UHR sample may have been too small to allow clear distinction of a 




2.4.3 Limitations  
The present study used a similar sampling method to both those by Demjaha et al. 
(2010) and Raballo (2011), with recruitment of UHR subjects who had been 
referred to a specialised mental health service from defined local catchment area 
populations. The UK data set used in the EFA had exactly the same referral and 
recruitment pathway as in the study by Demjaha et al. (2010), and a proportion of 
the Non-UK sample (6.4%) used the same referral and recruitment pathway as 
Raballo (2011). However, despite these similarities there may still be sampling 
inconsistencies. Although the appropriate statistical tests were performed to 
ensure the statistical validity of combining the datasets, the UK sample was a 
combination of data collected from two different studies, over a period of 6 years. 
This was also the case with the non-UK data, with all the data collected as part of 
one overarching study over 5 years, but at different sites and by different 
researchers. 
The sample size was over double that in any previous study of symptom 
dimensions in UHR subjects  (94 (Hawkins et al., 2004), 30 (Lemos et al., 2006), 
122 (Demjaha et al., 2010), 223 (Raballo et al., 2011) and 461 in this study), and 
met minimum sample size requirements in statistical terms (MacCallum et al., 
1999). Nevertheless, ideally factor analyses require even larger datasets, and there 
is good evidence that the goodness of fit indices in CFA depend on the sample size 
(Marsh et al., 1988). Unlike many test statistics, the goodness of fit indices used in 
CFA do not have corresponding p-values, but use a set cut-off point to determine 
acceptance of the model. This cut-off point for relative fit indices has been 
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disputed and was previously 0.9, but Hu and Bentler (1999) have recommended a 
more stringent cut-off point of 0.95. Although this value is still widely used,  an 
even more stringent cut-off of 0.97 has been proposed (Schermelleh-Engel et al., 
2003), and some investigators have suggested that cut-offs should be abandoned 
altogether (Barrett, 2007). There have also been debates about the usefulness of 
the chi-square statistic, due to the limitations listed above, and there is 
disagreement as to whether, as suggested by Schermelleh-Engel et al. (2003), it is 
valid to accept a model despite a significant result (Barrett, 2007).  
In the present study, discrepancies in agreement over model fit indices have been 
addressed by including a range of statistics that have been shown to perform well 
with respect to sample size and model mis-specification, and that are appropriate 
for the sample size and type of data used here. Nevertheless, the inadequacy of 
these indices remains a topic of debate (Lance et al., 2016; Markland, 2007; Marsh 
et al., 2004). 
In spite of these limitations, the data indicate that the symptoms of the UHR state 
load onto five different dimensions, corresponding to Negative, Disorganised, 
Cognitive, Anxiety and Mania symptoms. 
2.4.4 Future Research Directions 
Dimensions provide a useful means of characterising and understanding 
symptomatology in psychosis. However, in UHR subjects, baseline symptom 
dimensions may be of particular interest in relation to other clinical and biological 
measures, and to long term clinical outcomes. 
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The following chapters will look at how the five symptom dimensions found here 
relate to neurobiological correlates, to clinical variables in UHR subjects at 




3 Neurobiological Correlates of Symptom Dimensions 
3.1 Introduction 
3.1.1 Resting Cerebral Blood Flow (rCBF) 
Brain function relies on aerobic metabolism, for which a consistent oxygenated 
blood supply is essential. In response to neural activity nearby vessels dilate, 
substantially increasing CBF. The phenomenon that links neural activity to a 
proportionate increase in CBF is termed Neurovascular coupling (NVC). We can 
therefore measure regional cerebral blood flow (CBF) to provide a direct and 
quantitative measure of perfusion and an indirect measure of neural function 
through NVC (Huneau et al., 2015). CBF can therefore be used to examine the 
level and location of neural activity in the human brain in vivo (Phillips et al., 
2016).  
In the 1940’s, Kety et al. (1948) applied a nitrous oxide inhalation method to study 
CBF in 30 subjects with schizophrenia and 35 controls. Their study did not show a 
difference between patients and controls, or between patients split by acute and 
chronic presentation. However, they proposed that as their method obtains only a 
mean value for the whole brain, their finding does not rule out the possibility of 
regional changes. Kety proposed that as schizophrenia is characterized by specific 
symptoms, rather than a global impairment of function, abnormalities of perfusion 




Since the development and wide usage of the nitrous oxide technique in the 1950s 
and 1960s, several technical advances to measure CBF have been developed. 
These will be discussed in the following sections. 
3.1.2 Measuring Cerebral Blood Flow 
1. Positron Emission Tomography (PET) – PET is a versatile imaging modality 
that provides dynamic information regarding the metabolism and 
physiology of the brain. Intravenous injection of positron-emitting 
radionuclides allows a visualization of the blood flow in the brain and 
provides quantitative information regarding the function. Initial 
investigations in to CBF and symptoms in schizophrenia by P. F. Liddle et al. 
(1992) used PET to measure resting CBF and found distinct patterns of CBF 
according to symptom type. However, a consideration for PET imaging 
studies is that they involve the injection of radioactive tracers, and require 
a cyclotron to produce the tracer, making them expensive and logistically 
difficult.  
2. Single Photon Emission Computed Tomography (SPECT) – similarly to PET, 
SPECT produces tomographic images of the distribution of radioactivity in 
the body. The uptake within the brain remains constant for several hours 
and is proportional to the cerebral blood flow. Unlike PET, SPECT measures 
flow, but not regional metabolism. It produces non-quantitative results and 
the imaging resolution is not as high as that of PET. SPECT was used by 
many studies in the 1990’s to measure CBF in schizophrenia finding distinct 
patterns of CBF according to positive or negative symptom divisions 
(Erkwoh et al., 1999; Lewis et al., 1992; Min et al., 1999; Sabri et al., 1997). 
85 
 
However, again it relies on intravenous injection and radioactive 
production. 
3. Arterial spin labelling (ASL) - More recently, rCBF has been examined using 
perfusion MRI - a technique that allows for quantitative measurement of 
CBF by using magnetically labelled arterial blood water as an endogenous 
tracer (Detre et al., 1992). Despite the value of PET and SPECT in informing 
the neurobiology of schizophrenia, both are limited by invasiveness, 
reliance on radioactive tracer material, and expense. These limitations 
make PET and SPECT imaging difficult to implement in large-scale, multi-
site studies. In contrast, the non-invasive nature of ASL, conducted using 
an MRI scanner, allows for repeated measurements with limited 
discomfort to participants. ASL provides quantitative measurement of CBF 
which has been shown to be stable, reliable and similar to PET/SPECT 
(Chen et al., 2008; Gevers et al., 2009; Wang et al., 2011). 
3.1.3 Cerebral Blood Flow in Psychosis 
Finding a unifying concept to account for the diversity of psychopathology in 
schizophrenia is a central challenge to contemporary research. One area in which 
extensive research has been conducted is in examining underlying neurobiology. 
The heterogeneity in symptom presentation and the wide range of courses and 
outcomes in schizophrenia however, mean that the search for neural substrates 
has been a complex process.  
After Ingvar and Franzén (1974) first described abnormal blood flow in frontal and 
temporal regions in patients with schizophrenia compared to controls, decreased 
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CBF in frontal and temporal regions was reported in many studies using either PET 
or SPECT (Andreasen et al., 1992; Buchsbaum et al., 1982; Ebmeier et al., 1993; 
Erkwoh et al., 1999; Tamminga et al., 1992), and hypofrontality was considered a 
key pathophysiological finding in schizophrenia (Ebmeier et al., 1993). However, 
some subsequent findings were contradictory (Catafau et al., 1994; Cleghorn et al., 
1989; Volkow et al., 1987), leading to questions about the robustness of this 
finding (Gur & Gur, 1995). The inconsistency of this finding has been attributed to 
many factors including: duration of illness, medication status and methods of 
brain imaging.  
More recently, several studies have used ASL to examine CBF in schizophrenia. 
Horn et al. (2009) found no group differences in CBF between patients and healthy 
controls but found a positive correlation between severity of thought disorder and 
increased blood flow in left inferior frontal gyrus (pars orbitalis), left posterior 
superior temporal gyrus /angular gyrus and the left anterior insula. Scheef et al. 
(2010) found patients had areas of hypoperfusion in bilateral frontal and parietal 
lobes and middle and anterior cingulate gyrus, but hyperperfusion in cerebellum, 
brainstem, and thalamus compared to controls. Both of these studies were in 
small sample sizes (n=13 and n=11 respectively), however two more recent 
studies, in larger sample sizes found an overall pattern of prefrontal 
hypoperfusion and subcortical/temporal  hyperperfusion: Pinkham et al. (2011) 
found patients showed increased CBF in left putamen/superior corona radiata and 
right middle temporal gyrus in a sample of 40 patients, and Zhu et al. (2015) found 
increased CBF in the bilateral inferior temporal gyri, thalami and putamen and 
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decreased CBF in the left insula and middle frontal gyrus and the bilateral anterior 
cingulate cortices and middle occipital gyri in a sample of 100 subjects. Both of 
these studies also investigated the correlation of CBF with anti-psychotic 
medication finding a positive dose-dependent response in left putamen and right 
middle temporal gyrus (respectively). 
3.1.4 Cerebral Blood flow and Symptoms of Psychosis 
Through refining analyses to look at groups of presenting symptoms, rather than 
all symptoms combined under the diagnostic category of schizophrenia, 
researchers may be able to provide a heuristic theoretical framework to better 
explore aetiology and clinical course to inform intervention, or enable prevention. 
This concept was initially explored by P. F. Liddle et al. (1992), who argued that the 
clinical heterogeneity of schizophrenia is likely to reflect heterogeneity in the 
underlying neuropathology. Liddle had previously shown using PCA that the 
psychotic symptoms of schizophrenia loaded on to three different 
psychopathological dimensions (Liddle, 1987; Liddle & Barnes, 1990): 
1. ‘Positive’ (reality distortion, delusions and hallucinations) 
2. ‘Negative’ (poverty of speech, flatness of affect and decreased 
spontaneous movement) 
3. ‘Disorganised’ (disorders of the form of thought and inappropriate affect) 
Using Positron Emission Tomography (PET), Liddle and his colleagues examined 
regional Cerebral Blood Flow (CBF), and found that each symptom dimension was 
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associated with a particular topographical pattern of CBF, the results from this 













n x y z 
Right caudate 20 16 12 0.55   
Left caudate -22 10 4 0.52   
Left dorsolateral 
prefrontal cortex 




-50 -44 32 -0.52   
right anterior 
cingulate 
8 30 16  0.54  
Mediodorsal 
thalamus 
2 -20 4  0.43  
Right ventrolateral 
prefrontal cortex 
26 32 0  -0.46  
Right angular gyrus 42 -60 8  -0.48  




-12 -28 -4   0.46 
Left ventral striatum -16 4 -4   0.43 
Right posterior 
cingulate 
10 -58 28   -0.53 
 
 
Additionally, the brain regions associated with each dimension were consistent 
with those predicted on the basis of behavioural and neuropsychological features 
characteristic of each syndrome. For example, the negative syndrome was linked 
to hypoperfusion of the prefrontal cortex and striatum, as shown in table 11. 
Subsequent studies using PET and SPECT examining the correlates of symptom 
dimensions have further clarified the relationships between symptomatology and 
regional hyper- and hypoperfusion at rest: negative symptoms have been 
associated with reduced CBF in frontal (Erkwoh et al., 1999; Lewis et al., 1992; 
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Sabri et al., 1997), temporal (Esel et al., 2000; Sabri et al., 1997) and thalamic 
regions (Min et al., 1999; Sabri et al., 1997), and positive symptoms have been 
associated with increased CBF in temporal (Esel et al., 2000; Kohno et al., 2006; 
Mathew et al., 1988; Parellada et al., 1998), parietal (Erkwoh et al., 1999; Esel et 
al., 2000; Franck et al., 2002; Mathew et al., 1988) and frontal regions (Erkwoh et 
al., 1999), and decreased CBF in posterior cingulate gyrus and lingual gyrus (Franck 
et al., 2002; Sabri et al., 1997). Notably, when scans were carried out on 
participants in both florid and remitted states, Erkwoh et al. (1999) and Sabri et al. 
(1997) both found correlations with increased CBF present in a florid state were 
no longer present after remission or neuroleptic treatment. 
All the studies mentioned above used PET/SPECT. The only study to date to use 
ASL to examine CBF using a dimensional approach was by Pinkham et al. (2011), 
who used ASL to distinguish differences in CBF associated with positive and 
negative symptoms. Severity of negative symptoms was associated with reduced 
CBF in bilateral superior temporal gyrus, cingulate gyrus, and left middle frontal 
gyrus, while severity of positive symptoms was related to both higher CBF in 
cingulate gyrus and superior frontal gyrus and decreased CBF in precentral 
gyrus/middle frontal gyrus.  
Understanding the pathophysiology of different symptoms may provide a rational 
basis for the development of novel treatments for specific psychotic symptoms. 
This is particularly relevant for negative symptoms, for which there are still no 
effective treatments (Fusar-Poli et al., 2015) 
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3.1.5 Neurobiological Characteristics of UHR  
Young adults at increased risk of developing psychotic disorders can be identified 
using standardized psychometric instruments such as the CAARMS with consistent 
reliability and good predictive value (P Fusar-Poli et al., 2016b). However, there is 
a particularly wide range of symptoms and presentations in people at Ultra High 
Risk (UHR) for psychosis, and the population is also markedly heterogeneous in 
terms of clinical outcome, with some individuals making a complete recovery, 
others having persistent symptoms, and another subgroup developing a psychotic 
disorder (P. Fusar-Poli et al., 2016). 
Recently preclinical models have been used to help understand the 
neurobiological mechanisms underlying the onset of psychosis. The 
methylazoxymethanol acetate (MAM) Model posits a key role for the 
hippocampal-midbrain-striatal circuit, and suggests that prior to onset of 
psychosis, hippocampal activity is elevated (Lodge & Grace, 2011). In keeping with 
this, recent neuroimaging studies in UHR subjects have shown both reduced 
hippocampal volume and increased hippocampal perfusion relative to controls 
(Allen et al., 2016; Mechelli et al., 2011; Schobel et al., 2009).  
The MAM model suggests that psychotic symptoms are generated when 
hippocampal hyperactivity drives hyperactivity in subcortical regions involved in 
dopamine signalling. Changes in hippocampal anatomy and function have been a 
consistent biological finding in schizophrenia (Heckers, 2001; Preston et al., 2005; 
Tamminga et al., 2010). 
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Allen et al. (2015) found evidence of resting state hyperperfusion in the 
hippocampus, midbrain, and basal ganglia of UHR subjects at clinical presentation; 
moreover, this hyperperfusion subsequently reduced as the presenting symptoms 
resolved. In particular, there was a longitudinal reduction in rCBF in the 
hippocampus and ventral striatum in the subgroup of UHR subjects who showed 
symptomatic improvement. Similarly, subjects whose symptoms had resolved to 
the extent that they no longer met UHR criteria showed a reduction in left 
hippocampal rCBF, whereas those who still met UHR criteria after 18 months or 
who had become psychotic did not. 
These findings are in line with data from a study that measured perfusion with 
steady-state gadolinium-enhanced fMRI (Schobel et al. (2009). Taken together, 
these findings support the notion that increased resting hippocampal perfusion is 
a feature of the UHR state, and is related to the severity of attenuated psychotic 
symptoms.  
3.1.6 Neurobiology of symptoms in UHR 
Relatively few neuroimaging studies have investigated the neural correlates of 
symptoms in UHR subjects. 
Using MRI, Smieskova et al. (2012) investigated the relationship between grey 
matter volume and clinical presentation in the UHR state. They reported that 
alterations in the volume of the insula were associated with negative symptoms 
and hallucinations. However, this study looked only at symptoms grouped in to 
positive and negative categories.  
93 
 
Two studies have looked at total CAARMS score: In a study using F-DOPA PET, 
Howes et al. (2009) reported that the severity of symptoms in UHR subjects, as 
indexed by the total CAARMS score, was correlated with the level of striatal 
dopamine function. However there were no correlations with specific types of 
symptom, and the finding was not replicated in a subsequent study (Egerton et al., 
2013). 
To my knowledge, there has yet to be an investigation of the neural correlates of 
symptom dimensions in UHR subjects. 
3.1.7 Review of Findings for Each Dimension 
The work described in this chapter aimed to investigate the neurobiological 
correlates of the five psychopathological dimensions in UHR state stablished in the 
previous chapter. I thus planned to examine the relationship between scores on 
the Negative, Disorganised – Behavioural, Disorganised -Cognitive, Affective 
Instability and Anxiety dimensions and resting CBF, measured using ASL. 
Negative symptoms in schizophrenia have been shown using PET and SPECT to be 
associated with decreased resting perfusion in frontal (Erkwoh et al., 1999; Lewis 
et al., 1992; Sabri et al., 1997), temporal (Esel et al., 2000; Sabri et al., 1997) and 
thalamic regions (Min et al., 1999; Sabri et al., 1997). Using PET, P. F. Liddle et al. 
(1992) found associations between a negative symptom dimension with resting 
blood flow in the right and left caudate, left dorsolateral prefrontal cortex and left 
superior parietal cortex. More recently, using ASL, a negative symptom dimension 
in schizophrenia was associated with reduced CBF in the superior temporal and 
cingulate gyri bilaterally, and in the left middle frontal gyrus (Pinkham et al. 
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(2011). A number of MRI studies have also linked negative symptoms to 
reductions in grey matter volume in prefrontal cortex (Chua & Murray, 1996). 
Liddle et al (1992) also found that loadings on a Disorganised symptom dimension 
were associated with increased rCBF in the right anterior cingulate cortex, and 
decreases in the right ventral prefrontal cortex and insula, and in the parietal 
cortex. While two studies specifically examining cognitive disorganisation have 
also found patterns of both increased and decreased perfusion: McGuire et al. 
(1998) found that verbal disorganisation (positive thought disorder) was inversely 
correlated with activity in the inferior frontal, cingulate and left superior temporal 
cortex, and positively correlated with activity in the parahippocampal/anterior 
fusiform region bilaterally, and in the body of the right caudate, Kircher et al. 
(2001) found that patients showed less activation in the right superior temporal 
gyrus than controls, but greater activation in the left inferior frontal, inferior 
temporal and fusiform gyri. 
When compared to healthy volunteers, UHR subjects were reported by Allen et al. 
(2016) to show elevated rCBF in the hippocampus, basal ganglia, and midbrain. 
Symptomatic improvement at follow-up was associated with reduced rCBF in the 
hippocampus and ventral striatum.  
The CAARMS measures not only attenuated psychotic symptoms, but also anxiety 
and mood symptoms. In schizophrenia, comorbid anxiety disorders have been 
shown to occur in up to 38% of cases (Braga et al., 2013) and presence and 
severity of symptoms of anxiety were found to be associated with more severe 
clinical features and poorer outcomes. 
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The amygdala has been shown to exhibit increased resting CBF in imaging studies 
of subjects with anxiety disorders (Rauch et al., 2003) and altered activity in the 
prefrontal cortex is also widely reported in anxiety disorders (Sylvester et al., 
2012). Activity in these regions is also known to be robustly altered in people with 
schizophrenia (Minzenberg et al., 2009; Tseng et al., 2016), who also demonstrate 
wide-ranging impairments in emotional functioning (Livingstone et al., 2009). A 
meta-analysis by A. Etkin and Wager (2007) found that patients with a range of 
anxiety disorders consistently showed greater activity than matched comparison 
subjects in the amygdala and insula. Thus we predicted that the anxiety factor will 
be associated with altered rCBF in both amygdala and Insula. 
The relationship between Affective Instability symptoms and rCBF has been 
investigated using SPECT in bipolar disorder finding that patients with mania had 
significantly reduced perfusion mainly in the left frontal area, also in the left 
anterior cingulate and parietal cortices (Bhardwaj et al., 2010). The anterior 
cingulate cortex is a key neural region implicated in mood regulation and 
processing of negative self-referential information (Price & Drevets, 2010), so this 
may be reflected in a correlation with Affective Instability symptoms. 
3.1.8 Aims and Objectives of this Study 
Previous neuroimaging findings in schizophrenia (described above), suggest that 
the negative and disorganised symptom dimensions may be associated with 
specific regional patterns of resting rCBF in UHR. A previous ASL study in UHR 
subjects suggests that total CAARMS severity is associated with increased 
perfusion in the hippocampus, basal ganglia and midbrain. On the other hand, the 
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deficits evident in both schizophrenia and anxiety disorders, suggest that altered 
perfusion in the insula and amygdala may correlate with anxiety symptoms in UHR 
states. Few studies have examined the neural correlates of Affective Instability 
symptoms or mania, but Affective Instability symptoms have been shown to be 
associated with perfusion in the anterior cingulate cortex in patients with bipolar 
disorder. 
Therefore a priori hypotheses about the neural correlates of the five UHR 
dimensions and the total CAARMS score are proposed here.  The analyses used a 
Regions of Interest (ROI) approach. ROIs were selected on the basis of previous 
findings, however as these symptoms have not previously been investigated in 
relation to CBF in UHR, I tested the following non directional hypotheses using this 
approach: 
1. The Negative factor will be associated with the level of perfusion in the 
dorsolateral prefrontal cortex, dorsal anterior cingulate gyrus and striatum 
(P. F. Liddle et al. (1992) 
2. The Disorganised-behavioural and Disorganised-cognitive factors will be 
associated with the level of perfusion in the anterior cingulate, ventral 
prefrontal and parietal cortex (Pinkham et al. (2011). 
3. The anxiety factor will be associated with the level of perfusion in the 
amygdala and insula (A. Etkin & Wager, 2007) 
4. The Affective Instability dimension will be associated with the level of 
perfusion in the basal ganglia, medial frontal gyrus and inferior frontal 
gyrus (Bhardwaj et al., 2010) 
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5. The Total CAARMS score will be associated with the level of perfusion in 
hippocampus, striatum and midbrain (Allen et al. (2016) 
Whole brain analyses will also be conducted to determine if there are associations 




The sample comprised a subset of the UHR sample studied in Chapter 2. There 
were 70 individuals meeting the PACE criteria for Ultra High Risk for Psychosis 
(UHR), aged 18-35 recruited through a Wellcome Trust funded programme at 
King’s College London (collected by the author). All subjects were recruited 
through clinical early detection services at three sites:  
• OASIS (Outreach and Support in South London), part of the South London 
and Maudsley NHS Trust, (n=47) 
• West London Early Intervention Service, part of the West London Mental 
Health NHS trust (n=7) 
• CAMEO, part of the Cambridge and Peterborough NHS trust (n=23) 
The study had National Research Ethics Service (NRES) approval and all 
participants gave written informed consent to participate. 
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3.2.2 Eligibility Criteria 
Participants were recruited from specialist early intervention services and 
assessed by trained researchers. According to the PACE criteria, an individual can 
be classed as UHR if they meet the threshold for one or more of the following 
subcategories: 
Group 1: Attenuated Psychotic Symptoms (APS) sub-threshold in frequency or 
intensity 
Group 2: Brief Limited Intermittent Psychotic Symptoms (BLIPS) that resolved 
within a week without use of anti-psychotic medication 
Group 3: Genetic risk combined with a significant recent decline in functioning. 
(The decline in functioning was only an inclusion criterion in the Genetic Risk 
group) 
Inclusion required that participants: 
➢ Met UHR criteria  
➢ Were aged 18 - 35 
 
The exclusion criteria were: 
➢ Neurological or medical illness or head injury 
➢ Meeting DSM-IV criteria for drug/alcohol abuse or dependency 
➢ Pregnancy 
➢ Treatment with antipsychotic medication for a week or more 
➢ Claustrophobia (preventing the subject from completing the scan) 
➢ Metallic tattoos  
➢ Cardiac pacemaker 
➢ Implanted catheter, clamp, clips, valves, or other metal 
➢ Insulin or infusion pump 
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3.2.3 Measures  
UHR status was determined using the Comprehensive Assessment of At Risk 
Mental State (CAARMS). This is described in detail in section 2.2.3. 
Severity and Frequency are scored on a scale of 0-6, and distress is scored as a 
subject reported percentage. As in previous studies, the Severity score was used 
to calculate total and dimension scores. 
Intake group was defined using CAARMS criteria. Sub-threshold intensity 
Attenuated Psychotic Symptoms are classified as a severity score of 3-5 and 
frequency score of 3-6 on any of the items in the Positive scale; Sub-threshold 
frequency Attenuated Psychotic Symptoms are classified as a frequency score of 3 
and a severity score of 6 on any of the items in the Positive scale. Brief Limited 
Intermittent Psychotic Symptoms (BLIPS) are defined as a severity score of 6, with 
frequency greater than 4 on any of the items in the Positive scale, but each 
symptom is present for less than one week, with spontaneous remission.  
The CAARMS was implemented by a trained researcher. Inter-rater reliability was 
ensured via online training tools for the CAARMS incorporating inter-rater 
reliability standard requirement for completion of the training. Language 
inconsistencies for centres not conducting assessments in English was address 
through back translation. 
Symptom Dimensions were determined using factor analysis described in the 
previous chapter. Unit weighted composite scores for each dimension were 
calculated as a mean score of all the items loading on the respective factor. A 
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diagram of the dimensions and the symptoms that they include is shown in figure 
4 in section 2.3.4. 
3.2.4 pCASL Protocol  
Arterial spin labelling (ASL) is a relatively new and non-invasive perfusion imaging 
modality that can be used for visualization and quantification of CBF. Arterial spin 
labelling uses magnetically labelled arterial blood water protons as an endogenous 
tracer of flow. In Continuous ASL (CASL), the ‘labelled’ image is acquired after the 
inversion of the arterial water spins by an adiabatic sequence consisting of a 
relatively long off-resonance radiofrequency pulse and a constant gradient in the 
direction of the flow (Williams et al, 1992). A ‘control’ image is also acquired after 
the same sequence but with a sine-modulated radiofrequency pulse to ideally 
produce no net magnetic inversion of the spins (Alsop and Detre, 1998). A CBF 
image is computed by subtracting the labelled from the control image and then 
applying a set of measured or assumed physiological and MRI parameters to 
obtain voxel-wise flow values in absolute units (i.e., mL/100 g/min). 
For this study subjects were scanned with their eyes open using a General Electric 
Signa HDX 3.0T scanner, fitted with a receive only 8-channel phased array head 
coil at the Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology 
and Neuroscience, King’s College London. For image registration both a high 
resolution T2-weighted Fast Spin Echo (FSE) image (0.468x0.468x4mm, 
TE=54.58ms, TR=4380ms, Flip angle 90deg, FoV=240) and a high-resolution T1-
weighted Spoiled Gradient Recalled (SPGR) image (1.1x1.1x1.1mm, TE=2.848, 
TR=7.144ms, Flip angle=20deg, FoV=280) were acquired. Resting Cerebral Blood 
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Flow (rCBF) was measured using Continuous Arterial Spin Labelling (CASL) scans 
acquired with a 3D Fast Spin Echo (FSE) spiral multi-shot readout, following a post-
labelling delay of 1.5s. 
The spiral acquisition used a short (4ms) TE, and 8 spiral arms (interleaves) with 
512 points in each arm. (FSE TE 32ms/TR = 5500ms; ETL = 64). Images were 
reconstructed to a 2562 matrix, giving a final spatial resolution of 1x1 mm in 
plane. 60 slices of 3mm thickness were obtained. Three pairs of tagged-untagged 
images were collected. Background suppression included selective saturation of 
the image slab at 4.3s before acquisition, selective inversion 3s before acquisition 
and non-selective inversions at 1.5s, 764ms, 334ms and 84ms before imaging. This 
repeated inversion achieved successful suppression of the background static tissue 
signal, maximizing the sensitivity to blood perfusion.  
Calibration images were collected with the same imaging sequence but with 
inversion recovery preparation instead of CASL. One sequence with saturation of 
4.3s and then an inversion at 1650ms before imaging was used to create a fluid 
suppressed image. A second sequence with saturation at 4.3s and then inversion 
at both 2408ms and 511ms was also acquired to create a fluid and white matter 
suppressed image. For both these sequences, the receiver gain was automatically 
lowered by 21 dB relative to the ASL sequence to avoid receiver saturation. These 
images were used to quantify blood flow in physiological units (ml blood/100gm 
tissue/min).  
The sensitivity of the image to water was calibrated at each voxel 1-3. When multi-
channel coils are employed, the spatially non-uniform sensitivity complicates this 
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calibration. Often the underlying tissue signal is used as an indicator of water 
sensitivity, but a water density in each voxel, or partition coefficient, must then be 
assumed. We observed that the signal intensity in the inversion-prepared fluid-
suppressed image was relatively constant for different tissues. This is likely 
because more complete recovery occurs for shorter T1 tissues, which tend to have 
lower water density.  
Using a neighbourhood maximum algorithm to avoid regions with partial volume 
of suppressed fluid, a low resolution sensitivity map was created. This map was 
calibrated for water sensitivity by assuming the tissue was white matter with a 
water concentration of 0.735 gm/ml 4 and a T1 of 900ms, and using the equations 
for inversion recovery signal attenuation. By assuming grey matter with a water 
concentration of 0.88 gm/ml and a T1 of 1150 there was only a 5% calibration 
difference. This calibration produced a sensitivity map, C, equal to the fully relaxed 
MRI signal intensity produced by 1gm of water per ml of brain tissue.  
With this co-registered sensitivity map C, we calculated cerebral blood flow (CBF) 
using the equation:  
 
Where ρb is 1.05g/ml (the density of brain tissue;4, α is the labelling efficiency 
(assumed to be 95% for labelling times 75% for background suppression; 5, w is 
1.5s (the post-labelling delay;2, tl is 500ms (the labelling duration), T1a is 1.4 ms 
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(the T1 of arterial blood which was slightly lower than the value of Lu et al. 2004), 
ωa 0.85 g/ml (the density of water in blood; 4, Sl and Sc are the signal intensities 
in the labelled and control images, respectively).  
The whole ASL pulse sequence, including the acquisition of calibration images, was 
performed in 6:08min. Images were acquired on the same day as the CAARMS was 
administered. 
3.2.5 Image Pre-processing  
Arterial spin labelling allows the quantification of resting cerebral blood flow 
(rCBF) measures in units of ml/100g of tissue/second. To maximise the 
correspondence between regional perfusion and neural activity, p-CASL images 
were acquired after a long (1.5s) post-labelling delay, to ensure that the data 
reflected perfusion at the level of capillary micro-circulation, which is most closely 
associated with neural function (Hirano et al., 2011). 
For each participant, one Spoiled Gradient Recalled (SPGR) scan was used in the 
pre-processing steps in addition to the T2 images acquired at the time of the CASL 
image, which ensured that the normalization parameters applied to each scan 
were identical for each individual.  
The following steps were then taken: 
I. Extra-cerebral signal from the T2 scan was removed using the “Brain 
Extraction Tool” (BET) of FSL 7. The skull stripped T2 volume and its 
corresponding binary mask were then co-registered to the rCBF map.  
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II. The co-registered binary mask was multiplied by the rCBF map to 
remove extra-cerebral signal from this scan. The skull stripped T2 and 
rCBF maps were then co-registered back to the space of the original T2 
scan (returned to their original frame of reference). 
III. The T2 scan was subsequently co-registered to each subjects structural 
(SPGR) scan, with the co-registration parameters applied to the 
corresponding rCBF maps and brain extracted T2 scans 
IV. The SPGR was normalized to MNI space using a non-linear approach 
using FNIRT 8 (FMRIB Non-linear Image Registration Tool) and the 
transformation matrix was applied to the rCBF map and the T2 scans. 
V. All data were then smoothed using a 6 mm Gaussian Smoothing kernel. 
 
3.2.6 Image Analysis 
Statistical analyses of rCBF data were performed using Statistical Parametric 
Mapping (SPM) Version 8 (http://www.fil.ion.ucl.ac.uk/spm/software/spm8).  
The dimensional structure described above was then used to determine a mean 
score for each participant for each dimension. Unit weighted composite dimension 
scores were applied as contrasts in SPM. 
For the Negative, Disorganised and total CAARMS score, regions of interest based 
on the hypotheses in section 3.1.8 were defined using the MNI coordinates 
determined from the corresponding previous study.  A small volume correction 
(SVC) with a 6mm sphere was applied in the statistical analysis.    
For the Negative factor the coordinates were taken from Pinkham et al. (2011): 
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• Right superior temporal gyrus (55, -55, 10) 
• Left inferior frontal gyrus (-59, 18, 8) 
• Anterior Cingulate gyrus (0, 3, 27) 
• Left middle frontal gyrus (− 32, 15, 36) 
The Pinkham study did not examine a disorganised dimension, only positive and 
negative symptoms. The coordinates for the Disorganised-behavioural and 
Disorganised-cognitive factors were therefore taken from Liddle et al. (1992): 
• Right anterior cingulate (8, 30, 16) 
• Mediodorsal thalamus (2, -2,  4) 
• Right ventrolateral prefrontal cortex (26, 32, 0) 
• Right angular gyrus (42, -60, 8) 
• Left angular gyrus (-40, -74, 16) 
For the total CAARMS scores, the coordinates were taken from Allen et al. (2016): 
• Left subiculum/hippocampus (-22 -28 -8) 
• Right subiculum/hippocampus (20 -28 -8) 
• Right pallidum (22 -12 -4) 
• Left pallidum/putamen (-18 -8 -4) 
• Left midbrain (-10 -32 -18) 
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For the Anxiety and Affective Instability dimensions, as there were no studies 
directly examining these symptoms in UHR, pre-defined anatomical masks were 
used, as provided by the AAL software using the WFU_Pickatlas toolbox in SPM8.  
For the Anxiety Dimension a mask of the amygdala and insula was used (A. Etkin & 
Wager, 2007), for the Affective Instability dimension a mask of the basal ganglia, 
medial temporal gyrus, and inferior frontal gyrus was used (Bhardwaj et al., 2010). 
ROI analyses are reported at a corrected voxel-wise level of P <.05 Family Wise 
Error (FWE).  Exploratory whole brain analyses were conducted at p < .001 KE > 50 
and results were considered significant if they survived cluster level family-wise 
error (FWE) correction (p <.05). Findings that were evident at an uncorrected 
threshold of p<0.001 are reported as trends.  
As antipsychotic medication is known to affect rCBF (Handley et al., 2013), 
additional confirmatory analyses were conducted after subjects who were 
receiving antipsychotic medication had been excluded.   
3.3 Results 
3.3.1 Sample Characteristics  
The average age of the sample was 22 years and 4 months of age (range: 18-36), 
with 59% males and 67% of white ethnicity, with the remainder belonging to 
minority ethnic groups. Eight of the participants were being treated with low 
doses of antipsychotic medication (Quetiapine n=4; Olanzapine n=2; Risperidone 













Gender (male) 41 (59%) 
Ethnicity 
White 47 (67%) 
BME 23 (33%) 
Intake Group 
APS 70 (100%) 





3.3.2 Clinical Characteristics  
Seventy five subjects met UHR criteria for Attenuated Psychotic Symptoms (APS), 
five had experienced Brief Limited Intermittent Psychosis, and two had a 
combined genetic vulnerability (first degree relative with diagnosis of 
schizophrenia or previous diagnosis of schizotypal personality disorder). 
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CAARMS total scores ranged from 13 to 81, with an average score of 42. 
Dimension scores were calculated as a mean of items that loaded on each factor 
as determined in the factor analysis in the previous chapter. Information on 
CAARMS total scores and dimension scores are shown in table 13 below. 
 
Table 13: Mean, Standard Deviation and range of CAARMS Scores of 70 UHR subjects 
 Min Max Mean SD 









0 3.25 0.49 0.63 
Disorganised 
– Cognitive 
0 3.25 1.48 0.80 
Affective 
Instability 
0 4.33 1.89 1.27 




3.3.3 Total CAARMS score and rCBF  
ROI Analysis: 
ROI analysis in the regions specified from Allen et al. (2016) revealed a significant 
correlation between the total CAARMS score and decreased rCBF in the left 
hippocampus. Results are shown in the table 14 below. No significant correlation 
was found in the right hippocampus, left pallidum, left midbrain or right pallidum. 
SPM output is shown in Appendices 7-9. 









x y z 
Left hippocampus 14 3.54 0.002 -28 -28 -8 
 
Whole brain analysis: 
Whole brain analysis showed that there were trends (p<.001, uncorrected) for the 
total CAARMS score to be negatively correlated with perfusion in the 
parahippocampal gyrus (x, y, z = -30, -26, -12; Z = 3.88; KE = 210), cerebellum (x, y, 
z = -8, -78, -16; Z = 4.15; KE = 278), right thalamus (x, y, z = 16, -18, 12; Z = 3.92; KE 
= 222), and superior frontal gyrus (x, y, z = -28, 54, -4; Z = 3.54; KE = 54). However, 
after FWE correction, only the negative correlation in the left thalamus remained 
significant (x, y, z = -10, -40, -2; Z = 3.86; KE = 719; pFWE = 0.041).  










3.3.4 Negative Dimension and rCBF 
ROI Analysis: 
ROI analysis of the 5 regions specified in (Pinkham et al., 2011) found no 
significant correlations between Negative dimension scores and rCBF in any area. 
Whole brain analysis: 
Whole brain analysis found no significant correlations between Negative 
dimension scores and rCBF. 
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3.3.5 Disorganised dimensions and rCBF 
ROI Analysis: 
ROI Analysis in the areas specified by Liddle et al. (1992) showed a significant 
correlation between decreased perfusion in the mediodorsal thalamus and scores 
on the Disorganised – Behavioural dimension. Results are shown in table 15 
below. There were no significant correlations between Disorganised – Behavioural 
or Disorganised - Cognitive dimension scores and the right anterior cingulate, right 
ventrolateral prefrontal cortex, or angular gyri ROIs. SPM output is shown in 
Appendix 10 










x y z 
Mediodorsal thalamus 93 
4.09 0.000 -4 -20 4 
3.44 0.000 8 -20 4 
 
Whole brain analysis: 
Scores on the Disorganised – Behavioural dimension were negatively correlated 
with perfusion in the left hippocampus (x, y, z = -30, -28, -8;  Z = 4.51; KE = 2944; 
pFWE = 0.002),  the left cerebellum (x, y, z = -20, -88, -18; Z = 4.09; KE = 1378; pFWE = 
0.003), and the occipital gyrus (x, y, z = -32, -84, 30; Z = 4.04; KE = 1964; pFWE = 
0.001). 
There were additional trends (p<.001, uncorrected) for negative correlations with 
rCBF in the inferior and middle temporal  (x, y, z = -38, -84, 12; Z = 3.77; KE = 213; 
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x, y, z = 58, -60, 4; Z = 3.69; KE = 37), inferior frontal (x, y, z = -18, 30, -2; Z = 3.48; 
KE = 69), and postcentral gyri (x, y, z = -56, -24, 22; Z = 3.23; KE = 116).  
The results are shown in figure 11 and SPM output is given in Appendix 5. 
 




3.3.6 Anxiety dimension and rCBF 
 
ROI Analysis: 
ROI analysis in the insula and amygdala in a single mask showed a significant 
negative correlation between rCBF in the left insula and anxiety scores (x, y, z = -
44, 8, 4; Z = 3.56; KE = 63, pFWE = 0.03). Results are shown in figure 12 and SPM 




Figure 12: Statistical parametric maps showing rCBF correlation with Anxiety dimension scores (p = .05 FWE 
Corrected). 
 
Whole brain analysis: 
There were no correlations with scores on the Anxiety dimension that survived 
FWE correction. There were trends (p<.001, uncorrected) for negative correlations 
with rCBF in the right medial frontal (x, y, z = 12, 28, 38; Z = 3.51; KE = 72), left 
inferior frontal (x, y, z =-32, 32, -14; Z = 3.65; KE = 33), and left angular gyri (x, y, z 
=-44,-66, 36; Z = 3.21; KE = 6), and in the left insula (x, y, z =-44, 8, 4; Z = 3.90; KE = 
183).  





Figure 13: Statistical parametric maps showing rCBF correlation with Anxiety dimension scores (p = .05 FWE 
Corrected). 
 
3.3.7 Affective Instability dimension and rCBF 
 
ROI Analysis: 
ROI analysis of the 5 regions specified in Bhardwaj et al. (2010) found no 
significant correlations between Affective Instability dimension scores and rCBF in 
any area. 
Whole brain analysis: 
Whole brain analysis found no significant correlations between Affective Instability 
dimension scores and rCBF. 
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3.3.8 Summary of Significant Results (after correction for multiple 
comparisons) 
The ROI analysis indicated that Disorganised – Behavioural dimension was 
associated with decreased perfusion in the mediodorsal thalamus, while whole 
brain analysis revealed additional associations with decreased perfusion in the left 
hippocampus, cerebellum and occipital gyrus. 
The ROI analysis indicated that the total CAARMS Score was associated with 
decreased perfusion in the left hippocampus, the left pallidum, and the left 
midbrain, while whole brain analysis revealed an additional association with 
decreased perfusion in the left thalamus. 
The ROI analysis for the Anxiety Dimension showed a negative significant 
correlation with  perfusion in the insula. 
 
3.4 Discussion 
3.4.1 Aims and Results of the Study 
This study examined the relationship between resting cerebral blood flow and 
severity scores on CAARMS symptom dimensions and the CAARMS total score in a 
sample of 70 UHR subjects. The results showed a significant correlation between 
total CAARMS severity and rCBF in the left thalamus, as well as finding significant 
decreases in CBF in three ROI’s specified by Allen et al. (2016): the left 
hippocampus, left pallidum and left midbrain. ROI analysis of Negative dimension 
scores did not show any correlation between negative dimension scores in the 
areas specified by Pinkham et al. (2011), however there were significant 
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reductions in CBF in one of the areas identified by P. F. Liddle et al. (1992): 
mediodorsal thalamus and the Disorganised – Behavioural dimension. Whole brain 
analysis based on the different psychopathological dimensions revealed significant 
negative correlations between scores on two of the five dimensions: Disorganised 
– Behavioural with left hippocampus, left cerebellum and occipital gyrus; and 
Anxiety with medial and inferior frontal gyrus, although this finding did not survive 
correction for multiple comparisons. 
3.4.2 Comparison with Previous Studies 
The findings for the Disorganised - Behavioural dimension produced three robust, 
significant findings in three large clusters in the left hippocampus, left cerebellum 
and occipital gyrus, as well as replicating a previous finding from (Liddle et al., 
1992) in an ROI analysis of the mediodorsal thalamus.  
The hippocampus has been consistently shown to play a key role in cognitive 
organisation in both animal models (Wesierska et al., 2005) and humans (Olypher 
et al., 2006). In schizophrenia, several studies have found a link between 
disorganisation and hippocampal rCBF / volume (Chua et al., 1997; McGuire et al., 
1998; Prasad et al., 2004), and it has also been one of the most robust 
neurobiological findings in UHR (Allen et al., 2015; Allen et al., 2016; Schobel et al., 
2009). However, this study only examined scores within UHR subjects, and found 
that perfusion decreased with higher scores in the disorganised dimension, 
whereas previous studies have shown that when UHR subjects are compared with 
healthy controls, increased hippocampal perfusion is evident in the UHR group 
(Allen et al., 2016). This contrast may be due to the within group design of the 
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study – examining only severity of symptoms and rCBF between patients, rather 
than comparing patients with controls, or may be due to the differential patterns 
of individual symptoms (in this case Disorganised) rather than looking at the UHR 
group as a whole. 
The significant correlation of disorganised symptoms with perfusion in the 
thalamus is in a replication of the  P. F. Liddle et al. (1992) finding in schizophrenia 
and in keeping with Pollak et al. (2015), who found a significant association with 
perfusion in the pulvinar and ketamine-induced disorganised symptoms. The 
pulvinar nucleus projects to several cortical areas, including prefrontal and limbic 
regions, as well as having projections to and from sensory cortices. Disruption to 
this region can produce deficits in verbal and non-verbal processing (Ojemann et 
al. 1968) and its function is abnormal in schizophrenia (Andrews et al. 2006). 
The cerebellum is historically considered part of the motor system that integrates 
information from sensory systems of the spinal cord and from other parts of the 
brain to fine tune motor activity (Fine et al., 2002). The finding of a negative 
correlation between the Disorganised - Behavioural dimension and CBF in the 
cerebellum makes sense with the inclusion of motor symptoms such as Impaired 
Motor Function in the dimension. The cerebellum has been linked to development 
of psychosis (Marcelis et al., 2003) and a recent meta-analysis found decreased 
activity in the cerebellum in schizophrenia (Matheson et al., 2014) as well as 
consistent findings in UHR (J. A. Bernard et al., 2014; Pantelis et al., 2003; 
Ziermans et al., 2012). 
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The correlation of disorganised symptoms with perfusion in the anterior cingulate, 
right ventrolateral prefrontal cortex, or angular gyri that were found in by Liddle et 
al. (1992) were not replicated in the regional analysis in this study. 
The whole brain findings examining all CAARMS symptoms found decreased 
perfusion in a smaller cluster in the thalamus. There is considerable evidence that 
the thalamus and associated cortical connections are abnormal in psychotic 
disorders (Cronenwett & Csernansky, 2010; Sim et al., 2006) and reduced resting 
state connectivity (Woodward et al., 2012) and volume (Qiu et al., 2009) have 
been found in psychosis. More recently the thalamus has been found to play a key 
role in the developmental course of schizophrenia (Walker et al., 2008) and the 
development of positive symptoms in UHR (Jessica A. Bernard et al., 2015). This 
ties in with the inclusion of positive symptoms in the overall CAARMS scores, but 
not in the dimensional scores. 
Abnormalities in the thalamus have been found in UHR using other imaging 
modalities. Glutamate in the thalamus has been found to be reduced in UHR 
subjects (Egerton et al., 2013; Stone et al., 2009) and thalamic volume is reduced 
in UHR  (Dietsche et al., 2017) and schizophrenia (Adriano et al., 2010; Buchmann 
et al., 2014).  
The regional analysis of the total CAARMS score found decreased perfusion in the 
left hippocampus, left basal ganglia and left midbrain was evident as with higher 
total CAARMS scores. This is in direct contrast to the findings by Allen et al. (2016) 
where elevated rCBF in the hippocampus, basal ganglia, and midbrain was found 
in UHR compared to controls, and symptomatic improvement was associated with 
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a reduction in rCBF in the hippocampus and ventral striatum. The present study 
involves a within-UHR analysis as opposed to UHR vs controls. The brain changes 
associated with UHR state may not purely reflect the presence of symptoms 
measured by the CAARMS – there is also a functional impairment, cognitive 
impairments and probably genetic vulnerability to psychosis. There is some 
evidence that the GAF score is associated with rCBF in First Episode Psychosis 
(FEP) (Koike et al., 2016), however this has not yet been shown for cognition and 
genetic load.  
Although none of the whole brain findings for the Anxiety dimension survived 
correction for multiple comparisons, the findings in the medial and inferior frontal 
gyrus were in keeping with previous studies: both the medial and inferior frontal 
gyrus have been shown to play a role in threat-induced anxiety (Gold et al., 2015), 
trait anxiety (Modi et al., 2015) and impaired cognitive function associated with 
anxiety (Minzenberg et al., 2009). Finally, reduced insula volume has been shown 
in schizophrenia patients (T. Takahashi et al., 2005) and it has been shown to be 
hyperactive in anxiety disorders (A. Etkin & T. D. Wager, 2007). The insula and 
amygdala are directly anatomically connected in a reciprocal manner and studies 
have proposed insula–amygdala interactions on the basis of the finding that both 
structures are activated conjointly and similarly during experimentally induced 
anxiety (Carlson et al., 2011; Phelps et al., 2001). Thus, although this finding also 
did not remain significant, it aligns with previous findings. 
The ROI analysis based on the Anxiety dimension, showed a significant association 
between higher Anxiety scores and lower CBF in the insula. This is in direct 
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contrast to what would be expected and what has been found previously (A. Etkin 
& Wager, 2007). A possible explanation for this may be reached when examining 
the items that are included in this dimension. Anxiety and Impaired Tolerance to 
Normal Stress are typical anxiety symptoms and may be expected to correlate 
with increased perfusion, however Impaired Role Function and Social Isolation, 
which group with the Anxiety symptoms in this model are more likely to be 
considered negative symptoms. It may be that the cooccurrence of these 
symptoms in one dimension are distorting the findings that would be expected for 
symptoms of anxiety. 
3.4.3 Limitations  
Although many of the findings in this study are consistent with previous studies in 
both UHR and schizophrenia, they should be considered in the context of potential 
limitations. 
Although most UHR subjects were medication-naïve, a small number (8 of 70) had 
been treated with low doses of antipsychotic medication. Medication in these 
subjects may have altered the severity of their psychotic symptoms, and may also 
have direct effects on activity and rCBF (Goozée et al., 2014). However, as only 
11% of the sample had been treated, this is unlikely to have had a major impact on 
the results.  
The symptom ratings were not conducted at exactly the same time as the ASL 
scans, so it is possible that the symptom levels at the time of scanning were 
different to those at clinical presentation. The pattern of activity associated with 
psychotic symptoms can vary within subjects over time. For example, several 
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studies have shown that resting cortical activity varies within patients with 
schizophrenia over time in the presence or absence of auditory and visual 
hallucinations (McGuire et al., 1993; Shergill et al., 2001).  
Liddle (1992) previously sought to address this issue by defining symptom 
dimensions on the basis of symptom scores that were stable over a prolonged 
period of time in patients with chronic schizophrenia. However, although 2-year 
follow up CAARMS data was collected, this was not feasible in the present study as 
UHR subjects symptoms are more likely to change quickly over time than in 
chronic patients. Ideally, subjects would be rated on the CAARMS e.g., every day 
for 5 days and then the average scores could be used to define the dimensions. 
However, this would be logistically demanding and difficult to implement in 
practice.  
The validity of the symptom dimensions also depends on the accuracy and 
reliability of the CAARMS ratings. Although both trained raters completed training 
and met inter-rater reliability standard requirements before implementing the 
CAARMS, there were two different raters, and most of the symptoms ratings are 
subjective, which relies on full disclosure from the subject. If the UHR subject is 
guarded about revealing symptoms the scores may not reflect the true 
psychopathology. 
CAARMS scores may also be influenced by substance use. 13 subjects reported 
that positive symptoms occurred in relation to substance use as well as at other 
times as well. However this rating is only included in the positive symptom scale, 
and may affect other symptoms. 
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3.4.4 Future Research Directions 
These findings are derived from the first examination of symptom dimensions and 
CBF in UHR, and will therefore need replication. It would also be interesting to 
examine CBF and symptom dimensions in a longitudinal context. It has been 
shown that CBF normalises with improvement in the total CAARMS score (Allen et 
al., 2016), and further work is needed to determine the stability of symptom 
dimensions and their neurobiological correlates over time.  
As a reflection of neural activity, the regional CBFs of different brain regions are 
not independent. Instead, the CBFs of brain regions from the same functional 
network may change synchronously to fulfil the function of the network (Melie-
García et al., 2013). This is also true of the symptom dimensions, which are not 
independent. It may add to the understanding to examine CBF in subjects 
longitudinally, as symptomatic presentation changes, to determine neural 
correlates of such change. 
This study is an initial exploration of neural correlates of symptom dimensions in 
UHR, and provides some degree of pathophysiological validation to the previously 
identified symptom constructs. However, both the statistical and neurobiological 
exploration of these dimensions has included only baseline information and 
therefore further examination of these constructs and their correlates over time 





4 Clinical Correlates of Symptom Dimensions  
4.1 Introduction 
4.1.1 Symptom Dimensions and Outcome in Psychosis 
In order to clarify the degree to which psychotic symptoms are predictive of 
course and outcome of illness, it is necessary to relate dimensions longitudinally to 
follow up information. This relationship has been examined in psychosis 
extensively, with many studies concluding that symptom dimensions prove to be a 
more powerful tool in explaining variance of outcome than categorical sub-
diagnoses (Russo et al., 2014; Salokangas, 2003).  
An initial exploration of psychopathological syndromes and their association with 
course and outcome was conducted by van Os et al. (1996), who found negative 
and disorganised symptom dimensions in patients with psychosis were associated 
with a worse course of illness. 
Although there is not a consistent agreement on the factor structure present in 
psychosis, with results varying according to the categorical diagnosis of the 
subjects included and the instrument used to measure symptomatic presentation 
(Wallwork et al., 2012), the association between negative and disorganised 
dimensions and poor outcome has been replicated for both negative (Levine & 
Leucht, 2013; Rabinowitz et al., 2012; Salokangas et al., 2002), and disorganised 
dimensions (Manuel J Cuesta et al., 1994; Ortiz et al., 2013; Owens et al., 2010) by 
many studies since. More recent studies such as that by Sánchez-Torres et al. 
(2017), found that lifetime negative symptoms predicting poor functional outcome 
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in schizophrenia and disorganization symptoms showed the greatest impact in 
functioning, preventing patients from achieving remission (Ortiz et al., 2015). 
These consistent findings across schizophrenia spectrum disorders, particularly for 
negative and disorganised dimensions, indicate that a similar pattern of 
differentiation of outcomes according to symptomatic presentation may be 
present in UHR.  
4.1.2 Outcomes in the UHR Population 
In order to examine the relationship between dimensions and outcome in the UHR 
population, we must ascertain definitive outcome measures, as this group does 
not have a categorically defined diagnosis or course of illness. 
Outcome Defined by Transition to Psychosis: 
The UHR criteria use the clinical risk factors, such as functional decline and 
prodromal symptoms, to determine those who have an imminent risk of 
developing a psychotic disorder. Thus, the predominant aim in investigating this 
population is to determine risk factors for the development of psychosis. Initial 
studies examining the rate of transition to psychosis found high rates of 30 - 40% 
within one year (Cannon et al., 2008; Yung et al., 2003). A recent meta-analysis 
found lower rates of transition, with a rate of 22% after 1 year, 29% after 2 years, 
and 36% after 3 years (Fusar-Poli et al., 2012); however, several studies found 
transition rates as low as 10% (Demjaha et al., 2010; Lemos-Giráldez et al., 2009; 
McGorry et al., 2008). In fact, the meta-analysis conducted by Fusar-Poli et al. 
(2012) found a significant reduction in transitions rates over time. These low 
transition rates mean that meeting UHR criteria, although indicative of a 
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significant increase compared to the general population, is not indicative of a 
psychosis prodrome in the majority of subjects, and it is therefore important to 
determine outcome not only according to transition. 
 A meta-analysis in 2011 found that although on average 76% of UHR subjects did 
not transition to psychosis; over half of the 31 studies included provided no 
characteristics of those UHR subjects who did not develop psychosis. Since then, 
several studies have investigated the outcome in those who do not transition to 
psychosis, and for instance Jean Addington et al. (2011) found that at least one 
attenuated positive symptom was still present for 43% of the UHR sample after 1 
year and for 41% after 2 years. Furthermore, social and role functioning were 
significantly poorer in the clinical sample relative to controls. Furthermore, Lin et 
al. (2015)  found that individuals at UHR for psychosis who do not transition to 
psychosis are at significant risk for continued attenuated psychotic symptoms and 
persistent or recurrent disorders, with 68% experiencing non-psychotic disorder 
over a two year follow up.  
An examination of comorbid disorders in UHR by Fusar-Poli et al. (2014) found 
that 73% of UHR subjects had a comorbid diagnosis of anxiety of depression and 
that comorbidity was not associated with transition to psychosis but rather with 
poor global functioning. There has therefore been a recent focus on risk for non-
psychotic disorders and functional outcome. 
Both these findings point to the importance of a functionally defined outcome as 
well as transition to psychosis. Although initially the primary outcome of interest 
in investigation of the UHR population has been the development of psychotic 
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disorder, Lin et al. (2012), argued that it is important not to consider only the 
arbitrary threshold at which psychotic symptoms progress from attenuated to 
frank psychotic disorder, but that defined outcome  in UHR should be broadened 
to incorporate non-psychotic diagnoses, functioning and negative symptoms. 
Outcome Defined by Level of Function: 
Lin et al. (2011) proposed that the detection of UHR individuals with poor 
functioning at follow-up may yield a valid group in which to study biomarkers and 
treatment of schizophrenia. Deficits in function have long been recognised as a 
key factor in psychosis, causing a significant and long-lasting health, social, and 
financial burden, not only for patients but also for families, other caregivers, and 
the wider society (Knapp et al., 2004). It has also been highlighted as a substantial 
economic burden on society, with Wu et al. (2005) estimating that functional 
disability accounts for up to 52% of the costs associated with schizophrenia. Even 
when positive symptoms are in remission, this does not necessarily coincide with a 
functional recovery, especially in the early stages of the illness (Robinson et al., 
2004), and it is therefore crucial to understand the factors leading to long-term 
disability in psychotic disorders.  
van Os et al. (1999) found that different symptoms dimensions are associated with 
different levels of functional and social outcome across a large sample of chronic 
psychotic illnesses, and subsequently, both negative (Levine & Leucht, 2013; 
Rabinowitz et al., 2012; Salokangas et al., 2002), and disorganised (Manuel J 
Cuesta et al., 1994; Ortiz et al., 2013; Owens et al., 2010) symptom dimensions 
have been shown to determine functional outcome in multiple studies. 
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In UHR, several studies support the increasing emphasis on functional decline as a 
critically important outcome to be considered alongside the rate of transition to 
psychosis (Cornblatt et al., 2012; Schlosser et al., 2012). It is important to 
determine to what extent UHR subjects who do not transition to psychosis 
represent false positives. Subjects can only be considered to be no longer at 
imminent risk for psychosis if presenting symptoms and functional deficits that 
define the UHR status remit within the follow up period. Although Addington et al. 
(2011) found that subjects that did not transition in the North American Prodrome 
Longitudinal Study cohort showed symptomatic and functional improvement after 
2 years, a significant proportion still met UHR criteria. This is also the case in the 
PACE sample, with 23% of non-transition cases still meeting APS criteria after 2 
years, and 68% meeting diagnostic criteria for at least one non-psychotic disorder 
(Lin et al., 2015). This suggests that both psychosis and long-term functional 
disability are equally important targets for prevention (Carrión et al., 2013). 
Functional disability, as well as an important consideration as an outcome 
measure on its own merit, has also been show to increase the risk of transition 
(Dragt et al., 2011; Velthorst et al., 2010). 
The identification of factors that reliably differentiate UHR subjects that are at 
high risk for long term functional impairments from those who are not may 
provide a framework to understand the disability associated with both those who 
transition and those who do not. Moreover, this approach may lead to better 
understanding of the underlying mechanisms of functional impairments at a 
critical phase in the illness, and inform advancements in improved interventions 
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for those at an increased risk for functional disability, as well as those at risk of 
transition to psychosis. 
4.1.3 Symptom Dimensions and Outcome in UHR 
Symptom Dimensions and Transition to Psychosis: 
There have been inconsistent links between individual symptoms and risk of 
transition to psychosis in UHR. Several studies found that symptoms such as 
perceptual disturbances, unusual thought content, and ideas of reference are 
associated with later transition to psychosis (Cannon et al., 2008; Haroun et al., 
2006). Two large studies of the North America Prodrome Longitudinal Study 
(NAPLS) (Cannon et al., 2008) and the Personal Assistance and Clinical Evaluation 
(PACE) study in Australia (Thompson et al., 2011) confirmed the high Positive 
Predictive Value (PPV) of subjects reporting high unusual thought content scores 
as well as low functioning and having genetic risk with functional decline. 
However, when examining symptom dimensions, using both the CAARMS and 
SOPS, there has been no link between positive symptoms and transition to 
psychosis (Demjaha et al., 2010; Fernández et al., 2006; Raballo et al., 2011). 
Replicating the finding in psychosis (van Os et al., 1996), there have been several 
studies highlighting the importance of negative symptoms in the UHR population 
(Lencz et al., 2004), linking negative symptoms and transition to psychosis (Mason 
et al., 2004; Valmaggia et al., 2013; Velthorst et al., 2009; Yung et al., 2005) and 
finding persistency of negative symptoms even after treatment (Fusar-Poli et al., 
2015; Piskulic et al., 2012). Again, replicating psychosis (Ortiz et al., 2015), 
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disorganised symptoms have been shown to predict transition in UHR (Lam et al., 
2006; Mason et al., 2004; Riecher-Rössler et al., 2009). 
Three of the four studies examining symptom dimensions in UHR (Demjaha et al., 
2010; Fernández et al., 2006; Hawkins et al., 2004; Raballo et al., 2011) have used 
dimensions to determine risk of transition. Using the SIPS/SOPS Fernández et al. 
(2006) found that Negative and Disorganised dimensions had a 96.7% and 90% 
PPV respectively for transition to psychosis after 1 year, in a sample of 30 subjects 
of whom 8 made transition to psychosis. Using the CAARMS, Demjaha et al. (2010) 
confirmed this result using Cox Proportional Hazards Regression, finding both the 
negative (hazard ratio = 1.68, 95% confidence interval = 1.01 – 2.80, p = 0.044) and 
disorganised dimension (hazard ratio = 1.70, 95% confidence interval = 1.16 – 
2.29, p = 0.005) were associated with increased risk of subsequent transition to 
psychosis (n = 122). This was confirmed, also using Cox Proportional Hazards 
Regression on dimensions determined from the CAARMS by Raballo (2011) for the 
disorganised dimension (hazard ratio = 1.43, 95% confidence interval = 1.03 – 
2.18), however not for the negative dimension. 
Symptom Dimensions and Functional Outcome: 
As described above, there has been a shift in focus in more recent longitudinal 
studies of UHR, to move beyond the singular determination of outcome in terms 
of psychotic transition, to consider outcome in terms of functional disability. 
When determining outcome using functional criteria rather than transition to 
psychosis, several studies have found links between symptoms and functional 
outcome (Allen et al., 2015).  
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Schlosser et al. (2012) found that subjects presenting with lower severity of 
negative and affective symptoms at baseline were more likely to present with 
symptomatic and functional recovery after 2 years, and Lin et al. (2011) found that 
the presence of negative symptoms and neurocognitive decline at baseline, 
regardless of transition to psychosis, were associated with poor functional 
outcome in UHR, whereas positive symptoms and baseline GAF were not. 
Disorganised and negative symptoms have been consistently shown to predict 
functional outcome in UHR (B. A. Cornblatt et al., 2007; Fulford et al., 2013; 
Niendam et al., 2007; H. Takahashi et al., 2005) as well as after long term follow up 
of 6 years (Ziermans et al., 2014). 
Of the four studies that examined symptom dimensions in UHR,  both Demjaha et 
al. (2010) and Raballo et al. (2011) looked at functional disability at baseline and 
found that all factors were associated with worse functioning at presentation, 
however neither study went on to examine how the dimensions relate to 
functional outcome. 
 
4.1.4 Aims and Objectives of this Study 
This chapter will examine the relationship between the symptom dimensions 
described in chapter 2 and baseline demographic (age/gender) and clinical 
variables (Global Assessment of Functioning). The association between CAARMS 
intake group (APS/BLIP/Genetic Vulnerability) will also be examined to determine 
any symptomatic differentiation between the groups. 
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The relationship between baseline dimension scores and outcome at follow up will 
then be examined, using transition to psychosis and level of functioning as the two 
outcome measures. On the basis of data from previous studies (Demjaha et al., 
2010; Raballo et al., 2011), I tested the hypothesis that high scores on the negative 




The total sample comprised of 509 individuals meeting the PACE criteria for Ultra 
High Risk for Psychosis (UHR), aged 18-35 recruited through three different studies 
conducted between 2008 and 2017. Fifty-five participants were recruited through 
an MRC-funded study at King’s College London; ninety through a Wellcome Trust 
funded programme at King’s College London (collected by the author); and three 
hundred and sixty four from an FP7 project funded by the European Union, 
involving sites in the UK, Netherlands, Austria, Switzerland, France, Spain, Turkey, 
Australia, Belgium, Germany and Brazil. A breakdown of the total sample by 
location is shown in the table below. All studies had National Research Ethics 




Table 16: Geographical Composition of Sample 
 




MRC Study UK - London – South London 55 
48.9 Wellcome Study 
UK - London – South London 49 
UK - Cambridge  21 
UK  - London – West London  10 
EU Study 
UK – London – South London  104 
The Netherlands – Amsterdam 19 
19.1 
The Netherlands - Den Haag 68 
Austria – Vienna 7 1.3 
Switzerland – Basel 19 3.7 
Germany – Cologne 16 3.1 
Australia – Melbourne 25 4.9 
Denmark - Copenhagen 19 3.7 
France – Paris 17 3.3 
Spain – Barcelona 23 4.5 
Brazil - Sao Paulo 17 3.3 
 
 
4.2.2 Eligibility Criteria 
Participants were recruited from specialist early intervention services and 
assessed by researchers trained to administer the measures. The eligibility criteria 
were the same as those used for the sample in chapter 2; detailed criteria can be 





The Comprehensive Assessment of At Risk Mental State (CAARMS): 
UHR status was determined using the Comprehensive Assessment of At Risk 
Mental State (CAARMS). This is described in detail in section 2.2.3. 
The CAARMS was conducted at both baseline and Follow up. 
The Global Assessment of Function (GAF): 
A standard method used to assess a patients’ overall level of psychological, social, 
and occupational functioning (American Psychiatric Association, 2000)            . 
Ratings are based on a 1–100 scale, with 100 representing an absence of 
symptoms and superior functioning. Guidelines for rating the GAF describe 
symptoms and levels of functioning in 10-point intervals: 
• 100 – 91: No symptoms or superior functioning in a wide range of 
activities, life’s problems never seem to get out of hand, is sought out by 
others because of his or her many positive qualities 
• 90 – 81: Absent or minimal symptoms (e.g. mild anxiety before an exam, 
generally satisfied with life), no more than everyday problems or concerns 
(e.g. occasional arguments with family members). Good functioning in all 
areas, interested and involved in a wide range of activities, socially 
effective 
• 80 – 71: If symptoms are present, they are transient and expectable 
reactions to psychological stressors (e.g. difficulty concentrating after 
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family argument). No more than slight impairment in social, occupational 
or school functioning (e.g. temporarily falling behind in school work) 
• 70 -61: Some mild symptoms (e.g. depressed mood and mild insomnia). 
Some difficulty in social, occupational or school functioning (e.g. occasional 
truancy or theft within the household), but generally functioning pretty 
well, has some meaningful interpersonal relationships 
• 60 – 51: Moderate symptoms (e.g. flat affect and circumstantial speech, 
occasional panic attacks). Moderate difficulty in social, occupational or 
school functioning (e.g. few friends, conflicts with co-workers) 
• 50 – 41: Serious symptoms (e.g. suicidal ideation, severe obsessional 
rituals, frequent shoplifting). Any serious impairment in social, 
occupational or school functioning (e.g. no friends, unable to keep a job) 
• 40 – 31: Some impairment in reality testing, or communication (e.g. speech 
is at times illogical, obscure or irrelevant). Major impairment in several 
areas, such as work or school, family relations, judgement, thinking or 
mood (e.g. depressed man avoids friends, neglects family and is unable to 
work; child frequently beats up younger children, is defiant at home and is 
failing in school) 
• 30 -21: Behaviour is considerably influenced by delusions or hallucinations. 
Serious impairment in communication or judgement (e.g. sometimes 
incoherent, acts grossly inappropriately, suicidal preoccupation). Inability 




• 20 -11: Some danger of hurting self or others (e.g. suicide attempts without 
clear expectation of death, frequently violent, Affective Instability 
excitement), gross impairment in communication (e.g. largely incoherent 
or mute). Occasionally fails to maintain minimal personal hygiene (e.g. 
smears faeces) 
• 10 – 1: Persistent danger of severely hurting self or others (e.g. recurrent 
violence). Serious suicidal act with clear expectation of death. Persistent 
inability to maintain minimal personal hygiene 
The GAF was implemented by a trained clinician and it was conducted at baseline 
and follow up. Two of the studies (92% of the sample) used a separate GAF – 
Symptoms and GAF – Disability rating scales, and the remaining study used only 
one overall rating. 
4.2.4 Symptom Dimensions 
The symptom dimensions were those determined in chapter 2. The dimensions 
and CAARMS items that load on them are shown in figure 4 in section 2.3.4. 
4.2.5 Outcome Measures 
Both the CAARMS and GAF assessments were conducted at 2-year follow up. 
CAARMS scores and clinical records were used to determine whether a subject 
had made a transition to psychosis. A severity score of 6, with frequency greater 
than 4 on any of the items in the Positive scale was classified as Psychotic. If 
CAARMS ratings were not available (e.g. because a subject did not participate in a 
follow up visit), transition to psychosis was determined on the basis of the 
diagnosis made by clinical services. 
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GAF scores were used to determine functional outcome. Subjects were divided 
into two functional outcome groups on the basis of their scores at 2 year follow-
up: 
1. Good functional outcome – defined as GAF score ≥ 65 
2. Poor functional outcome – defined as GAF score ≤ 64  
This approach follows that previously used in the study by (Allen et al., 2015).  
Scores in the 61–70 range are associated with “some difficulty in social, 
occupational or school functioning, but generally functioning pretty well”. 
4.2.6 Missing Data 
Listwise deletion of missing data was used - cases are dropped from analysis if 
they have a missing value in at least one of the specified variables. A complete 
CAARMS baseline score for all items was needed to calculate total CAARMS score 
and scores for each dimension. After removal of subjects for whom there were 
missing data the sample size was 493. There were also several subjects who were 
included in more than one of the studies. Of an initial sample of 509, after removal 
of these subjects the sample size was 463. This is a larger total sample as the data 
extraction for this analysis was conducted three months later than the extraction 
for the analysis in chapter 2, during which time CAARMS data for two participants 
had been added. 
4.2.7 Statistical analysis 
As the data came from three different studies, an initial group comparison was 
performed to determine whether the respective data sets were sufficiently 
statistically similar to be pooled. This required that they have statistically similar 
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subjects by age and gender, and shared the same structure of CAARMS scores, 
which would be expected if they represented different samples of the same 
population. 
Pearson product-moment correlation coefficient was used to determine which 
dimensions were associated with other baseline variables, grouped as 
sociodemographic and functional variables - age and GAF score. Chi square test 
was used to assess if any difference was present between the dimensions 
according to gender, and analysis of variance for comparisons of the total scores 
between inclusion groups. 
Both previous studies (Demjaha et al., 2010; Raballo et al., 2011) used Cox 
Proportional Hazards Regression to examine the relationship between the derived 
factors and transition to psychosis/functional outcome, this is because both 
studies had not completed a two year period of observation to allow for valid 
determination of transition to psychosis (Fusar-Poli et al., 2012). This method is 
suitable for investigating the effect of variables upon the time a specified event 
takes to happen, and will therefore take in to account the continued risk of 
transition. As the follow up time period of over two years for this study, logistic 
regression will be used to determine the relationship between dimensions and 
outcome. This will determine the statistical likelihood of the outcome at two 





4.3.1 Test of Homogeneity 
In order to combine the three data sets, a one way analysis of variance was 
conducted to compare means of age and gender between the groups and no 
significant differences were present (age: t(2) = 2.528, p = 0.876; gender: t(2) = 
0.019, p = 0.926). Levene’s test of homogeneity of variance was performed on the 
CAARMS scores for the three data sets. This indicated equal variances of Total 
CAARMS scores (F = 1.65, p = 0.193) between the three samples, which suggested 
that the data sets could be pooled. 
4.3.2 Sample Characteristics 
Demographic information:  
The final pooled sample consisted of CAARMS scores for 463 participants. The 
sample was 55% male, the mean age was 22 years and 7 months, and 63% of the 
subjects were white, 18% black and 14% from other ethnic minorities. 86% of the 
sample met the inclusion criteria for Attenuated Psychotic Symptoms (APS), 7% 
Brief Limited Psychotic Period (BLIP) and 7% Genetic Vulnerability. Gender, age, 
ethnicity and CAARMS intake group breakdowns for each sample are show in the 













Sample Size 90 55 364 509 
Number included 85 50 328 463 
Age  
Mean 22.47 22.56 22.22 22.66 





























































CAARMS Scores:  
Baseline CAARMS scores recorded in the total sample ranged from 0-6 for each 
item, and every item was present (scored above 0) in at least 10% of the sample. 
The mean total score was 40.39 (SD = 20.33). A breakdown of scores for each item 
is shown in table 18 below. 
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Table 18: Mean, Standard Deviation and Range of all CAARMS Item 
CAARMS group Number CAARMS Item Minimum Maximum Mean SD 
1. Positive Symptoms 
1.1 Unusual thought content and non-bizarre ideas 0 6 2.50 1.641 
1.2 Perceptual abnormalities 0 6 2.59 1.847 
1.3 Disorganized speech 0 6 1.54 1.484 
2. Cognitive Change Attention/Concentration 
2.1 Subjective cognitive change 0 5 2.05 1.305 
2.2 Observed cognitive change 0 5 0.70 1.005 
3. Emotional Disturbance 
3.1 Subjective emotional disturbance 0 5 1.73 1.532 
3.2 Observed blunter affect 0 6 0.84 1.217 
3.3 Observed inappropriate affect 0 6 0.34 0.892 
4. Negative Symptoms 
4.1 Alogia 0 5 1.21 1.258 
4.2 Avolition/apathy 0 6 2.53 1.699 
4.3 Anhedonia 0 6 2.39 1.870 
5. Behavioural Change 
5.1 Social isolation 0 6 2.20 1.738 
5.2 Impaired role function 0 6 2.42 1.887 
5.3 Disorganizing/odd/stigmatising behaviour 0 5 0.56 1.071 
5.4 Aggression/dangerous behaviour 0 6 1.88 1.640 
6. Motor/Physical Changes 
6.1 Subjective complaints of impaired motor functioning 0 4 0.49 0.914 
6.2 Informant reported or observed changes in motor functioning 0 4 0.15 0.520 
6.3 Subjective complaints of impaired bodily sensation 0 6 0.63 1.253 
6.4 Subjective complaints of impaired autonomic functioning 0 5 0.85 1.332 
7. General Psychopathology 
7.1 Mania 0 6 0.61 1.218 
7.2 Depression 0 6 2.75 1.600 
7.3 Suicidality and self-harm 0 6 1.56 1.571 
7.4 Mood swings/lability 0 5 1.32 1.499 
7.5 Anxiety 0 6 2.67 1.716 
7.6 Obsessive compulsive symptoms 0 6 1.11 1.550 
7.7 Dissociative symptoms 0 6 0.98 1.494 
7.8 Impaired tolerance to normal stress 0 5 1.80 1.793 
Total CAARMS Score 0 92 40.39 20.33 
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Two hundred and fifty two subjects (54%) of the sample completed the CAARMS at 
follow up. The average follow up time was 639 days (range 95 – 1002). The mean 
total CAARMS score at follow up was 34.46 (SD = 21.81). Of those who completed 
follow up CAARMS 39% were in symptomatic remission 49% still met APS Criteria, 
2% met criteria for a BLIP and 9% had transitioned to psychosis. Of the total sample 
(including those who did not complete follow up CAARMS) fifty-one (11.8%) 
subjects made transition to psychosis in the two years from first contact 
(determined from clinical records for those who did not come in for follow up 
interview). 
GAF Scores:  
Four hundred and fifty eight subjects completed GAF at baseline (four hundred and 
eight of those had separate scores for symptoms and disability and the remaining 
fifty had only a total score). The mean symptom score was 59.31 (SD = 14.68, range 
= 15-100), the mean disability score was 69.82 (SD = 15.25, range = 30-100) and the 
mean total score was 59.16 (SD = 13.72, range = 30-100). 
Two hundred and forty eight subjects completed GAF at follow up (two hundred 
and fourteen of those had separate scores for symptoms and disability and the 
remaining thirty four had only a total score). The mean symptom score was 63.05 
(SD = 15.56, range = 15-100), the mean disability score was 63.94 (SD = 16.64, range 
= 15-100) and the mean total score was 62.32 (SD = 15.33, range = 15-100). 
Symptom Dimensions: 
Dimension scores were calculated as a mean of items that loaded on each factor as 
determined in the factor analysis in the second chapter. Information on baseline 
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CAARMS total scores and dimension scores are shown in table 19 below. Two 
hundred and fifty one subjects (54%) of the sample completed the CAARMS at 
follow up, follow up dimension scores are also shown in table 19. 
Regression weights of the items on each factor (as determined by baseline CAARMS 




Table 19: Descriptive Statistics of CAARMS Scores of 463 UHR subjects at baseline and 240 UHR subjects at Follow Up 
 
Baseline Follow Up 
Min Max Mean SD Min Max Mean SD 
CAARMS Total Score 





0 5.25 2.34 1.41 0 5.00 1.85 1.39 
Disorganised - 
Behavioural 
0 3.50 0.38 0.58 0 2.50 0.28 0.48 
Disorganised – 
Cognitive 
0 4.00 1.37 0.91 0 5.00 1.07 0.94 
Affective 
Instability 
0 4.67 1.14 0.99 0 4.33 1.02 0.94 
Anxiety 










Characteristics of Patients not Followed Up: 
Two hundred and fifty-two participants completed the full follow up interview, 
including the CAARMS and GAF. The mean duration of follow-up in this subgroup 
was 639 days (Median = 728 days, SD = 245 days). Two hundred and eleven 
subjects did not complete the follow up interview. In this subgroup, outcome data 
were obtained from clinical records. A comparison of the demographic and clinical 












Not Followed Up 
n 463 252 211 
Age 
Mean 22.66 24.25 24.63 
SD 4.351 4.516 4.839 
Gender (male) 254 (55%) 137 (54%) 120 (56%) 
Ethnicity 
White 310 (67%) 173 (69%) 144 (68%) 
BME 153 (33%) 79 (31%) 67 (32%) 
 Intake 
Group 
APS 398 (86%) 234 (93%) 178 (84%) 
BLIP 28 (7%) 8 (3%) 17 (8%) 
Genetic 
Vulnerability 











































A Chi Square test for association showed there was a significant difference in the 
intake group for those followed up and those not χ (2) = 6.182, p = .045. Those 
who completed follow up were more likely to have met APS CAARMS criteria but 
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less likely to have met BLIP criteria. There were no other significant differences 
between the two groups. 
4.3.3 Baseline Correlates of Symptom Dimensions 
Pearson product-moment correlation coefficient showed a positive correlation 
between age and the Affective Instability dimension, which was statistically 
significant (r = -0.154, p = .001) despite the correlation coefficient being small. 
There was no correlation between any of the other dimensions and age.  An 
independent samples t-test showed that there was a significant difference 
between males and females for the Anxiety and Negative dimensions, with 
females scoring higher on both Negative (male: 2.20 ± 1.47; female: 2.47 ± 1.36; 
t(447) = -2.032, p = 0.043) and anxiety (male: 2.08 ± 1.41; female 2.43 ± 1.31; 
t(447) = -2.720, p = 0.007) dimensions. There was no significant difference 
between any of the other factors according to gender. 
For all of the dimensions, a high score was correlated with a lower total GAF at 
baseline (Table 21 below). The strongest (negative) correlation (r = -0.600, p = 
.000) was between the scores on the Negative dimension and the GAF, which was 
considerably stronger than the correlation between Total CAARMS score and GAF 


































One-way ANOVA revealed a significant difference across the Inclusion groups 
(APS/BLIP/Genetic Vulnerability) for the Negative (F (2, 409) = 3.091, p = .047); 
Anxiety (F (2, 409) = 6.169, p = .002) and Disorganised - Cognitive (F (2, 409) = 
7.052, p = .001) dimensions. Post hoc Tukey tests indicated that this reflected the 
APS group having higher mean scores on both the Negative (2.64 ± 1.25; 2.08 ± 
1.38; p = .05) and the Anxiety dimensions (2.56 ± 1.21; 1.78 ± 1.15; p = .003) than 
the Genetic Vulnerability group, and the APS group having a higher mean score on 
the Disorganised - Cognitive dimension than the BLIP group (1.58 ± 0.83; 1.04 ± 
0.89; p = .005). There was no statistically significant difference between the 
inclusion groups on the Affective Instability (p = .194) and Disorganised – 
Behavioural (p = .278) dimensions. The mean scores for each dimension in each 
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inclusion group are shown in figure 15 below. Multinomial logistic regression of 











4.3.4 Symptom Dimensions and Clinical Outcome 
Transition to Psychosis: 
Participants were followed up 24 months after baseline to assess whether 
psychosis had occurred. The mean duration of follow-up was 639 days (median = 
728 days, SD = 245 days).  
59 participants (11.8%) converted to psychosis during the follow up period. The 
mean number of days from baseline to transition to psychosis was 322 days 
(range: 5-1109). Of the subjects who transitioned, 59% were male and their 
average age at baseline was 22.2 years. Chi squared tests showed that there was 
no significant difference in age, gender or ethnicity between those who 
transitioned and those who did not.  
An independent samples t-test examining differences in the five baseline 
dimensions scores and total CAARMS score of those who transitioned and those 
who did not showed that subjects who transitioned scored significantly higher in 
the CAARMS severity overall (transition: 49.74 ± 15.51; non-transition: 43.02 ± 
16.83; t(490) = -2.904, p = 0.004) and on the Anxiety dimension than those who 
did not (transition: 11.56 ± 4.76; non-transition: 9.68 ± 4.98; t(485) = -2.722, p = 
0.007). 
Independent logistic regressions with age and gender as covariates for scores on 
each dimension and the total CAARMS score showed that scores on the Anxiety 
and the Affective Instability dimensions as well as the total CAARMS score were 
associated with an increased rate of transition to psychosis. In each case, subjects 
who made a transition scored higher at baseline than those who did not become 
152 
 
psychotic. The effects for the Anxiety dimension and the total CAARMS score were 
stronger than for the Affective Instability dimension. There were no significant 
differences between these those who did and did not transition to psychosis for 





Table 22: Table to show Separate Regression Analyses (P values) for Each of the Five Dimensions (Predictor Variables) and Transition to Psychosis 





Negative 0.053 0.029 3.413 0.065 1.055 0.997 1.116 
Disorganised – 
Behavioural 
0.094 0.052 3.276 0.070 1.099 0.992 1.217 
Disorganised – 
Cognitive 
0.067 0.042 2.532 0.112 1.070 0.985 1.162 
Affective Instability 0.097 0.048 4.002 0.045** 1.102 1.002 1.212 
Anxiety 0.081 0.030 7.306 0.007** 1.085 1.023 1.150 
Total CAARMS Score 0.026 0.009 8.642 0.003** 1.027 1.009 1.045 
 




The mean total GAF score at follow up was 62.32 (SD = 15.33, range = 15-100). 
One hundred and fifty three (56.5%) of those who completed GAF at follow up 
were defined as having a poor functional outcome (GAF < 65). Subjects who had a 
poor functional outcome had an average age of 22.4 years and were 54% male; 
Chi squared test showed no significant difference in age, gender or ethnicity 
between those who had a poor functional outcome and those who did not.  
Of the 41 transitioned subjects who completed follow up GAF, 35 (85%) had poor 
functional outcome but 6 had a good functional outcome. However, in these 6 
subjects there was a relatively long delay between the date of transition and the 
follow up GAF assessment: 163 days, as opposed to 48 days in the transition 
subjects with a poor functional outcome.  
An independent samples t-test comparing the dimensions scores at baseline in 
those with a poor and a good functional outcome at follow up showed that the 




Table 23: Table to show the Difference Between Baseline Composite Symptom Dimension Scores in Good 












Good 10.02 4.99 5.74 249.00 0.000 2.45 5.01 




Good 1.96 2.46 6.25 248.00 0.000 1.07 2.05 
Poor 0.40 0.99 6.82 191.60 0.000 1.11 2.01 
Disorganised 
– Cognitive 
Good 5.50 3.68 4.61 254.00 0.000 1.14 2.83 
Poor 3.51 3.06 4.71 253.30 0.000 1.15 2.81 
Affective 
Instability 
Good 4.13 2.93 7.52 249.00 0.000 1.80 3.07 
Poor 1.69 1.94 7.89 243.05 0.000 1.83 3.04 
Anxiety 
Good 10.23 4.57 9.81 249.00 0.000 4.36 6.56 
Poor 4.77 4.12 9.94 243.76 0.000 4.38 6.54 
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Independent logistic regressions with age and gender as covariates for each 
dimension and the total CAARMS score revealed that the Disorganised – 
Behavioural dimension was associated with an increased risk of a poor functional 
outcome:  subjects with a poor functional outcome scored higher on this 
dimension than those with a good outcome. In this analysis there were no 
significant differences in relation to functional outcome on the other four 





Table 24: Table to show Separate Regression Analyses (P values) for Each of the Five Dimensions (Predictor Variables) and Transition to Psychosis 





Negative -0.014 0.025 0.310 0.578 0.986 0.939 1.036 
Disorganised – 
Behavioural 
-0.136 0.061 4.895 0.027** 0.873 0.774 0.985 
Disorganised – 
Cognitive 
-0.041 0.040 1.058 0.304 0.960 0.888 1.038 
Affective 
Instability 
-0.059 0.046 1.665 0.197 0.942 0.861 1.031 
Anxiety -0.041 0.027 2.301 0.129 0.960 0.910 1.012 
Total CAARMS 
Score 
-0.012 0.008 2.463 0.117 0.988 0.972 1.003 
 





4.4.1 Aims and Results of the Study 
At baseline, higher severity scores on all five factors were associated with a lower 
level of functioning, with scores on the Negative dimension being most strongly 
correlated with lower functioning. Although there were significant differences 
between scores on the Negative, Disorganised and Affective Instability dimensions 
between inclusion groups for the UHR state, none of the dimensions determined 
inclusion group.  
After an average of 1 year and 9 months of follow up, 51 subjects (12%) in this 
sample had transitioned to psychosis. The regression analyses of follow up data 
showed that scores on the Anxiety dimension and the total CAARMS score, and to 
a lesser extent the Affective Instability dimension predicted later transition to 
psychosis. Scores on the Disorganised - Behavioural dimension predicted a poor 
functional outcome, independent of whether a subject became psychotic or not. 
4.4.2 Comparison with Previous Studies 
Both Demjaha et al. (2010) and Raballo (2011) found strong links between a 
negative dimension and later transition to psychosis, which was not the case in 
this sample. This is also in direct contrast to findings in schizophrenia, where a 
negative dimension has consistently been linked to a worse clinical outcome 
(Levine & Leucht, 2013; Rabinowitz et al., 2012; van Os et al., 1996). This apparent 
discrepancy may be because two items (Impaired Role Function and Social 
Isolation) that were included in the negative dimension in both the Demjaha and 
the Raballo models (in figures 1 and 2 in section 2.1.3 and 2.1.4 respectively) were 
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included in the Anxiety dimension in the current model (shown in figure 4 in 
section 2.3.4. A detailed comparison of the three models is in section 2.4.2).  
A link between anxiety items and Impaired Role Function and Social Isolation is 
not unexpected. In the Raballo model all these items loaded on their 
Negative/Interpersonal dimension and it was this dimension, including both 
negative and anxiety symptoms that was linked to transition. Anxiety symptoms in 
UHR subjects have also been linked to a poor functional outcome (Fusar-Poli et al., 
2014).  
The deficits in emotional and executive functioning that are widely reported in 
anxiety disorders (Sylvester et al., 2012) are also significant impairments in 
patients with schizophrenia (Minzenberg et al., 2009; Tseng et al., 2016), therefore 
it may be that these symptoms in UHR are critical in determining the risk of 
transition to psychosis, rather than specifically the anxiety symptoms. A 
breakdown of the link between each of the four items (Anxiety, Impaired Role 
Function, Impaired Tolerance to Normal Stress and Social Isolation) included in the 
Anxiety dimension and their relationship to transition would determine this. 
The finding that Affective Instability symptoms (Mood Swings, Aggression and 
Dangerous Behaviour and Suicidality and Self Harm) were associated with later 
transition to psychosis has not previously been found. It may be that these 
symptoms are not indicative of transition in themselves, but that they are 
symptoms that arise in response to the presence of severe positive symptoms 
(that did not load on any factor, so are not included). This is supported by the 
finding that higher total CAARMS score, which includes all the positive item scales, 
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predicts transition. In general, the finding that increased severity of baseline 
presentation indicates an increased risk of transition to psychosis is in line with 
expectations and has been found in several UHR studies (Cannon et al., 2008; 
Ruhrmann et al., 2003; Valmaggia et al., 2013; Yung et al., 2005). 
At baseline, all symptom dimensions were linked to lower functioning, a finding in 
line with those from both previous UHR studies (Demjaha et al., 2010; Raballo, 
2011). However, previous studies did not look at the relationship between 
baseline dimension scores and level of functioning at follow up. My finding that 
the Disorganised – Behavioural dimension was linked to poor functional outcome 
is consistent with findings in patients with psychosis (Fulford et al., 2013; O'Leary 
et al., 2000; Ortiz et al., 2015) reporting disorganised symptoms are associated 
with repeated admissions and poor social and role functioning. The link between 
disorganised symptoms and poor functional outcome has also been found in 
several previous studies of UHR subjects (Carrión et al., 2013; Niendam et al., 
2007; Ziermans et al., 2014). 
However, in the present study it was the Disorganised - Behavioural dimension 
that was associated with poor functional outcome, as opposed to the Disorganised 
– Cognitive dimension. Several previous studies have found a link between 
neurocognitive functioning and functional outcome in the UHR group (Lin et al., 
2011; Niendam et al., 2007). This differentiation between cognitive and 
behavioural disorganisation may mirror the distinction made by B. A. Cornblatt et 
al. (2007) between social and role function in the NAPLS study, who argued that 
these represent two distinct domains that need to be disentangled to avoid 
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confounding functioning with psychiatric symptoms. When measuring functioning 
in terms of social (appropriate relationships and social interaction) and role 
(performance and cognitive ability) functioning, B. A. Cornblatt et al. (2007) found 
that impairments in social functioning were relatively stable and were associated 
with later transition, whereas impaired role functioning became worse in the lead 
up to presentation but then improved during clinical follow up. This finding has 
been replicated by Velthorst et al. (2010), and is in line with poor outcome being 
linked to behavioural (social) disorganisation rather than cognitive (role) 
disorganisation.  
4.4.3 Limitations 
Although at baseline there were no significant demographic or clinical differences 
between subjects who completed follow up and subjects who did not, differences 
in functioning at the time of follow up could have influenced the results. Subjects 
with relatively poor functioning may be less likely to attend a follow up interview. 
Therefore the follow up information may not be representative of the entire 
population after two years.  
Binary logistic regression was used in this analysis to determine the relationship 
with outcome, however, this uses a fixed time point to determine outcome. As 
determined by Fusar-Poli et al. (2012), a small proportion of UHR subjects may 
develop psychosis more than two years after presentation. It is thus possible that 
further subjects in the present sample will go on to become psychotic, and this 
might alter the findings. It may also have contributed to the transition rate (11%) 
being relatively low (see general discussion). The majority of subjects in the 
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present study were recruited through clinical services, so it should be possible to 
obtain information on clinical outcomes beyond the two year follow up period, 
even though the original research studies have now been completed.  
The low transition rate could be due to: a) incomplete follow up – only 2 years b) 
selection bias whereby more severely ill / impaired UHR subjects decline to take 
part in intensive and demanding research projects. For Example: EU-GEI entailed 
multiple and lengthy assessment interviews, while other projects involved multi-
modal neuroimaging. C) referral bias – as clinical services for UHR become well 
known, the typeof UHR person referred may change, such that less obviously ill / 
impaired individuals are referred. (Fusar-Poli et al, 2017)] 
4.4.4 Future Research Directions 
The distinction of outcome according to function is an important step in 
considering the risk in the UHR population not only as transition to psychosis. By 
doing so we are categorising all those who do not transition in to one outcome 
group, whereas the functional outcome considers the effect on personal, social 
and employment outcomes. However, there are several more considerations that 
would be interesting to investigate. For this study, we determined outcome in 
terms of binary functionality, however, it would be valuable to include comorbid 
diagnosis to differentiate this (Meyer et al., 2005). Future studies could attempt to 
further distinguish the sample according to presence of comorbidity, both when 
linking baseline predictors to functional outcomes and also when considering 
diagnostic outcome. It would also be interesting to discover, as has been shown by 
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Schlosser et al. (2012), whether there are any symptomatic predictors of 
remission. 
This study has begun to examine the phenomenology of symptoms in UHR and 
how it differs from psychosis, however there are many more considerations, in 
terms of baseline and outcome variables, that would add to the model and refine 
its structure and application. 
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5 General Discussion 
5.1 Summary of Main Findings 
5.1.1 Factor Structure 
An exploratory factor analysis identified a 5-factor structure that fitted the data, 
including 19 of the 27 CAARMS items, in a sample of 461 subjects at UHR of 
psychosis from multiple sites. Confirmatory factor analysis compared this model 
with those previously described in the literature, and found it to be the best fit in 
an independent data set.  
The five dimensions were: 
• Negative 
• Disorganised – Behavioural 
• Disorganised – Cognitive 
• Anxiety 
• Affective Instability 
5.1.2 Symptom Dimensions and rCBF 
ASL was used to examine the relationship between rCBF and severity scores for 
each dimension and total CAARMS scores. In the subsample of subjects who were 
scanned and had usable data (n=70), ROI analysis of the areas previously found by 
Allen et al. (2016) the left hippocampus, left pallidum and left midbrain. ROI 
analysis of Negative dimension scores did not show any correlation between 
negative dimension scores in the areas specified by Pinkham et al. (2011), 
165 
 
however there were significant reductions in CBF in one of the areas identified by 
P. F. Liddle et al. (1992): mediodorsal thalamus and the Disorganised – Behavioural 
dimension. Whole Brain analysis showed decreased perfusion in the scores on the 
Disorganised – Behavioural factor were found to correlate with a significant 
reduction in rCBF in the left hippocampus and the thalamus bilaterally. Scores on 
the Anxiety dimension were correlated with significant reductions in rCBF in 
bilateral prefrontal and cingulate cortex. 
5.1.3 Symptom Dimensions and Clinical Presentation and Outcome 
Higher scores on all dimensions were associated with worse functional 
presentation at baseline. The analysis of the relationship between factor scores 
and transition to psychosis showed that higher scores on the Anxiety and Affective 
Instability dimension and higher total CAARMS score were associated with 
increased risk of transition to psychosis, and higher scores on the Disorganised – 
Behavioural dimension was associated with worse functional outcome at 21 
month follow up. 
5.2 Discussion 
The poor social and economic outcome, functional impairments and health and 
societal costs of psychotic disorders (Boonstra et al., 2012), have led to an 
increasing focus on early clinical detection and intervention. The UHR state is a 
clinical syndrome that is associated with a very high risk of developing psychosis. 
However, the majority of UHR subjects do not go on to develop a psychotic 
disorder (Fusar-Poli et al., 2012) and a significant proportion have substantial 
clinical needs even if they do not become psychotic (Fusar-Poli et al., 2014). The 
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most recent Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
(DSM-V) has included ‘attenuated psychosis syndrome’ in its Appendix (Section III) 
as a disorder that merits further study. Attenuated psychosis syndrome, however 
is not determined solely in terms of risk of transition to psychosis; it is rather 
defined as ‘a currently relevant clinical condition leading to help seeking, with 
many more clinical outcomes other than conversion to psychosis.’ Given the 
diversity of clinical outcomes in the UHR group, it is may be helpful to consider 
their clinical presentation in terms of symptom dimensions, which are 
independent of diagnostic categories.  
This study indicates that there are five distinct dimensions of symptoms measured 
by the CAARMS. Two previous studies looked at the dimensional structure of 
symptoms in the UHR using the SOPS (Comparelli et al., 2011; Hawkins et al., 
2004).  Both identified a three factor structure roughly comprising Positive, 
Negative and Disorganised symptoms, (n = 128 and n = 49 respectively). However, 
a study conducted concurrently with this one, also in a large UHR sample (n=334) 
and using PAF with an oblique rotation, reported that a four factor structure fitted 
the data better, with the items that were previously grouped on to one dimension 
in the three factor models, splitting exactly in to two separate dimensions (Tso et 
al., 2017). Using Principle Axis Factoring this study found four latent factors 
explaining 36.1% of the total variance: positive symptoms; distress; negative 
symptoms; and deteriorated thought process. The sample in this study was 
younger (age range: 12-25, mean: 17) and included both high and low clinical risk 
as well as very early first episode psychosis. 
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This pattern of the large dimensions splitting in to two underlying ones has also 
been found in the present study using the CAARMS, with the five factor structure 
very similar to Demjaha et al. (2010), and almost exactly splitting two of the three 
factors found by Raballo et al. (2011) each in to two separate factors 
demonstrated in figures 16 and 17. This may be because a larger sample allows 
the distinctions between the two underlying factors to become more distinct, 
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Figure 17: Figure to Show Comparison of Negative Dimensions of Raballo Model and Current Model 
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This finding of larger dimensions splitting in to two smaller ones in both CAARMS 
and SOPS may suggest a hierarchical factor structure. This was initially suggested 
by M. J. Cuesta and Peralta (2001) and confirmed in First Episode psychosis by 
Russo et al. (2014) where factor analyses identified 6 first-order factors (mania, 
negative, disorganization, depression, hallucinations, and delusions) and 2 high-
order factors (affective and non-affective psychoses).  
Furthermore, this thesis suggests that symptom dimensions in the UHR state may 
have distinct neural correlates. Although this has previously been described for 
symptom dimensions in schizophrenia (Liddle et al., 1992), this is the first evidence 
that this may also be true of the UHR state. Although the sample in the present 
study was relatively large for a neuroimaging study, the findings require 
replication, ideally in even larger UHR samples.  
 The finding that scores on symptom dimensions may be related to the risk of later 
transition to psychosis and functional outcome is of great interest, as it raises the 
possibility that measures of dimensions could ultimately be useful in clinical tools 
that are designed to predict the risk of psychosis. Such tools are still in their 
infancy, and it is unclear which types of baseline measures (clinical, cognitive, 
genomic, neuroimaging) will be most useful as predictors in a clinical setting 
(McGuire et al., 2015).  
Further research in this area could build on the outcomes examined here to 
determine whether any particular dimension scores at baseline predicted 
remission from UHR state as opposed to persistent UHR symptoms, or whether 
baseline dimensions predicted the type of psychosis that developed (e.g.: Affective 
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Instability –bipolar; Negative –schizophrenia); or the development of other mental 
health diagnoses. 
A possible application of symptom dimension scores in the UHR group is that 
these could provide a guide to the most appropriate form of clinical intervention. 
For example, there is some evidence that in psychosis patients, Cognitive 
Remediation has a selective effect on scores on disorganised and negative 
dimensions (Cella et al., 2014). 
The finding that the anxiety dimension predicts transition is of clinical relevance as 
Cognitive Behavioural Therapy (CBT) for anxiety could be used instead of CBT for 
psychosis – which has questionable efficacy. In a systematic review and meta-
analysis of the effectiveness of CBT for schizophrenic symptoms Jauhar et al. 
(2014) found that CBT has a low therapeutic effect on schizophrenic symptoms 
which reduces further when sources of bias, particularly masking, are controlled 
for. 
Two meta-analyses examining intervention in the UHR group have found low 
(Marshall & Rathbone, 2011) to moderate (Stafford et al., 2013) effects of 
intervention at this stage, indicating that a more specialised focus is needed to 
target lower transition rate and better functional outcome. 
The key role of the Anxiety factor in determining transition is an interesting finding 
in UHR, since previous studies have highlighted the importance of negative 
symptoms (Valmaggia et al., 2013). Anxiety is known to affect emotional 
regulation and attentional control and wide ranging impairments in emotional and 
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executive functioning are evident in schizophrenia (Minzenberg et al., 2009). In 
the Tso et al. (2017) SOPS model, this is also reflected with the distress factor 
accounting for a larger proportion of the variance than the negative or 
disorganised factors, and confirms the importance of anxiety and mood symptoms 
highlighted in many recent studies (Fulford et al., 2013; Lin et al., 2015; Rietdijk et 
al., 2013).These findings suggest that the young people at UHR of psychosis may 
resemble an affectively disturbed group (A. P. Morrison et al., 2012) which has 
clinical implications for assessment, intervention, and treatment. Rather than a 
specific focus on positive symptoms of psychosis, this study highlights the 
importance of intervention aimed at treating affective dysregulation, which may in 
turn affect the rate of transition. 
The transition rate in this large sample was 11% at two years, which is significantly 
lower than the 29% determined in the meta-analysis by Fusar-Poli et al. (2012). 
This may be due to the increasing clinical focus on early detection of UHR subjects, 
such that more recent studies are recruiting individuals at an earlier stage or who 
are less severely ill than in previous studies. Clinical UHR services may now be 
more likely to provide active clinical intervention, as opposed to passive 
monitoring. In a recent analysis of transition rates Nelson et al. (2016) found that 
patients with a short duration of UHR symptoms had lower transition rates. It may 
also be due to a selection bias – the interview for participating in the studies used 
was up to three hours long and included multimodal imaging. More severely ill 
patients may not have agreed to this long process or may not have been able to 
complete it. The rate of 11% in this study is in line with more recent studies in 
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London (Allen et al., 2015; Allen et al., 2016) as well as elsewhere (A. P. Morrison 
et al., 2012; Velthorst et al., 2009). 
5.3 Limitations  
Specific limitations for each experimental chapter are considered in their 
respective sections; however, there is one overarching limitation to be considered 
when working with UHR cohorts. Due to the non-specific nature of prodromal 
symptoms, there are reasonable concerns about premature labelling as clinical 
features can be difficult to distinguish from benign conditions and normal 
experience. This is why research in this population needs to be cognisant of the 
‘false positive’ group, and why determination of outcomes other than transition to 
psychosis need to be considered. 
This study also uses the UHR group as a whole, including participants who meet all 
three inclusion groups: APS, BLIP and Genetic Vulnerability (as has been the case 
in the previous CAARMS and SOPS factor analyses). There has been recent 
discussion of whether it makes clinical sense to combine the three groups after 
studies such as P Fusar-Poli et al. (2016a) found differing risk of transition in the 
BLIP group compared to APS and Genetic Vulnerability, APS alone and Genetic 
Vulnerability alone groups. Although the APS group makes up the majority of the 
sample (86%), the clinical and symptomatic presentation across the groups vary, 
and therefore it would interesting to investigate or confirm the factor structure in 





One of the fundamental goals in understanding the Ultra High Risk state is linking 
the observable symptoms to the underlying unobservable pathophysiology, and 
discerning their clinical relevance. This study shows that a dimensional approach 
to psychopathology may facilitate the assessment of the clinical heterogeneity of 
this population and their underlying distinct neurobiology. It also shows that 
presenting symptomatology can be characterised by dimensions that have distinct 
associations with outcome, whilst highlighting the importance of continued 
research to inform the understanding of the development of psychosis and the 





Addington, J., Cadenhead, K. S., Cannon, T. D., Cornblatt, B., McGlashan, T. H., Perkins, D. 
O., . . . Woods, S. W. (2007). North American Prodrome Longitudinal Study: a 
collaborative multisite approach to prodromal schizophrenia research. 
Schizophrenia Bulletin, 33(3), 665-672.  
Addington, J., Cornblatt, B. A., Cadenhead, K. S., Cannon, T. D., McGlashan, T. H., Perkins, 
D. O., . . . Woods, S. W. (2011). At clinical high risk for psychosis: outcome for 
nonconverters. American Journal of Psychiatry, 168(8), 800-805.  
Adriano, F., Spoletini, I., Caltagirone, C., & Spalletta, G. (2010). Updated meta-analyses 
reveal thalamus volume reduction in patients with first-episode and chronic 
schizophrenia. Schizophr Res, 123(1), 1-14. doi: 10.1016/j.schres.2010.07.007 
Allen, Chaddock, C. A., Egerton, A., Howes, O. D., Barker, G., Bonoldi, I., . . . McGuire, P. 
(2015). Functional outcome in people at high risk for psychosis predicted by 
thalamic glutamate levels and prefronto-striatal activation. Schizophrenia Bulletin, 
41(2), 429-439.  
Allen, Chaddock, C. A., Egerton, A., Howes, O. D., Bonoldi, I., Zelaya, F., . . . McGuire, P. 
(2016). Resting Hyperperfusion of the Hippocampus, Midbrain, and Basal Ganglia 
in People at High Risk for Psychosis. Am J Psychiatry, 173(4), 392-399. doi: 
10.1176/appi.ajp.2015.15040485 
Andreasen, N. C., Arndt, S., Alliger, R., Miller, D., & Flaum, M. (1995). Symptoms of 
schizophrenia: methods, meanings, and mechanisms. Archives of General 
Psychiatry, 52(5), 341-351.  
Andreasen, N. C., Rezai, K., Alliger, R., Swayze, V. W., Flaum, M., Kirchner, P., . . . O'Leary, 
D. S. (1992). Hypofrontality in neuroleptic-naive patients and in patients with 
chronic schizophrenia: Assessment with xenon 133 single-photon emission 
computed tomography and the Tower of London. Archives of General Psychiatry, 
49(12), 943-958.  
Arbuckle, J. L. (2014). Amos (Version 23.0) [Computer Program] (Version 23): Chicago: IBM 
SPSS.  
Arndt, S., Andreasen, N. C., Flaum, M., Miller, D., & Nopoulos, P. (1995). A longitudinal 
study of symptom dimensions in schizophrenia: prediction and patterns of 
change. Archives of General Psychiatry, 52(5), 352-360.  
Association, A. P. (2000). DSM-IV-TR: Diagnostic and statistical manual of mental 
disorders, text revision. Washington, DC: American Psychiatric Association, 75.  
Barrett, P. (2007). Structural equation modelling: Adjudging model fit. Personality and 
Individual differences, 42(5), 815-824.  
Beiser, M. E., David; Fleming, Jonathan; Iacono, William. (1993). Establishing the onset of 
psychotic illness. American Journal of Psychiatry, 150(9), 1349-1354. doi: 
doi:10.1176/ajp.150.9.1349 
Bernard, J. A., Dean, D. J., Kent, J. S., Orr, J. M., Pelletier-Baldelli, A., Lunsford-Avery, J. R., . 
. . Mittal, V. A. (2014). Cerebellar networks in individuals at ultra high-risk of 
psychosis: impact on postural sway and symptom severity. Hum Brain Mapp, 
35(8), 4064-4078. doi: 10.1002/hbm.22458 
Bernard, J. A., Orr, J. M., & Mittal, V. A. (2015). Abnormal hippocampal–thalamic white 
matter tract development and positive symptom course in individuals at ultra-
high risk for psychosis. NPJ Schizophrenia, 1, 15009. doi: 10.1038/npjschz.2015.9 
176 
 
Berrios, G. E., & Porter, R. (1995). A History of Clinical Psychiatry: The Origin and History of 
Psychiatric Disorders: Athlone Press. 
Bhardwaj, R., Chakrabarti, S., Mittal, B. R., & Sharan, P. (2010). A single photon emission 
computerized tomography (SPECT) study of regional cerebral blood flow in bipolar 
disorder. World J Biol Psychiatry, 11(2 Pt 2), 334-343. doi: 
10.3109/15622970802575977 
Birchwood, M., Todd, P., & Jackson, C. (1998). Early intervention in psychosis: the critical-
period hypothesis. International Clinical Psychopharmacology, 13, S31-S40.  
Bollen, K. A. (1990). Overall fit in covariance structure models: Two types of sample size 
effects. Psychological bulletin, 107(2), 256.  
Boonstra, N., Klaassen, R., Sytema, S., Marshall, M., De Haan, L., Wunderink, L., & 
Wiersma, D. (2012). Duration of untreated psychosis and negative symptoms - A 
systematic review and meta-analysis of individual patient data. Schizophrenia 
Research, 142(1-3), 12-19. doi: 10.1016/j.schres.2012.08.017 
Braga, R. J., Reynolds, G. P., & Siris, S. G. (2013). Anxiety comorbidity in schizophrenia. 
Psychiatry Res, 210(1), 1-7. doi: 10.1016/j.psychres.2013.07.030 
Brown, T. A., & Barlow, D. H. (2009). A proposal for a dimensional classification system 
based on the shared features of the <em>DSM-IV</em> anxiety and mood 
disorders: Implications for assessment and treatment. Psychological Assessment, 
21(3), 256-271. doi: 10.1037/a0016608 
Buchmann, A., Dentico, D., Peterson, M. J., Riedner, B. A., Sarasso, S., Massimini, M., . . . 
Ferrarelli, F. (2014). Reduced mediodorsal thalamic volume and prefrontal cortical 
spindle activity in schizophrenia. NeuroImage, 102 Pt 2, 540-547. doi: 
10.1016/j.neuroimage.2014.08.017 
Buchsbaum, M. S., Ingvar, D. H., Kessler, R., Waters, R. N., Cappelletti, J., Van Kammen, D. 
P., . . . Flynn, R. W. (1982). Cerebral glucography with positron tomography: Use in 
normal subjects and in patients with schizophrenia. Archives of General 
Psychiatry, 39(3), 251-259.  
Cannon, T. D., Cadenhead, K., Cornblatt, B., Woods, S. W., Addington, J., Walker, E., . . . 
Heinssen, R. (2008). Prediction of psychosis in youth at high clinical risk: a 
multisite longitudinal study in North America. Archives of General Psychiatry, 
65(1), 28-37. doi: 10.1001/archgenpsychiatry.2007.3 
Carlson, J. M., Greenberg, T., Rubin, D., & Mujica-Parodi, L. R. (2011). Feeling anxious: 
Anticipatory amygdalo-insular response predicts the feeling of anxious 
anticipation. Social Cognitive and Affective Neuroscience, 6(1), 74-81. doi: 
10.1093/scan/nsq017 
Carrión, R. E., McLaughlin, D., Goldberg, T. E., Auther, A. M., Olsen, R. H., Olvet, D. M., . . . 
Cornblatt, B. A. (2013). Prediction of functional outcome in individuals at clinical 
high risk for psychosis. JAMA Psychiatry, 70(11), 1133-1142.  
Catafau, A. M., Parellada, E., Lomeña, F. J., Bernardo, M., Pavía, J., Ros, D., . . . Gonzalez-
Monclús, E. (1994). Prefrontal and temporal blood flow in schizophrenia: resting 
and activation technetium-99m-HMPAO SPECT patterns in young neuroleptic-
naive patients with acute disease. Journal of nuclear medicine: official publication, 
Society of Nuclear Medicine, 35(6), 935-941.  
Cella, M., Reeder, C., & Wykes, T. (2014). It is all in the factors: effects of cognitive 
remediation on symptom dimensions. Schizophr Res, 156(1), 60-62. doi: 
10.1016/j.schres.2014.03.032 
Chen, J. J., Wieckowska, M., Meyer, E., & Pike, G. B. (2008). Cerebral blood flow 
measurement using fMRI and PET: a cross-validation study. International journal 
of biomedical imaging, 2008.  
Child, D. (1990). The essentials of factor analysis: Cassell Educational. 
177 
 
Chua, S. E., & Murray, R. M. (1996). The neurodevelopmental theory of schizophrenia: 
evidence concerning structure and neuropsychology. Ann Med, 28(6), 547-555.  
Chua, S. E., Wright, I. C., Poline, J. B., Liddle, P. F., Murray, R. M., Frackowiak, R. S., . . . 
McGuire, P. K. (1997). Grey matter correlates of syndromes in schizophrenia. A 
semi-automated analysis of structural magnetic resonance images. British Journal 
of Psychiatry, 170, 406-410.  
Cleghorn, J. M., Garnett, E. S., Nahmias, C., Firnau, G., Brown, G. M., Kaplan, R., . . . 
Szechtman, B. (1989). Increased frontal and reduced parietal glucose metabolism 
in acute untreated schizophrenia. Psychiatry Research, 28(2), 119-133.  
Comparelli, A., Savoja, V., Kotzalidis, G., Woods, S., Mosticoni, S., Vassallo, F., . . . Pucci, D. 
(2011). Factor–structure of the Italian version of the Scale Of Prodromal 
Symptoms (SOPS): a comparison with the English version. Epidemiology and 
Psychiatric Sciences, 20(01), 45-54.  
Comrey, A. L. (1973). A First Course in Factor Analysis: Academic Press. 
Cornblatt, Carrion, R. E., Addington, J., Seidman, L., Walker, E. F., Cannon, T. D., . . . Lencz, 
T. (2012). Risk factors for psychosis: impaired social and role functioning. 
Schizophr Bull, 38(6), 1247-1257. doi: 10.1093/schbul/sbr136 
Cornblatt, B. A., Auther, A. M., Niendam, T., Smith, C. W., Zinberg, J., Bearden, C. E., & 
Cannon, T. D. (2007). Preliminary findings for two new measures of social and role 
functioning in the prodromal phase of schizophrenia. Schizophrenia Bulletin, 
33(3), 688-702.  
Cronenwett, W. J., & Csernansky, J. (2010) Thalamic pathology in schizophrenia. Vol. 4. 
Current Topics in Behavioral Neurosciences (pp. 509-528). 
Crumlish, N., Whitty, P., Clarke, M., Browne, S., Kamali, M., Gervin, M., . . . Larkin, C. 
(2009). Beyond the critical period: longitudinal study of 8-year outcome in first-
episode non-affective psychosis. The British Journal of Psychiatry, 194(1), 18-24.  
Cuesta, M. J., & Peralta, V. (2001). Integrating psychopathological dimensions in 
functional psychoses: a hierarchical approach. Schizophrenia Research, 52(3), 215-
229. doi: http://doi.org/10.1016/S0920-9964(00)00190-0 
Cuesta, M. J., Peralta, V., & De Leon, J. (1994). Schizophrenic syndromes associated with 
treatment response. Progress in Neuro-Psychopharmacology and Biological 
Psychiatry, 18(1), 87-99.  
Curran, P. J., West, S. G., & Finch, J. F. (1996). The robustness of test statistics to 
nonnormality and specification error in confirmatory factor analysis. Psychological 
Methods, 1(1), 16.  
De Koning, M., Bloemen, O., Van Amelsvoort, T., Becker, H., Nieman, D., Van Der Gaag, 
M., & Linszen, D. (2009). Early intervention in patients at ultra high risk of 
psychosis: benefits and risks. Acta Psychiatrica Scandinavica, 119(6), 426-442.  
Demjaha, A., Valmaggia, L., Stahl, D., Byrne, M., & McGuire, P. (2010). 
Disorganization/cognitive and negative symptom dimensions in the at-risk mental 
state predict subsequent transition to psychosis. Schizophr Bull, 38(2), 351-359. 
doi: 10.1093/schbul/sbq088 
Detre, J. A., Leigh, J. S., Williams, D. S., & Koretsky, A. P. (1992). Perfusion imaging. 
Magnetic Resonance in Medicine, 23(1), 37-45. doi: 10.1002/mrm.1910230106 
Dietsche, B., Kircher, T., & Falkenberg, I. (2017). Structural brain changes in schizophrenia 
at different stages of the illness: A selective review of longitudinal magnetic 
resonance imaging studies. Aust N Z J Psychiatry, 51(5), 500-508. doi: 
10.1177/0004867417699473 
Dikeos, D. G., Wickham, H., McDonald, C., Walshe, M., Sigmundsson, T., Bramon, E., . . . 
Sham, P. C. (2006). Distribution of symptom dimensions across Kraepelinian 
178 
 
divisions. British Journal of Psychiatry, 189, 346-353. doi: 
10.1192/bjp.bp.105.017251 
Dragt, S., Nieman, D. H., Veltman, D., Becker, H. E., van de Fliert, R., de Haan, L., & Linszen, 
D. H. (2011). Environmental factors and social adjustment as predictors of a first 
psychosis in subjects at ultra high risk. Schizophrenia Research, 125(1), 69-76.  
Drake, R., Pickles, A., Bentall, R., Kinderman, P., Haddock, G., Tarrier, N., & Lewis, S. 
(2004). The evolution of insight, paranoia and depression during early 
schizophrenia. Psychol Med, 34(02), 285-292.  
Ebmeier, K., Blackwood, D., Murray, C., Souza, V., Walker, M., Dougall, N., . . . Goodwin, G. 
(1993). Single-photon emission computed tomography with 99m Tc-exametazime 
in unmediated schizophrenic patients. Biological Psychiatry, 33(7), 487-495.  
Edwards, J., & McGorry, P. D. (2002). Implementing early intervention in psychosis: A 
guide to establishing psychosis services. London: Martin Dunitz.  
Egerton, A., Chaddock, C. A., Winton-Brown, T. T., Bloomfield, M. A. P., Bhattacharyya, S., 
Allen, P., . . . Howes, O. D. (2013). Presynaptic Striatal Dopamine Dysfunction in 
People at Ultra-high Risk for Psychosis. Biological Psychiatry, 74(2), 106-112. doi: 
10.1016/j.biopsych.2012.11.017 
Erkwoh, R., Sabri, O., Willmes, K., Steinmeyer, E. M., Büll, U., & Saß, H. (1999). Active and 
remitted schizophrenia: psychopathological and regional cerebral blood flow 
findings. Psychiatry Research: Neuroimaging, 90(1), 17-30.  
Esel, E., Kula, M., Gonul, A., Tutus, A., Basturk, M., Turan, T., . . . Yilmaz, S. (2000). 
Negative and positive symptoms: in relation to regional cerebral blood flow in 
drug-free schizophrenic patients. Bulletin of Clinical Psychopharmacology, 20, 57-
63.  
Etkin, A., & Wager. (2007). Functional neuroimaging of anxiety: a meta-analysis of 
emotional processing in PTSD, social anxiety disorder, and specific phobia. 
American Journal of Psychiatry, 164(10), 1476-1488.  
Etkin, A., & Wager, T. D. (2007). Functional neuroimaging of anxiety: A meta-ana lysis of 
emotional processing in PTSD, social anxiety disorder, and specific phobia. 
American Journal of Psychiatry, 164(10), 1476-1488. doi: 
10.1176/appi.ajp.2007.07030504 
Falloon, I. R. (1992). Early intervention for first episodes of schizophrenia: a preliminary 
exploration. Psychiatry, 55(1), 4-15.  
Fernández, P., Ortega, J., García, P., Gutiérrez, A., García, A., Bobes, J., & Miller, T. (2006). 
Predictive validity of the Scale of Prodromal Symptoms (SOPS). Actas Esp 
Psiquiatr, 34(4), 216-223.  
Fine, E. J., Ionita, C. C., & Lohr, L. (2002). The history of the development of the cerebellar 
examination. Seminars in Neurology, 22(4), 375-384. doi: 10.1055/s-2002-36759 
Franck, N., O'Leary, D. S., Flaum, M., Hichwa, R. D., & Andreasen, N. C. (2002). Cerebral 
blood flow changes associated with Schneiderian first-rank symptoms in 
schizophrenia. The Journal of Neuropsychiatry and Clinical Neurosciences, 14(3), 
277-282.  
Fulford, D., Niendam, T. A., Floyd, E. G., Carter, C. S., Mathalon, D. H., Vinogradov, S., . . . 
Loewy, R. L. (2013). Symptom dimensions and functional impairment in early 
psychosis: More to the story than just negative symptoms. Schizophrenia 
Research, 147(1), 125-131. doi: https://doi.org/10.1016/j.schres.2013.03.024 
Fusar-Poli, P., Bonoldi, I., Yung, A. R., & et al. (2012). Predicting psychosis: Meta-analysis 
of transition outcomes in individuals at high clinical risk. Archives of General 
Psychiatry, 69(3), 220-229. doi: 10.1001/archgenpsychiatry.2011.1472 
179 
 
Fusar-Poli, P., Cappucciati, M., Borgwardt, S., Woods, S. W., Addington, J., Nelson, B., . . . 
Riecher-Rössler, A. (2016a). Heterogeneity of psychosis risk within individuals at 
clinical high risk: a meta-analytical stratification. JAMA Psychiatry, 73(2), 113-120.  
Fusar-Poli, P., Cappucciati, M., Borgwardt, S., Woods, S. W., Addington, J., Nelson, B., . . . 
McGuire, P. K. (2016). Heterogeneity of Psychosis Risk Within Individuals at 
Clinical High Risk: A Meta-analytical Stratification. JAMA Psychiatry, 73(2), 113-
120. doi: 10.1001/jamapsychiatry.2015.2324 
Fusar-Poli, P., Cappucciati, M., Rutigliano, G., Lee, T. Y., Beverly, Q., Bonoldi, I., . . . 
McGuire, P. (2016b). Towards a Standard Psychometric Diagnostic Interview for 
Subjects at Ultra High Risk of Psychosis: CAARMS versus SIPS. Psychiatry Journal, 
2016, 11. doi: 10.1155/2016/7146341 
Fusar-Poli, P., Nelson, B., Valmaggia, L., Yung, A. R., & McGuire, P. K. (2014). Comorbid 
Depressive and Anxiety Disorders in 509 Individuals With an At-Risk Mental State: 
Impact on Psychopathology and Transition to Psychosis. Schizophrenia Bulletin, 
40(1), 120-131. doi: 10.1093/schbul/sbs136 
Fusar-Poli, P., Papanastasiou, E., Stahl, D., Rocchetti, M., Carpenter, W., Shergill, S., & 
McGuire, P. (2015). Treatments of Negative Symptoms in Schizophrenia: Meta-
Analysis of 168 Randomized Placebo-Controlled Trials. Schizophr Bull, 41(4), 892-
899. doi: 10.1093/schbul/sbu170 
Gevers, S., Majoie, C., Van den Tweel, X., Lavini, C., & Nederveen, A. (2009). Acquisition 
time and reproducibility of continuous arterial spin-labeling perfusion imaging at 
3T. American Journal of Neuroradiology, 30(5), 968-971.  
Goghari, V. M., Sponheim, S. R., & MacDonald Iii, A. W. (2010). The functional 
neuroanatomy of symptom dimensions in schizophrenia: A qualitative and 
quantitative review of a persistent question. Neuroscience & Biobehavioral 
Reviews, 34(3), 468-486. doi: https://doi.org/10.1016/j.neubiorev.2009.09.004 
Gold, A. L., Morey, R. A., & McCarthy, G. (2015). Amygdala–Prefrontal Cortex Functional 
Connectivity During Threat-Induced Anxiety and Goal Distraction. Biological 
Psychiatry, 77(4), 394-403. doi: https://doi.org/10.1016/j.biopsych.2014.03.030 
Good, K. P., Rabinowitz, J., Whitehorn, D., Harvey, P. D., DeSmedt, G., & Kopala, L. C. 
(2004). The relationship of neuropsychological test performance with the PANSS 
in antipsychotic naıve, first-episode psychosis patients. Schizophrenia Research, 
68(1), 11-19.  
Goozée, R., Handley, R., Kempton, M. J., & Dazzan, P. (2014). A systematic review and 
meta-analysis of the effects of antipsychotic medications on regional cerebral 
blood flow (rCBF) in schizophrenia: association with response to treatment. 
Neuroscience & Biobehavioral Reviews, 43, 118-136.  
Gur, R., & Gur, R. (1995). Hypofrontality in schizophrenia: RIP. The Lancet, 345(8962), 
1383-1384. doi: http://dx.doi.org/10.1016/S0140-6736(95)92591-0 
Handley, R., Zelaya, F. O., Reinders, A. A., Marques, T. R., Mehta, M. A., O'Gorman, R., . . . 
Dazzan, P. (2013). Acute effects of single-dose aripiprazole and haloperidol on 
resting cerebral blood flow (rCBF) in the human brain. Hum Brain Mapp, 34(2), 
272-282. doi: 10.1002/hbm.21436 
Haroun, N., Dunn, L., Haroun, A., & Cadenhead, K. S. (2006). Risk and Protection in 
Prodromal Schizophrenia: Ethical Implications for Clinical Practice and Future 
Research. Schizophrenia Bulletin, 32(1), 166-178. doi: 10.1093/schbul/sbj007 
Harrigan, S. M., McGorry, P., & Krstev, H. (2003). Does treatment delay in first-episode 
psychosis really matter? Psychol Med, 33(01), 97-110.  
Hawkins, K., McGlashan, T., Quinlan, D., Miller, T., Perkins, D. O., Zipursky, R., . . . Woods, 
S. (2004). Factorial structure of the Scale of Prodromal Symptoms. Schizophrenia 
Research, 68(2), 339-347.  
180 
 
Heckers, S. (2001). Neuroimaging studies of the hippocampus in schizophrenia. 
Hippocampus, 11(5), 520-528.  
Heckers, S. (2011). Bleuler and the neurobiology of schizophrenia. Schizophrenia Bulletin, 
37(6), 1131-1135.  
Herrman, H. (2014). Early intervention as a priority for world psychiatry. Early intervention 
in psychiatry, 8(4), 305-306. doi: 10.1111/eip.12198 
Hirano, Y., Stefanovic, B., & Silva, A. C. (2011). Spatiotemporal evolution of the functional 
magnetic resonance imaging response to ultrashort stimuli. J Neurosci, 31(4), 
1440-1447. doi: 10.1523/JNEUROSCI.3986-10.2011 
Horn, H., Federspiel, A., Wirth, M., Müller, T. J., Wiest, R., Wang, J.-J., & Strik, W. (2009). 
Structural and metabolic changes in language areas linked to formal thought 
disorder. The British Journal of Psychiatry, 194(2), 130-138.  
Howes, O. D., Montgomery, A. J., Asselin, M.-C., Murray, R. M., Valli, I., Tabraham, P., . . . 
Grasby, P. M. (2009). Elevated Striatal Dopamine Function Linked to Prodromal 
Signs of Schizophrenia. Archives of General Psychiatry, 66(1), 13-20. doi: 
10.1001/archgenpsychiatry.2008.514 
Hu, L. t., & Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance structure 
analysis: Conventional criteria versus new alternatives. Structural equation 
modeling: a multidisciplinary journal, 6(1), 1-55.  
Huneau, C., Benali, H., & Chabriat, H. (2015). Investigating Human Neurovascular Coupling 
Using Functional Neuroimaging: A Critical Review of Dynamic Models. Frontiers in 
Neuroscience, 9, 467. doi: 10.3389/fnins.2015.00467 
Ingvar, D., & Franzén, G. (1974). Distribution of cerebral activity in chronic schizophrenia. 
The Lancet, 304(7895), 1484-1486.  
Jackson, D. L. (2007). The effect of the number of observations per parameter in 
misspecified confirmatory factor analytic models. Structural equation modeling, 
14(1), 48-76.  
Jackson, H. J., & McGorry, P. D. (2009). The recognition and management of early 
psychosis: a preventive approach: Cambridge University Press. 
Jauhar, S., McKenna, P., Radua, J., Fung, E., Salvador, R., & Laws, K. (2014). Cognitive-
behavioural therapy for the symptoms of schizophrenia: systematic review and 
meta-analysis with examination of potential bias. The British Journal of Psychiatry, 
204(1), 20-29.  
Jean Addington, Barbara A. Cornblatt, Kristin S. Cadenhead, Tyrone D. Cannon, Thomas H. 
McGlashan, Diana O. Perkins, . . . Robert Heinssen. (2011). At Clinical High Risk for 
Psychosis: Outcome for Nonconverters. American Journal of Psychiatry, 168(8), 
800-805. doi: 10.1176/appi.ajp.2011.10081191 
Johnstone, E. C., Ebmeier, K. P., Miller, P., Owens, D. G., & Lawrie, S. M. (2005). Predicting 
schizophrenia: findings from the Edinburgh High-Risk Study. British Journal of 
Psychiatry, 186, 18-25. doi: 10.1192/bjp.186.1.18 
Kety, S., Woodford, R., Harmel, M., Freyhan, F., Appel, K., & Schmidt, C. (1948). Cerebral 
blood flow and metabolism in schizophrenia: the effects of barbiturate semi-
narcosis, insulin coma and electroshock. American Journal of Psychiatry, 104(12), 
765-770.  
Kircher, T. T., Bulimore, E. T., Brammer, M. J., Williams, S. C., Broome, M. R., Murray, R. 
M., & McGuire, P. K. (2001). Differential activation of temporal cortex during 
sentence completion in schizophrenic patients with and without formal thought 
disorder. Schizophr Res, 50(1-2), 27-40.  
Kirkbride, J. B., Errazuriz, A., Croudace, T. J., Morgan, C., Jackson, D., Boydell, J., . . . Jones, 
P. B. (2012). Incidence of schizophrenia and other psychoses in England, 1950–
2009: a systematic review and meta-analyses. PLoS One, 7(3), e31660.  
181 
 
Kirkbride, J. B., Fearon, P., Morgan, C., & et al. (2006). Heterogeneity in incidence rates of 
schizophrenia and other psychotic syndromes: Findings from the 3-center æsop 
study. Archives of General Psychiatry, 63(3), 250-258. doi: 
10.1001/archpsyc.63.3.250 
Klaassen, R. M. C., Velthorst, E., Nieman, D. H., de Haan, L., Becker, H. E., Dingemans, P. 
M., . . . Linszen, D. H. (2011). Factor Analysis of the Scale of Prodromal Symptoms: 
Differentiating between Negative and Depression Symptoms. Psychopathology, 
44(6), 379-385.  
Knapp, M., Mangalore, R., & Simon, J. (2004). The global costs of schizophrenia. Schizophr 
Bull, 30(2), 279-293.  
Kohno, T., Shiga, T., Kusumi, I., Matsuyama, T., Kageyama, H., Katoh, C., . . . Tamaki, N. 
(2006). Left temporal perfusion associated with suspiciousness score on the Brief 
Psychiatric Rating Scale in schizophrenia. Psychiatry Research: Neuroimaging, 
147(2), 163-171.  
Koike, S., Satomura, Y., Kawasaki, S., Nishimura, Y., Takano, Y., Iwashiro, N., . . . Kasai, K. 
(2016). Association between rostral prefrontal cortical activity and functional 
outcome in first-episode psychosis: a longitudinal functional near-infrared 
spectroscopy study. Schizophr Res, 170(2-3), 304-310. doi: 
10.1016/j.schres.2016.01.003 
Lam, M. M., Hung, S.-F., & Chen, E. Y. (2006). Transition to psychosis: 6-month follow-up 
of a Chinese high-risk group in Hong Kong. Australian and New Zealand Journal of 
Psychiatry, 40(5), 414-420.  
Lance, C. E., Beck, S. S., Fan, Y., & Carter, N. T. (2016). A taxonomy of path-related 
goodness-of-fit indices and recommended criterion values. Psychological 
Methods, 21(3), 388.  
Lemos-Giráldez, S., Vallina-Fernández, O., Fernández-Iglesias, P., Vallejo-Seco, G., 
Fonseca-Pedrero, E., Paíno-Piñeiro, M., . . . Alonso-Bada, S. (2009). Symptomatic 
and functional outcome in youth at ultra-high risk for psychosis: a longitudinal 
study. Schizophrenia Research, 115(2), 121-129.  
Lencz, T., Smith, C. W., Auther, A., Correll, C. U., & Cornblatt, B. (2004). Nonspecific and 
attenuated negative symptoms in patients at clinical high-risk for schizophrenia. 
Schizophrenia Research, 68(1), 37-48.  
Levine, S. Z., & Leucht, S. (2013). Attaining and sustaining remission of predominant 
negative symptoms. Schizophrenia Research, 143(1), 60-64.  
Lewis, S., Ford, R., Syed, G. M., Reveley, A., & Toone, B. (1992). A controlled study of 99m 
Tc-HMPAO single-photon emission imaging in chronic schizophrenia. Psychol Med, 
22(01), 27-35.  
Liddle, Friston, K., Frith, C., Hirsch, S., Jones, T., & Frackowiak, R. (1992). Patterns of 
cerebral blood flow in schizophrenia. The British Journal of Psychiatry, 160(2), 
179-186.  
Liddle, P. F. (1987). The symptoms of chronic schizophrenia. A re-examination of the 
positive-negative dichotomy. British Journal of Psychiatry, 151, 145-151.  
Liddle, P. F. (1992). Regional brain abnormalities associated with specific syndromes of 
persistent schizophrenic symptoms. Clin Neuropharmacol, 15 Suppl 1 Pt A, 401a-
402a.  
Liddle, P. F., & Barnes, T. R. (1990). Syndromes of chronic schizophrenia. British Journal of 
Psychiatry, 157, 558-561.  
Liddle, P. F., Friston, K., Frith, C., Hirsch, S., Jones, T., & Frackowiak, R. (1992). Patterns of 




Lin, A., Nelson, B., & Yung, A. (2012). ‘At-risk’for psychosis research: where are we 
heading? Epidemiology and Psychiatric Sciences, 21(04), 329-334.  
Lin, A., Wood, S., Nelson, B., Brewer, W., Spiliotacopoulos, D., Bruxner, A., . . . Yung, A. 
(2011). Neurocognitive predictors of functional outcome two to 13years after 
identification as ultra-high risk for psychosis. Schizophrenia Research, 132(1), 1-7.  
Lin, A., Wood, S. J., Nelson, B., Beavan, A., McGorry, P., & Yung, A. R. (2015). Outcomes of 
nontransitioned cases in a sample at ultra-high risk for psychosis. Am J Psychiatry, 
172(3), 249-258. doi: 10.1176/appi.ajp.2014.13030418 
Lindenmayer, J.-P., Bernstein-Hyman, R., Grochowski, S., & Bark, N. (1995a). 
Psychopathology of schizophrenia: initial validation of a 5-factor model. 
Psychopathology, 28(1), 22-31.  
Lindenmayer, J.-P., Grochowski, S., & Hyman, R. B. (1995b). Five factor model of 
schizophrenia: replication across samples. Schizophrenia Research, 14(3), 229-
234.  
Linszen, D., Lenior, M., De Haan, L., Dingemans, P., & Gersons, B. (1998). Early 
intervention, untreated psychosis and the course of early schizophrenia. The 
British Journal of Psychiatry.  
Livingstone, K., Harper, S., & Gillanders, D. (2009). An exploration of emotion regulation in 
psychosis. Clinical psychology & psychotherapy, 16(5), 418.  
Lodge, D. J., & Grace, A. A. (2011). Hippocampal dysregulation of dopamine system 
function and the pathophysiology of schizophrenia. Trends Pharmacol Sci, 32(9), 
507-513. doi: 10.1016/j.tips.2011.05.001 
MacCallum, R. C., Widaman, K. F., Zhang, S., & Hong, S. (1999). Sample size in factor 
analysis. Psychological Methods, 4(1), 84.  
Marcelis, M., Suckling, J., Woodruff, P., Hofman, P., Bullmore, E., & Van Os, J. (2003). 
Searching for a structural endophenotype in psychosis using computational 
morphometry. Psychiatry Research - Neuroimaging, 122(3), 153-167. doi: 
10.1016/S0925-4927(02)00125-7 
Marengo, J., Harrow, M., Herbener, E. S., & Sands, J. (2000). A prospective longitudinal 10-
year study of schizophrenia's three major factors and depression. Psychiatry 
Research, 97(1), 61-77.  
Markland, D. (2007). The golden rule is that there are no golden rules: A commentary on 
Paul Barrett’s recommendations for reporting model fit in structural equation 
modelling. Personality and Individual differences, 42(5), 851-858. doi: 
http://dx.doi.org/10.1016/j.paid.2006.09.023 
Marsh, H. W., Balla, J. R., & McDonald, R. P. (1988). Goodness-of-fit indexes in 
confirmatory factor analysis: The effect of sample size. Psychological bulletin, 
103(3), 391.  
Marsh, H. W., Hau, K.-T., Balla, J. R., & Grayson, D. (1998). Is more ever too much? The 
number of indicators per factor in confirmatory factor analysis. Multivariate 
behavioral research, 33(2), 181-220.  
Marsh, H. W., Hau, K.-T., & Wen, Z. (2004). In search of golden rules: Comment on 
hypothesis-testing approaches to setting cutoff values for fit indexes and dangers 
in overgeneralizing Hu and Bentler's (1999) findings. Structural equation 
modeling, 11(3), 320-341.  
Marshall, M., Lewis, S., Lockwood, A., Drake, R., Jones, P., & Croudace, T. (2005). 
Association between duration of untreated psychosis and outcome in cohorts of 
first-episode patients: a systematic review. Archives of General Psychiatry, 62(9), 
975-983.  
Marshall, M., & Rathbone, J. (2011). Early intervention for psychosis. Cochrane Database 
Syst Rev(6), Cd004718. doi: 10.1002/14651858.CD004718.pub3 
183 
 
Mason, O., Startup, M., Halpin, S., Schall, U., Conrad, A., & Carr, V. (2004). Risk factors for 
transition to first episode psychosis among individuals with ‘at-risk mental states’. 
Schizophrenia Research, 71(2–3), 227-237. doi: 
https://doi.org/10.1016/j.schres.2004.04.006 
Matheson, S., Shepherd, A., & Carr, V. (2014). How much do we know about 
schizophrenia and how well do we know it? Evidence from the Schizophrenia 
Library. Psychol Med, 44(16), 3387-3405.  
Mathew, R. J., Wilson, W. H., Tant, S. R., Robinson, L., & Prakash, R. (1988). Abnormal 
resting regional cerebral blood flow patterns and their correlates in schizophrenia. 
Archives of General Psychiatry, 45(6), 542-549.  
McGlashan, T. H. (1988). A selective review of recent North American long-term followup 
studies of schizophrenia. Schizophrenia Bulletin, 14(4), 515.  
McGlashan, T. H. (1998). Early detection and intervention of schizophrenia: rationale and 
research. The British Journal of Psychiatry.  
McGlashan, T. H., & Johannessen, J. O. (1996). Early detection and intervention with 
schizophrenia: rationale. Schizophrenia Bulletin, 22(2), 201-222.  
McGorry, P. D., Bell, R. C., Dudgeon, P. L., & Jackson, H. J. (1998). The dimensional 
structure of first episode psychosis: an exploratory factor analysis. Psychol Med, 
28(4), 935-947.  
McGorry, P. D., Killackey, E., & Yung, A. (2008). Early intervention in psychosis: concepts, 
evidence and future directions. World Psychiatry, 7(3), 148-156. doi: 
10.1002/j.2051-5545.2008.tb00182.x 
McGorry, P. D., Nelson, B., Amminger, G. P., Bechdolf, A., Francey, S. M., Berger, G., . . . 
Yung, A. R. (2009). Intervention in individuals at ultra-high risk for psychosis: a 
review and future directions. J Clin Psychiatry, 70(9), 1206-1212. doi: 
10.4088/JCP.08r04472 
McGorry, P. D., Yung, A., & Phillips, L. (2001). Ethics and early intervention in psychosis: 
keeping up the pace and staying in step. Schizophrenia Research, 51(1), 17-29.  
McGuire, P. K., Murray, R. M., & Shah, G. M. S. (1993). Increased blood flow in Broca's 
area during auditory hallucinations in schizophrenia. The Lancet, 342(8873), 703-
706. doi: 10.1016/0140-6736(93)91707-S 
McGuire, P. K., Quested, D., Spence, S., Frith, C. D., Murray, R. M., & Liddle, P. F. (1998). 
Pathophysiology of 'positive' thought disorder in schizophrenia. British Journal of 
Forensic Psychiatry, 173, 231-235.  
McGuire, P. K., Sato, J. R., Mechelli, A., Jackowski, A., Bressan, R. A., & Zugman, A. (2015). 
Can neuroimaging be used to predict the onset of psychosis? The Lancet 
Psychiatry, 2(12), 1117-1122. doi: 10.1016/S2215-0366(15)00308-9 
McIntosh, A., Forrester, A., Lawrie, S., Byrne, M., Harper, A., Kestelman, J., . . . Owens, D. 
(2001). A factor model of the functional psychoses and the relationship of factors 
to clinical variables and brain morphology. Psychol Med, 31(01), 159-171.  
Mechelli, A., Riecher-Rössler, A., Meisenzahl, E. M., Tognin, S., Wood, S. J., Borgwardt, S. 
J., . . . Phillips, L. J. (2011). Neuroanatomical abnormalities that predate the onset 
of psychosis: a multicenter study. Archives of General Psychiatry, 68(5), 489-495.  
Melie-García, L., Sanabria-Diaz, G., & Sánchez-Catasús, C. (2013). Studying the topological 
organization of the cerebral blood flow fluctuations in resting state. NeuroImage, 
64(1), 173-184. doi: 10.1016/j.neuroimage.2012.08.082 
Meyer, S. E., Bearden, C. E., Lux, S. R., Gordon, J. L., Johnson, J. K., O'Brien, M. P., . . . 
Cannon, T. D. (2005). The psychosis prodrome in adolescent patients viewed 
through the lens of DSM-IV. Journal of Child & Adolescent Psychopharmacology, 
15(3), 434-451.  
184 
 
Miller, T., McGlashan, T. H., Rosen, J. L., Cadenhead, K., Ventura, J., McFarlane, W., . . . 
Woods, S. W. (2003). Prodromal Assessment With the Structured Interview for 
Prodromal Syndromes and the Scale of Prodromal Symptoms: Predictive Validity, 
Interrater Reliability, and Training to Reliability. Schizophrenia Bulletin, 29(4), 703-
715.  
Miller, T., McGlashan, T. H., Rosen, J. L., Somjee, L., Markovich, P. J., Stein, K., & Woods, S. 
W. (2002). Prospective diagnosis of the initial prodrome for schizophrenia based 
on the Structured Interview for Prodromal Syndromes: preliminary evidence of 
interrater reliability and predictive validity. American Journal of Psychiatry, 
159(5), 863-865.  
Miller, T., McGlashan, T. H., Woods, S. W., Stein, K., Driesen, N., Corcoran, C. M., . . . 
Davidson, L. (1999). Symptom assessment in schizophrenic prodromal states. 
Psychiatric Quarterly, 70(4), 273-287.  
Min, S. K., An, S. K., Jon, D.-I., & Lee, J. D. (1999). Positive and negative symptoms and 
regional cerebral perfusion in antipsychotic-naive schizophrenic patients: a high-
resolution SPECT study. Psychiatry Research: Neuroimaging, 90(3), 159-168.  
Minzenberg, M. J., Laird, A. R., Thelen, S., Carter, C. S., & Glahn, D. C. (2009). Meta-
analysis of 41 functional neuroimaging studies of executive function in 
schizophrenia. Archives of General Psychiatry, 66(8), 811-822. doi: 
10.1001/archgenpsychiatry.2009.91 
Modi, S., Kumar, M., Kumar, P., & Khushu, S. (2015). Aberrant functional connectivity of 
resting state networks associated with trait anxiety. Psychiatry Res, 234(1), 25-34. 
doi: 10.1016/j.pscychresns.2015.07.006 
Morrison, French, P., Walford, L., Lewis, S. W., Kilcommons, A., Green, J., . . . Bentall, R. P. 
(2004). Cognitive therapy for the prevention of psychosis in people at ultra-high 
risk: randomised controlled trial. British Journal of Psychiatry, 185, 291-297. doi: 
10.1192/bjp.185.4.291 
Morrison, A. P., French, P., Stewart, S. L., Birchwood, M., Fowler, D., Gumley, A. I., . . . 
Murray, G. K. (2012). Early detection and intervention evaluation for people at 
risk of psychosis: multisite randomised controlled trial. BMJ, 344, e2233.  
Mortimer, A., Lund, C., & McKenna, P. (1990). The positive: negative dichotomy in 
schizophrenia. The British Journal of Psychiatry, 157(1), 41-49.  
Nelson, B., Yuen, H. P., Lin, A., Wood, S. J., McGorry, P. D., Hartmann, J. A., & Yung, A. R. 
(2016). Further examination of the reducing transition rate in ultra high risk for 
psychosis samples: The possible role of earlier intervention. Schizophr Res, 174(1-
3), 43-49. doi: 10.1016/j.schres.2016.04.040 
Nenadic, I., Sauer, H., & Gaser, C. (2010). Distinct pattern of brain structural deficits in 
subsyndromes of schizophrenia delineated by psychopathology. NeuroImage, 
49(2), 1153-1160.  
Niendam, T. A., Bearden, C. E., Zinberg, J., Johnson, J. K., O'brien, M., & Cannon, T. D. 
(2007). The course of neurocognition and social functioning in individuals at ultra 
high risk for psychosis. Schizophrenia Bulletin, 33(3), 772-781.  
O'Leary, D. S., Flaum, M., Kesler, M. L., Flashman, L. A., Arndt, S., & Andreasen, N. C. 
(2000). Cognitive Correlates of the Negative, Disorganized, and Psychotic 
Symptom Dimensions of Schizophrenia. The Journal of Neuropsychiatry and 
Clinical Neurosciences, 12(1), 4-15. doi: doi:10.1176/jnp.12.1.4 
Olypher, A. V., Klement, D., & Fenton, A. A. (2006). Cognitive Disorganization in 
Hippocampus: A Physiological Model of the Disorganization in Psychosis. The 
Journal of Neuroscience, 26(1), 158-168. doi: 10.1523/jneurosci.2064-05.2006 
185 
 
Organization, W. H. (1992). The ICD-10 classification of mental and behavioural disorders: 
clinical descriptions and diagnostic guidelines: Geneva: World Health 
Organization. 
Ortiz, B. B., Araújo Filho, G. M. d., Neto, A., de Alencar, A. G., Medeiros, D., & Bressan, R. 
A. (2013). Is disorganized schizophrenia a predictor of treatment resistance? 
Evidence from an observational study. Revista Brasileira de Psiquiatria, 35(4), 432-
434.  
Ortiz, B. B., Gadelha, A., Higuchia, C. H., Noto, C., Medeiros, D., Pitta, J. C., . . . Bressan, R. 
A. (2015). Disorganized symptoms predicted worse functioning outcome in 
schizophrenia patients with established illness. Clin Schizophr Relat Psychoses, 1-
18. doi: 10.3371/csrp.orga.022015 
Owens, D. C., Johnstone, E. C., Miller, P., Macmillan, J. F., & Crow, T. J. (2010). Duration of 
untreated illness and outcome in schizophrenia: test of predictions in relation to 
relapse risk. The British Journal of Psychiatry, 196(4), 296-301.  
Pantelis, C., Velakoulis, D., McGorry, P. D., Wood, S. J., Suckling, J., Phillips, L. J., . . . 
Soulsby, B. (2003). Neuroanatomical abnormalities before and after onset of 
psychosis: a cross-sectional and longitudinal MRI comparison. The Lancet, 
361(9354), 281-288.  
Parellada, E., Catafau, A. M., Bernardo, M., Lomeña, F., Catarineu, S., & González-
Monclús, E. (1998). The resting and activation issue of hypofrontality: a single 
photon emission computed tomography study in neuroleptic-naive and 
neuroleptic-free schizophrenic female patients. Biological Psychiatry, 44(8), 787-
790.  
Peralta, V., & Cuesta. (1999). Dimensional structure of psychotic symptoms: an item-level 
analysis of SAPS and SANS symptoms in psychotic disorders. Schizophrenia 
Research, 38(1), 13-26. doi: http://dx.doi.org/10.1016/S0920-9964(99)00003-1 
Peralta, V., Cuesta, M. J., Giraldo, C., Cardenas, A., & Gonzalez, F. (2002). Classifying 
psychotic disorders: issues regarding categorial vs. dimensional approaches and 
time frame to assess symptoms. Eur Arch Psychiatry Clin Neurosci, 252(1), 12-18.  
Peralta, V., de Leon, J., & Cuesta, M. J. (1992). Are there more than two syndromes in 
schizophrenia? A critique of the positive-negative dichotomy. British Journal of 
Psychiatry, 161, 335-343.  
Perkins, D. O., Gu, H., Boteva, K., & Lieberman, J. A. (2005). Relationship between duration 
of untreated psychosis and outcome in first-episode schizophrenia: a critical 
review and meta-analysis. American Journal of Psychiatry, 162(10), 1785-1804.  
Phelps, E. A., O'Connor, K. J., Gatenby, J. C., Gore, J. C., Grillon, C., & Davis, M. (2001). 
Activation of the left amygdala to a cognitive representation of fear. Nature 
Neuroscience, 4(4), 437-441. doi: 10.1038/86110 
Phillips, A. A., Chan, F. H. N., Zheng, M. M. Z., Krassioukov, A. V., & Ainslie, P. N. (2016). 
Neurovascular coupling in humans: Physiology, methodological advances and 
clinical implications. Journal of Cerebral Blood Flow & Metabolism, 36(4), 647-664. 
doi: 10.1177/0271678X15617954 
Pinkham, A., Loughead, J., Ruparel, K., Wu, W.-C., Overton, E., Gur, R., & Gur, R. (2011). 
Resting quantitative cerebral blood flow in schizophrenia measured by pulsed 
arterial spin labeling perfusion MRI. Psychiatry Research: Neuroimaging, 194(1), 
64-72. doi: http://doi.org/10.1016/j.pscychresns.2011.06.013 
Piskulic, D., Addington, J., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Heinssen, R., . . 
. McGlashan, T. H. (2012). Negative symptoms in individuals at clinical high risk of 




Pollak, T. A., De Simoni, S., Barimani, B., Zelaya, F. O., Stone, J. M., & Mehta, M. A. (2015). 
Phenomenologically distinct psychotomimetic effects of ketamine are associated 
with cerebral blood flow changes in functionally relevant cerebral foci: a 
continuous arterial spin labelling study. Psychopharmacology (Berl), 232(24), 
4515-4524. doi: 10.1007/s00213-015-4078-8 
Prasad, K. M., Patel, A. R., Muddasani, S., Sweeney, J., & Keshavan, M. S. (2004). The 
entorhinal cortex in first-episode psychotic disorders: a structural magnetic 
resonance imaging study. Am J Psychiatry, 161(9), 1612-1619. doi: 
10.1176/appi.ajp.161.9.1612 
Preston, A. R., Shohamy, D., Tamminga, C. A., & Wagner, A. D. (2005). Hippocampal 
function, declarative memory, and schizophrenia: anatomic and functional 
neuroimaging considerations. Current neurology and neuroscience reports, 5(4), 
249-256.  
Price, J. L., & Drevets, W. C. (2010). Neurocircuitry of mood disorders. 
Neuropsychopharmacology, 35(1), 192-216. doi: 10.1038/npp.2009.104 
Qiu, A., Zhong, J., Graham, S., Chia, M. Y., & Sim, K. (2009). Combined analyses of thalamic 
volume, shape and white matter integrity in first-episode schizophrenia. 
NeuroImage, 47(4), 1163-1171. doi: 10.1016/j.neuroimage.2009.04.027 
Raballo, A. (2011). Dimensional psychopathology and vulnerability to psychosis: 
envisaging the third generation of prodromal/ultra high-risk models. CNS 
spectrums, 15(06), 350-351.  
Raballo, A., & Larøi, F. (2009). Clinical staging: a new scenario for the treatment of 
psychosis. The Lancet, 374(9687), 365-367. doi: http://dx.doi.org/10.1016/S0140-
6736(09)61398-2 
Raballo, A., Nelson, B., Thompson, A., & Yung, A. (2011). The comprehensive assessment 
of at-risk mental states: from mapping the onset to mapping the structure. 
Schizophrenia Research, 127(1-3), 107-114.  
Rabinowitz, J., Levine, S. Z., Garibaldi, G., Bugarski-Kirola, D., Berardo, C. G., & Kapur, S. 
(2012). Negative symptoms have greater impact on functioning than positive 
symptoms in schizophrenia: analysis of CATIE data. Schizophrenia Research, 
137(1), 147-150.  
Rauch, S. L., Shin, L. M., & Wright, C. I. (2003) Neuroimaging studies of amygdala function 
in anxiety disorders. Vol. 985. Annals of the New York Academy of Sciences (pp. 
389-410). 
Riecher-Rössler, A., Pflueger, M. O., Aston, J., Borgwardt, S. J., Brewer, W. J., 
Gschwandtner, U., & Stieglitz, R.-D. (2009). Efficacy of using cognitive status in 
predicting psychosis: a 7-year follow-up. Biological Psychiatry, 66(11), 1023-1030.  
Rietdijk, J., Ising, H. K., Dragt, S., Klaassen, R., Nieman, D., Wunderink, L., . . . van der Gaag, 
M. (2013). Depression and social anxiety in help-seeking patients with an ultra-
high risk for developing psychosis. Psychiatry Research, 209(3), 309-313.  
Robinson, D. G., Woerner, M. G., McMeniman, M., Mendelowitz, A., & Bilder, R. M. 
(2004). Symptomatic and functional recovery from a first episode of schizophrenia 
or schizoaffective disorder. Am J Psychiatry, 161(3), 473-479. doi: 
10.1176/appi.ajp.161.3.473 
Rosenman, S., Korten, A., Medway, J., & Evans, M. (2003). Dimensional vs. categorical 
diagnosis in psychosis. Acta Psychiatrica Scandinavica, 107(5), 378-384.  
Ruhrmann, S., Schultze-Lutter, F., Bechdolf, A., & Klosterkotter, J. (2010a). Intervention in 
at-risk states for developing psychosis. Eur Arch Psychiatry Clin Neurosci, 260 
Suppl 2, S90-94. doi: 10.1007/s00406-010-0139-5 
187 
 
Ruhrmann, S., Schultze-Lutter, F., & Klosterkötter, J. (2003). Early detection and 
intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry, 
36(S 3), 162-167.  
Ruhrmann, S., Schultze-Lutter, F., Salokangas, R. K., Heinimaa, M., Linszen, D., Dingemans, 
P., . . . Heinz, A. (2010b). Prediction of psychosis in adolescents and young adults 
at high risk: results from the prospective European prediction of psychosis study. 
Archives of General Psychiatry, 67(3), 241-251.  
Russo, M., Levine, S. Z., Demjaha, A., Di Forti, M., Bonaccorso, S., Fearon, P., . . . 
Reichenberg, A. (2014). Association between symptom dimensions and 
categorical diagnoses of psychosis: a cross-sectional and longitudinal 
investigation. Schizophr Bull, 40(1), 111-119. doi: 10.1093/schbul/sbt055 
Sabri, O., Erkwoh, R., Schreckenberger, M., & Cremerius, U. (1997). Regional cerebral 
blood flow and negative/positive symptoms in 24 drug-naive schizophrenics. The 
Journal of Nuclear Medicine, 38(2), 181.  
Salokangas, R. K. (2003). Symptom dimensions and outcome in schizophrenia. World 
Psychiatry, 2(3), 172-178.  
Salokangas, R. K., Honkonen, T., Stengard, E., & Koivisto, A. M. (2002). Symptom 
dimensions and their association with outcome and treatment setting in long-
term schizophrenia. Results of the DSP project. Nord J Psychiatry, 56(5), 319-327. 
doi: 10.1080/080394802760322079 
Sánchez-Torres, A. M., Elosúa, M. R., Lorente-Omeñaca, R., Moreno-Izco, L., Peralta, V., & 
Cuesta, M. J. (2017). Lifetime psychopathological dimensions, cognitive 
impairment and functional outcome in psychosis. Schizophrenia Research, 179, 
30-35. doi: https://doi.org/10.1016/j.schres.2016.10.002 
Sato, T., Bottlender, R., Schröter, A., & Möller, H.-J. (2004). Psychopathology of early-
onset versus late-onset schizophrenia revisited: an observation of 473 
neuroleptic-naive patients before and after first-admission treatments. 
Schizophrenia Research, 67(2), 175-183.  
Scheef, L., Manka, C., Daamen, M., Kühn, K.-U., Maier, W., Schild, H. H., & Jessen, F. 
(2010). Resting-state perfusion in nonmedicated schizophrenic patients: a 
continuous arterial spin-labeling 3.0-T MR study. Radiology, 256(1), 253-260.  
Schermelleh-Engel, K., Moosbrugger, H., & Müller, H. (2003). Evaluating the fit of 
structural equation models: Tests of significance and descriptive goodness-of-fit 
measures. Methods of psychological research online, 8(2), 23-74.  
Schlosser, D. A., Jacobson, S., Chen, Q., Sugar, C. A., Niendam, T. A., Li, G., . . . Cannon, T. 
D. (2012). Recovery from an at-risk state: clinical and functional outcomes of 
putatively prodromal youth who do not develop psychosis. Schizophrenia Bulletin, 
38(6), 1225-1233.  
Schobel, S. A., Lewandowski, N. M., Corcoran, C. M., Moore, H., Brown, T., Malaspina, D., 
& Small, S. A. (2009). Differential targeting of the CA1 subfield of the hippocampal 
formation by schizophrenia and related psychotic disorders. Archives of General 
Psychiatry, 66(9), 938-946.  
Schreiber, J. B., Nora, A., Stage, F. K., Barlow, E. A., & King, J. (2006). Reporting Structural 
Equation Modeling and Confirmatory Factor Analysis Results: A Review. The 
Journal of Educational Research, 99(6), 323-338. doi: 10.3200/JOER.99.6.323-338 
Shergill, S. S., Cameron, L. A., Brammer, M. J., Williams, S. C. R., Murray, R. M., & McGuire, 
P. K. (2001). Modality specific neural correlates of auditory and somatic 




Sim, K., Cullen, T., Ongur, D., & Heckers, S. (2006). Testing models of thalamic dysfunction 
in schizophrenia using neuroimaging. Journal of Neural Transmission, 113(7), 907-
928. doi: 10.1007/s00702-005-0363-8 
Smieskova, R., Fusar-Poli, P., Aston, J., Simon, A., Bendfeldt, K., Lenz, C., . . . Borgwardt, S. 
J. (2012). Insular volume abnormalities associated with different transition 
probabilities to psychosis. Psychol Med, 42(8), 1613-1625. doi: 
10.1017/S0033291711002716 
Stafford, M. R., Jackson, H., Mayo-Wilson, E., Morrison, A. P., & Kendall, T. (2013). Early 
interventions to prevent psychosis: systematic review and meta-analysis. BMJ : 
British Medical Journal, 346. doi: 10.1136/bmj.f185 
Stone, J. M., Day, F., Tsagaraki, H., Valli, I., McLean, M. A., Lythgoe, D. J., . . . 
Bhattacharyya, S. (2009). Glutamate Dysfunction in People with Prodromal 
Symptoms of Psychosis. Biological Psychiatry, 66(6), 533-539. doi: 
10.1016/j.biopsych.2009.05.006 
Sullivan, H. S. (1927). THE ONSET OF SCHIZOPHRENIA. American Journal of Psychiatry, 
84(1), 105-134. doi: doi:10.1176/ajp.84.1.105 
Sylvester, C. M., Corbetta, M., Raichle, M. E., Rodebaugh, T. L., Schlaggar, B. L., Sheline, Y. 
I., . . . Lenze, E. J. (2012). Functional network dysfunction in anxiety and anxiety 
disorders. Trends in neurosciences, 35(9), 527-535. doi: 
https://doi.org/10.1016/j.tins.2012.04.012 
Takahashi, H., Iwase, M., Nakahachi, T., Sekiyama, R., Tabushi, K., Kajimoto, O., . . . 
Takeda, M. (2005). Spatial working memory deficit correlates with disorganization 
symptoms and social functioning in schizophrenia. Psychiatry Clin Neurosci, 59(4), 
453-460.  
Takahashi, T., Suzuki, M., Zhou, S. Y., Hagino, H., Tanino, R., Kawasaki, Y., . . . Kurachi, M. 
(2005). Volumetric MRI study of the short and long insular cortices in 
schizophrenia spectrum disorders. Psychiatry Research - Neuroimaging, 138(3), 
209-220. doi: 10.1016/j.pscychresns.2005.02.004 
Tamminga, Ana D. Stan, & Anthony D. Wagner. (2010). The Hippocampal Formation in 
Schizophrenia. American Journal of Psychiatry, 167(10), 1178-1193. doi: 
10.1176/appi.ajp.2010.09081187 
Tamminga, Thaker, G. K., Buchanan, R., Kirkpatrick, B., Alphs, L. D., Chase, T. N., & 
Carpenter, W. T. (1992). Limbic system abnormalities identified in schizophrenia 
using positron emission tomography with fluorodeoxyglucose and neocortical 
alterations with deficit syndrome. Archives of General Psychiatry, 49(7), 522-530.  
Thompson, A., Nelson, B., & Yung, A. (2011). Predictive validity of clinical variables in the 
"at risk" for psychosis population: international comparison with results from the 
North American Prodrome Longitudinal Study. Schizophr Res, 126(1-3), 51-57. doi: 
10.1016/j.schres.2010.09.024 
Tseng, H.-H., Roiser, J. P., Modinos, G., Falkenberg, I., Samson, C., McGuire, P., & Allen, P. 
(2016). Corticolimbic dysfunction during facial and prosodic emotional recognition 
in first-episode psychosis patients and individuals at ultra-high risk. NeuroImage: 
Clinical, 12, 645-654. doi: 10.1016/j.nicl.2016.09.006 
Tso, I. F., Taylor, S. F., Grove, T. B., Niendam, T., Adelsheim, S., Auther, A., . . . McFarlane, 
W. R. (2017). Factor analysis of the Scale of Prodromal Symptoms: data from the 
Early Detection and Intervention for the Prevention of Psychosis Program. Early 
intervention in psychiatry, 11(1), 14-22. doi: 10.1111/eip.12209 
Tucker, L. R., & Lewis, C. (1973). A reliability coefficient for maximum likelihood factor 
analysis. Psychometrika, 38(1), 1-10.  
Valmaggia, L. R., Stahl, D., Yung, A. R., Nelson, B., Fusar-Poli, P., McGorry, P. D., & 
McGuire, P. K. (2013). Negative psychotic symptoms and impaired role 
189 
 
functioning predict transition outcomes in the at-risk mental state: a latent class 
cluster analysis study. Psychol Med, 43(11), 2311-2325.  
van der Gaag, M., Cuijpers, A., Hoffman, T., Remijsen, M., Hijman, R., de Haan, L., . . . 
Wiersma, D. (2006). The five-factor model of the Positive and Negative Syndrome 
Scale I: Confirmatory factor analysis fails to confirm 25 published five-factor 
solutions. Schizophrenia Research, 85(1–3), 273-279. doi: 
http://dx.doi.org/10.1016/j.schres.2006.04.001 
van Os, J., Fahy, T. A., Jones, P., Harvey, I., Sham, P., Lewis, S., . . . Murray, R. (1996). 
Psychopathological syndromes in the functional psychoses: associations with 
course and outcome. Psychol Med, 26(1), 161-176.  
Van Os, J., Fahy, T. A., Jones, P., Harvey, I., Sham, P., Lewis, S., . . . Murray, R. (2009). 
Psychopathological syndromes in the functional psychoses: associations with 
course and outcome. Psychol Med, 26(1), 161-176. doi: 
10.1017/S0033291700033808 
van Os, J., Gilvarry, C., Bale, R., van Horn, E., Tattan, T., White, I., & Murray, R. (1999). To 
what extent does symptomatic improvement result in better outcome in 
psychotic illness? UK700 Group. Psychol Med, 29(5), 1183-1195.  
Velthorst, E., Nieman, D., Klaassen, R., Becker, H., Dingemans, P., Linszen, D., & De Haan, 
L. (2011). Three‐year course of clinical symptomatology in young people at ultra 
high risk for transition to psychosis. Acta Psychiatrica Scandinavica, 123(1), 36-42.  
Velthorst, E., Nieman, D. H., Becker, H. E., van de Fliert, R., Dingemans, P. M., Klaassen, R., 
. . . Linszen, D. H. (2009). Baseline differences in clinical symptomatology between 
ultra high risk subjects with and without a transition to psychosis. Schizophrenia 
Research, 109(1–3), 60-65. doi: https://doi.org/10.1016/j.schres.2009.02.002 
Velthorst, E., Nieman, D. H., Linszen, D., Becker, H., de Haan, L., Dingemans, P. M., . . . 
Heinimaa, M. (2010). Disability in people clinically at high risk of psychosis. The 
British Journal of Psychiatry, 197(4), 278-284.  
Volkow, N. D., Wolf, A. P., & Van Gelder, P. (1987). Phenomenological Correlates of 
Metabolic Activity. Am J Psychiatry, 144(2), 151.  
Walker, E., Mittal, V., & Tessner, K. (2008). Stress and the hypothalamic pituitary adrenal 
axis in the developmental course of schizophrenia. Annu Rev Clin Psychol, 4, 189-
216. doi: 10.1146/annurev.clinpsy.4.022007.141248 
Wallwork, R. S., Fortgang, R., Hashimoto, R., Weinberger, D. R., & Dickinson, D. (2012). 
Searching for a consensus five-factor model of the Positive and Negative 
Syndrome Scale for schizophrenia. Schizophr Res, 137(1-3), 246-250. doi: 
10.1016/j.schres.2012.01.031 
Wang, Y., Saykin, A. J., Pfeuffer, J., Lin, C., Mosier, K. M., Shen, L., . . . Hutchins, G. D. 
(2011). Regional reproducibility of pulsed arterial spin labeling perfusion imaging 
at 3T. NeuroImage, 54(2), 1188-1195.  
Wesierska, M., Dockery, C., & Fenton, A. A. (2005). Beyond Memory, Navigation, and 
Inhibition: Behavioral Evidence for Hippocampus-Dependent Cognitive 
Coordination in the Rat. The Journal of Neuroscience, 25(9), 2413-2419. doi: 
10.1523/jneurosci.3962-04.2005 
Wickham, H., Walsh, C., Asherson, P., Taylor, C., Sigmundson, T., Gill, M., . . . Sham, P. 
(2001). Familiality of symptom dimensions in schizophrenia. Schizophr Res, 47(2-
3), 223-232.  
Woodward, N. D., Karbasforoushan, H., & Heckers, S. (2012). Thalamocortical 
dysconnectivity in schizophrenia. American Journal of Psychiatry, 169(10), 1092-
1099. doi: 10.1176/appi.ajp.2012.12010056 
190 
 
Wu, E. Q., Birnbaum, H. G., Shi, L., Ball, D. E., Kessler, R. C., Moulis, M., & Aggarwal, J. 
(2005). The economic burden of schizophrenia in the United States in 2002. J Clin 
Psychiatry, 66(9), 1122-1129.  
Yung, A. R., Buckby, J. A., Cotton, S. M., Cosgrave, E. M., Killackey, E. J., Stanford, C., . . . 
McGorry, P. D. (2006). Psychotic-like experiences in nonpsychotic help-seekers: 
associations with distress, depression, and disability. Schizophrenia Bulletin, 32(2), 
352-359.  
Yung, A. R., & McGorry, P. D. (1996a). The initial prodrome in psychosis: descriptive and 
qualitative aspects. Australian and New Zealand Journal of Psychiatry, 30(5), 587-
599.  
Yung, A. R., & McGorry, P. D. (1996b). The prodromal phase of first-episode psychosis: 
past and current conceptualizations. Schizophrenia Bulletin, 22(2), 353-370.  
Yung, A. R., Phillips, L. J., McGorry, P. D., McFarlane, C. A., Francey, S., Harrigan, S., . . . 
Jackson, H. J. (1998). Prediction of psychosis. A step towards indicated prevention 
of schizophrenia. Br J Psychiatry Suppl, 172(33), 14-20.  
Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S. M., McFarlane, C. A., Hallgren, M., & 
McGorry, P. D. (2003). Psychosis prediction: 12-month follow up of a high-risk 
(“prodromal”) group. Schizophrenia Research, 60(1), 21-32.  
Yung, A. R., Yuen, H. P., McGorry, P. D., Phillips, L. J., Kelly, D., Dell'Olio, M., . . . Buckby, J. 
(2005). Mapping the onset of psychosis: the Comprehensive Assessment of At-
Risk Mental States. Australian & New Zealand Journal of Psychiatry, 39(11-12), 
964-971.  
Zhu, J., Zhuo, C., Qin, W., Xu, Y., Xu, L., Liu, X., & Yu, C. (2015). Altered resting-state 
cerebral blood flow and its connectivity in schizophrenia. J Psychiatr Res, 63, 28-
35. doi: 10.1016/j.jpsychires.2015.03.002 
Ziermans, T., de Wit, S., Schothorst, P., Sprong, M., van Engeland, H., Kahn, R., & Durston, 
S. (2014). Neurocognitive and clinical predictors of long-term outcome in 
adolescents at ultra-high risk for psychosis: a 6-year follow-up. PLoS One, 9(4), 
e93994. doi: 10.1371/journal.pone.0093994 
Ziermans, T., Schothorst, P. F., Schnack, H. G., Koolschijn, P. C., Kahn, R. S., van Engeland, 
H., & Durston, S. (2012). Progressive structural brain changes during development 































































































































































































































































































































7.3 Appendix 3: Histograms of distribution of Composite scores 

































7.5 Appendix 5: Whole Brain Analysis of Correlation with 




7.6 Appendix 6: Whole Brain Analysis of Correlation with Anxiety 
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7.7 Appendix 7: ROI Analysis of Left Hippocampus and Total 













7.10 Appendix 10: ROI Analysis of Mediodorsal Thalamus and 




7.11 Appendix 11: ROI Analysis of Insula and Anxiety Dimension 
 
